<0216610> ^FU+++++PMOD+ ^NULL
<h> ^FU++++++ ^NULL
Clinical ^J++ATRB++++ ^JJ
Scenario ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
You ^P+PER++2+++ ^PPY
are ^VA+++++BE+ ^VBR
working ^VL+ING+PRG++++ ^VVG
as ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
internal ^J++ATRB++++ ^JJ
medicine ^N+CM+SING+++PMOD+ ^NN1
resident ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
rheumatology ^N+CM+SING+++PMOD+ ^NN1
rotation ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
are ^VA+++++BE+ ^VBR
seeing ^VL+ING+PRG++++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
19 ^M+CARD+SING+MORE+++ ^MC
year-old ^J++ATRB+++ONLY+ ^JJ
woman ^N+CM+SING++++ ^NN1
who ^P++WH++++ ^PNQS
has ^VL+Z+++++ ^VHZ
had ^VL+ED+PRF++++ ^VHN
systemic ^J++ATRB++++ ^JJ
lupus ^N+CM+SING+++PMOD+ ^NN1
erythematosus ^N+CM+SING++++ ^NN1
diagnosed ^VL+EN+PRF++++ ^VVN
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
basis ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
characteristic ^J++ATRB++++ ^JJ
skin ^N+CM+SING+++PMOD+ ^NN1
rash ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
arthritis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
renal ^J++ATRB++++ ^JJ
disease ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
renal ^J++ATRB++++ ^JJ
biopsy ^N+CM+SING++++ ^NN1
has ^VL+Z+++++ ^VHZ
shown ^VL+EN+PRF++++ ^VVN
diffuse ^J++ATRB++++ ^JJ
proliferative ^J++ATRB++++ ^JJ
nephritis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
year ^N+CM+SING+++TIME+ ^NNT1
ago ^R+++++A+ ^RA
, ^Y+COM+++++ ^,
her ^D+PER+SING+3+GEN++ ^APPGE
creatinine ^N+CM+SING++++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
140 ^M+CARD+SING+MORE+++ ^MC
micromoles/litre ^FU++++++ ^FU
, ^Y+COM+++++ ^,
six ^M+CARD+SING+MORE+++ ^MC
months ^N+CM+PLUR+++TIME+ ^NNT2
ago ^R+++++A+ ^RA
180 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
blood ^N+CM+SING+++PMOD+ ^NN1
sample ^N+CM+SING++++ ^NN1
taken ^VL+EN++CLS+++ ^VVN
a ^D+AT+SING+INDEF+++ ^AT1
week ^N+CM+SING+++TIME+ ^NNT1
before ^C+SRD+++++ ^CS
this ^D+DEM+SING++++ ^DD1
clinic ^N+CM+SING+++PMOD+ ^NN1
visit ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
220 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Over ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
last ^M+ORD+++++ ^MD
year ^N+CM+SING+++TIME+ ^NNT1
she ^P+PER+SING+3+S++ ^PPHS1
has ^VL+Z+++++ ^VHZ
been ^VA+EN+PRF+++BE+ ^VBN
taking ^VL+ING+PRG++++ ^VVG
prednisone ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
over ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
last ^M+ORD+++++ ^MD
six ^M+CARD+SING+MORE+++ ^MC
months ^N+CM+PLUR+++TIME+ ^NNT2
, ^Y+COM+++++ ^,
cyclophosphamide ^VL+BF+++++ ^VV0
, ^Y+COM+++++ ^,
both ^R++++++ ^RR
in ^I++++++ ^II
appropriate ^J++ATRB++++ ^JJ
doses ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
You ^P+PER++2+++ ^PPY
are ^VA+++++BE+ ^VBR
distressed ^VL+EN+PSV+BY+++ ^VVN
by ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
rising ^J+ING+ATRB++++ ^JJ
creatinine ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
rheumatology ^N+CM+SING+++PMOD+ ^NN1
fellow ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
whom ^P++WH+REL+OBJ+PIED+ ^PNQO
you ^P+PER++2+++ ^PPY
discuss ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
problem ^N+CM+SING++++ ^NN1
suggests ^VL+Z+++++ ^VVZ
that ^C+SRD+THT+COMP+VERB++ ^CST
you ^P+PER++2+++ ^PPY
contact ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
hematology ^N+CM+SING+++PMOD+ ^NN1
service ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
consider ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
plasmapheresis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
She ^P+PER+SING+3+S++ ^PPHS1
states ^VL+Z+++++ ^VVZ
that ^D+DEM+SING++++ ^DD1
plasmapheresis ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
effective ^J++PRDV++++ ^JJ
in ^I++++++ ^II
reducing ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
level ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
antibodies ^N+CM+PLUR++++ ^NN2
responsible ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
nephritis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
cites ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
trials ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
have ^VL+BF+++++ ^VH0
suggested ^VL+EN+PRF+++THDEL+ ^VVN
therapy ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
beneficial ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
you ^P+PER++2+++ ^PPY
ask ^VL+BF+++++ ^VV0
her ^P+PER+SING+3+O++ ^PPHO1
if ^C+SRD++++CND+ ^CS
any ^D+AT+PLUR+INDEF+PRO++ ^DD
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
studies ^N+CM+PLUR++++ ^NN2
were ^VA+ED++++BE+ ^VBDR
randomized ^VL+EN+PSV+AGLS+++ ^VVN
clinical ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
she ^P+PER+SING+3+S++ ^PPHS1
acknowledges ^VL+Z+++++ ^VVZ
that ^C+SRD+THT+COMP+VERB++ ^CST
she ^P+PER+SING+3+S++ ^PPHS1
is ^VL+Z++COP+++ ^VBZ
uncertain ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
You ^P+PER++2+++ ^PPY
present ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
dilemma ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
attending ^VL+ING++COMP+VERB++ ^VVG
physician ^N+CM+SING+NOM+++ ^NN1
who ^P++WH++++ ^PNQS
responds ^VL+Z+++++ ^VVZ
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
suggestion ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+COMP+NOUN++ ^CST
, ^Y+COM+++++ ^,
before ^C+SRD+++++ ^CS
you ^P+PER++2+++ ^PPY
make ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
decision ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
review ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
relevant ^J++ATRB++++ ^JJ
literature ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
She ^P+PER+SING+3+S++ ^PPHS1
recommends ^VL+Z+++++ ^VVZ
that ^C+SRD+THT+COMP+VERB++ ^CST
you ^P+PER++2+++ ^PPY
bring ^VL+BF+++++MULTI1 ^VV0
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
back ^R+PART+PHRV++++MULTI2 ^RP
in ^I++++++ ^II
two ^M+CARD+SING+MORE+++ ^MC
weeks ^N+CM+PLUR+++TIME+ ^NNT2
, ^Y+COM+++++ ^,
at ^I++++++ ^II
which ^D++WH++++ ^DDQ
time ^VL+BF+++++ ^VV0
you ^P+PER++2+++ ^PPY
can ^VM+++++POS+ ^VM
offer ^VL+INF+++++ ^VVI
her ^P+PER+SING+3+O++ ^PPHO1
the ^DET+AT+SING+DEF+++ ^AT
appropriate ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
Search ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
You ^P+PER++2+++ ^PPY
decide ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
most ^R+++EST++DEG+ ^RGT
helpful ^J++ATRB++++ ^JJ
article ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
include ^VL+INF+++++ ^VVI
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
severe ^J++ATRB++++ ^JJ
lupus ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
threatens ^VL+Z+++++ ^VVZ
renal ^J++ATRB++++ ^JJ
function ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
who ^P++WH+REL+SUB++ ^PNQS
are ^VL+++COP+++ ^VBR
, ^Y+COM+++++ ^,
already ^R++++++ ^RR
receiving ^VL+ING++COMP+VERB++ ^VVG
immunosuppressive ^J++ATRB++++ ^JJ
agents ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Plasmapheresis ^N+CM+SING++++ ^NN1
must ^VM+++++NEC+ ^VM
be ^VA+INF++++BE+ ^VBI
compared ^VL+EN+PSV+AGLS+++ ^VVN
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
control ^N+CM+SING+++PMOD+ ^NN1
management ^N+CM+SING+NOM++PMOD+ ^NN1
strategy ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
patients ^N+CM+PLUR++++ ^NN2
must ^VM+++++NEC+ ^VM
be ^VA+INF++++BE+ ^VBI
randomized ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
receive ^VL+INF+++++ ^VVI
or ^C+CRD+++++ ^CC
not ^XX++++++ ^XX
receive ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
plasmapheresis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Finally ^R++++++ ^RR
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
must ^VM+++++NEC+ ^VM
report ^VL+INF+++++ ^VVI
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
deterioration ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
renal ^J++ATRB++++ ^JJ
function ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
are ^VL+++COP+++ ^VBR
familiar ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
software ^N+CM+SING+++PMOD+ ^NN1
program ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
Grateful ^J++PRDV++++ ^JJ
Med ^J++PRDV++++ ^JJ
" ^Y+QUO+++++ ^"
and ^C+CRD+++++ ^CC
use ^VL+BF+++++ ^VV0
it ^P+IM++3+++ ^PPH1
for ^I++++++ ^IF
your ^D+PER++2+GEN++ ^APPGE
search ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
program ^N+CM+SING++++ ^NN1
provides ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
listing ^N+ING+SING++++ ^NN1
of ^I++++++ ^IO
Medical ^J++ATRB++++ ^JJ
subject ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
MeSH ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
headings ^N+ING+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
you ^P+PER++2+++ ^PPY
quickly ^R++++++ ^RR
find ^VL+BF+++++ ^VV0
that ^D+DEM+SING++++ ^DD1
" ^Y+QUO+++++ ^"
lupus ^N+CM+SING+++PMOD+ ^NN1
nephritis ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
is ^VL+Z++COP+++ ^VBZ
one ^M+CARD+SING+ONE+++ ^MC1
such ^D++++PRO+A+ ^DA
heading ^N+ING+SING++++ ^NN1
and ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
plasmapheresis ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
another ^D++SING++PRO++ ^DD1
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
add ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
methodological ^J++ATRB++++ ^JJ
term ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
will ^VM+++++PRDN+ ^VM
restrict ^VL+INF+++++ ^VVI
your ^D+PER++2+GEN++ ^APPGE
results ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
high ^J++ATRB++++ ^JJ
quality ^N+CM+SING+NOM++PMOD+ ^NN1
studies ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
randomized ^VL+ED+++++ ^VVD
controlled ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
PT ^FO++++++ ^FO
) ^Y+PAR+RIGHT++++ ^)
" ^Y+QUO+++++ ^"
( ^Y+PAR+LEFT++++ ^(
PT ^N+CM+SING++++ ^NN1
stands ^VL+Z+++++MULTI1 ^VVZ
for ^I++PPVB++++MULTI2 ^IF
publication ^N+CM+SING+NOM++PMOD+ ^NN1
type ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
search ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
which ^D++WH++++ ^DDQ
you ^P+PER++2+++ ^PPY
restrict ^VL+BF+++++ ^VV0
to ^I++++++ ^II
English-language ^J++ATRB++++ ^JJ
articles ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
yields ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
total ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
three ^M+CARD+SING+MORE+++ ^MC
papers ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
One ^M+CARD+SING+ONE+++ ^MC1
is ^VL+Z++COP+++ ^VBZ
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
prednisone ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
cyclophosphamide ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
1 ^M+CARD+SING+ONE+++ ^MC1
&rsqb; ^Y+PAR+RIGHT++++ ^)
; ^Y+SCOL+CLP++++ ^;
a ^D+AT+SING+INDEF+++ ^AT1
second ^N+CM+SING+++TIME+ ^NNT1
examines ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
plasmapheresis ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
infection ^N+CM+SING+NOM+++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
2 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
third ^M+ORD+++++ ^MD
citation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
which ^D++WH++++ ^DDQ
describes ^VL+Z+++++ ^VVZ
" ^Y+QUO+++++ ^"
a ^D+AT+SING+INDEF+++ ^AT1
controlled ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
plasmapheresis ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
, ^Y+COM+++++ ^,
appears ^VL+Z+++++ ^VVZ
most ^D+++EST+PRO+A+ ^DAT
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
address ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
issue ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
hand ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
effectiveness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
plasmapheresis ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
improving ^VL+ING++COMP+PREP++ ^VVG
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
relevant ^J++ATRB++++ ^JJ
article ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
a ^D+AT+SING+INDEF+++ ^AT1
randomized ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
46 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
received ^VL+ED+++++ ^VVD
a ^D+AT+SING+INDEF+++ ^AT1
standard ^J++ATRB++++ ^JJ
therapeutic ^J++ATRB++++ ^JJ
regimen ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
prednisone ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
cyclophosphamide ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
40 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
received ^VL+ED+++++ ^VVD
standard ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
plus ^I++++++ ^II
plasmapheresis ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
3 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Despite ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
fact ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+COMP+NOUN++ ^CST
antibody ^N+CM+SING+++PMOD+ ^NN1
levels ^N+CM+PLUR++++ ^NN2
decreased ^VL+EN++CLS+++ ^VVN
in ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
undergoing ^VL+ING++COMP+VERB++ ^VVG
plasmapheresis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
there ^P+EX+++++ ^EX
was ^VL+ED++COP+++ ^VBDZ
a ^D+AT+SING+INDEF+++ ^AT1
trend ^N+CM+SING++++ ^NN1
toward ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
greater ^J++ATRB+ER+++ ^JJR
proportion ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
plasmapheresis-treated ^J+EN+ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
dying ^VL+ING++REL+SUBJ++ ^VVG
( ^Y+PAR+LEFT++++ ^(
20% ^N++++U++ ^NNU
versus ^I++++++ ^II
13% ^N++++U++ ^NNU
) ^Y+PAR+RIGHT++++ ^)
or ^C+CRD+++++ ^CC
developing ^J+ING+ATRB++++ ^JJ
renal ^J++ATRB++++ ^JJ
failure ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
25% ^N++++U++ ^NNU
versus ^I++++++ ^II
17% ^N++++U++ ^NNU
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
This ^P+DEM+SING++++ ^DD1
seems ^VL+Z++COP+++ ^VVZ
to ^TO+++COMP+VERB++ ^TO
settle ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
issue ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
whether ^C+SRD+WH+COMP+NOUN++ ^CSW
to ^TO++++++ ^TO
offer ^VL+INF+++++ ^VVI
your ^D+PER++2+GEN++ ^APPGE
patient ^J++ATRB++++ ^JJ
plasmapheresis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
wonder ^VL+BF+++++ ^VV0
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
whether ^C+SRD+WH+REL+OBJ++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
could ^VM+++++POS+ ^VM
have ^VL+INF+++++ ^VHI
led ^VL+EN+PRF++++ ^VVN
to ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
inaccurate ^J++ATRB++++ ^JJ
or ^C+CRD+PHRS++++ ^CC
biased ^J+EN+ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
remainder ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
paper ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
provide ^VL+INF+++++ ^VVI
you ^P+PER++2+++ ^PPY
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
tools ^N+CM+PLUR++++ ^NN2
to ^TO++++++ ^TO
address ^VL+INF+++++ ^VVI
this ^D+DEM+SING++++ ^DD1
question ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Introduction ^N+CM+SING+NOM++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
first ^M+ORD+++++ ^MD
section ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
we ^P+PER+PLUR+1+S++ ^PPIS2
introduced ^VL+ED+++++ ^VVD
a ^D+AT+SING+INDEF+++ ^AT1
framework ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
using ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
medical ^J++ATRB++++ ^JJ
literature ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
solve ^VL+INF+++++ ^VVI
patient ^J++ATRB++++ ^JJ
problems ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
provide ^VL+INF+++++ ^VVI
better ^J++ATRB+ER+++ ^JJR
clinical ^J++ATRB++++ ^JJ
care ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
4 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
second ^N+CM+SING+++PMOD+ ^NNT1
section ^N+CM+SING+NOM+++ ^NN1
begins ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
discussion ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
how ^P+G+WH+COMP+NOUN++ ^RRQ
to ^TO++++++ ^TO
use ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
article ^N+CM+SING++++ ^NN1
dealing ^VL+ING++REL+SUBJ++MULTI1 ^VVG
with ^I++PPVB++++MULTI2 ^IW
therapy ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
prevention ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
We ^P+PER+PLUR+1+S++ ^PPIS2
will ^VM+++++PRDN+ ^VM
use ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
term ^N+CM+SING+++PMOD+ ^NN1
therapy ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
broad ^J++ATRB++++ ^JJ
sense ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
As ^C+SRD+++++ ^CSA
we ^P+PER+PLUR+1+S++ ^PPIS2
've ^VL+BF+++CONT++ ^VH0
described ^VL+EN+PRF++++ ^VVN
elsewhere ^R+++++LOC+ ^RL
&lsqb; ^Y+PAR+LEFT++++ ^(
5 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
same ^D++++PRO+A+ ^DA
guides ^N+CM+PLUR++++ ^NN2
can ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
applied ^VL+EN+PSV+AGLS+++ ^VVN
to ^I++++++ ^II
evaluation ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
therapeutic ^J++ATRB++++ ^JJ
interventions ^N+CM+PLUR+NOM+++ ^NN2
( ^Y+PAR+LEFT++++ ^(
directed ^VL+EN+++++ ^VVN
at ^I++++++ ^II
reducing ^VL+ING++COMP+PREP++ ^VVG
symptoms ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
curing ^VL+ING++COMP+PREP++ ^VVG
disease ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
preventive ^J++ATRB++++ ^JJ
interventions ^N+CM+PLUR+NOM+++ ^NN2
( ^Y+PAR+LEFT++++ ^(
directed ^VL+EN+++++ ^VVN
at ^I++++++ ^II
reducing ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
disease ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
disease ^N+CM+SING+++PMOD+ ^NN1
complications ^N+CM+PLUR+NOM+++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
framework ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
As ^C+SRD+++++ ^CSA
with ^I++++++ ^IW
articles ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
other ^D++ATRB++++ ^JJ
clinical ^J++ATRB++++ ^JJ
questions ^N+CM+PLUR+NOM+++ ^NN2
, ^Y+COM+++++ ^,
one ^M+CARD+SING+ONE+++ ^MC1
can ^VM+++++POS+ ^VM
usefully ^R++++SPLT++ ^RR
pose ^VL+INF+++++ ^VVI
three ^M+CARD+SING+MORE+++ ^MC
questions ^N+CM+PLUR+NOM+++ ^NN2
about ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
article ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Are ^VL+++COP+++ ^VBR
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
valid ^J++PRDV++++ ^JJ
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
This ^D+DEM+SING++++ ^DD1
question ^N+CM+SING+NOM+++ ^NN1
has ^VM+Z++++NEC+MULTI1 ^VHZ
to ^VM_++++++MULTI2 ^TO
do ^VL+ING+++++MULTI1 ^VDI
with ^I++PPVB++++MULTI2 ^IW
the ^DET+AT+SING+DEF+++ ^AT
validity ^N+CM+SING+NOM+++ ^NN1
or ^C+CRD+++++ ^CC
accuracy ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
considers ^VL+Z+++++ ^VVZ
whether ^C+SRD+WH+CLS+++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
reported ^VL+EN++CLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
represents ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
direction ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
magnitude ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Another ^D++SING++++ ^DD1
way ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
state ^VL+INF+++++ ^VVI
this ^D+DEM+SING++++ ^DD1
question ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
do ^VA+BF++++DO+ ^VD0
these ^D+DEM+PLUR++++ ^DD2
results ^N+CM+PLUR++++ ^NN2
represent ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
unbiased ^J+EN+ATRB++++ ^JJ
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
have ^VL+BF+++++ ^VH0
they ^P+PER+PLUR+3+S++ ^PPHS2
been ^VA+EN+PRF+++BE+ ^VBN
influenced ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
some ^D+AT+PLUR+INDEF+++ ^DD
systematic ^J++ATRB++++ ^JJ
fashion ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
lead ^VL+INF+++++ ^VVI
to ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
false ^J++ATRB++++ ^JJ
conclusion ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
What ^P++WH+QUE+++ ^DDQ
were ^VL+ED++COP+++ ^VBDR
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
valid ^J++ATRB++++ ^JJ
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
likely ^R++++++ ^RR
yields ^VL+Z+++++ ^VVZ
an ^D+AT+SING+INDEF+++ ^AT1
unbiased ^J+EN+ATRB++++ ^JJ
assessment ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
worth ^I++++++ ^II
examining ^VL+ING++COMP+PREP++ ^VVG
further ^R+++ER+++ ^RRR
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
second ^N+CM+SING+++PMOD+ ^NNT1
question ^N+CM+SING+NOM+++ ^NN1
considers ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
size ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
precision ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
's ^GE++++++ ^GE
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
best ^J++ATRB+EST+++ ^JJT
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
that ^D+DEM+SING++++ ^DD1
effect ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
findings ^N+ING+PLUR++++ ^NN2
themselves ^P+PER+PLUR+3+X++ ^PPX2
; ^Y+SCOL+CLP++++ ^;
the ^DET+AT+SING+DEF+++ ^AT
precision ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
estimate ^N+CM+SING+NOM+++ ^NN1
will ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
superior ^J++PRDV++++ ^JJ
in ^I++++++ ^II
larger ^J++ATRB+ER+++ ^JJR
studies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Will ^VM+++++PRDN+ ^VM
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
help ^VL+INF+++++ ^VVI
me ^P+PER+SING+1+O++ ^PPIO1
in ^I++++++ ^II
caring ^VL+ING++COMP+PREP++MULTI1 ^VVG
for ^I++PPVB++++MULTI2 ^IF
my ^D+PER+SING+1+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
This ^D+DEM+SING++++ ^DD1
question ^N+CM+SING+NOM+++ ^NN1
has ^VL+Z+++++ ^VHZ
two ^M+CARD+SING+MORE+++ ^MC
parts ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
First ^M+ORD+++++ ^MD
, ^Y+COM+++++ ^,
are ^VL+++COP+++ ^VBR
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
applicable ^J++PRDV++++ ^JJ
to ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
You ^P+PER++2+++ ^PPY
should ^VM+++++NEC+ ^VM
hesitate ^VL+INF+++++ ^VVI
to ^I++++++ ^II
institute ^N+CM+SING++++ ^NN1
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
if ^C+SRD++++CND+ ^CS
either ^C++DOUB++++ ^RR
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
too ^R+++++DEG+ ^RG
dissimlar ^J++PRDV++++ ^JJ
from ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
outcome ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
has ^VL+Z+++++ ^VHZ
been ^VA+EN+PRF+++BE+ ^VBN
improved ^VL+EN+PSV+AGLS+++ ^VVN
is ^VL+Z++COP+++ ^VBZ
n't ^XX++++CONT++ ^XX
important ^J++PRDV++++ ^JJ
to ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Second ^M+ORD+++++ ^MD
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
applicable ^J++PRDV++++ ^JJ
what ^P++WH+QUE+++ ^DDQ
is ^VL+Z++COP+++ ^VBZ
the ^DET+AT+SING+DEF+++ ^AT
net ^J++ATRB+++ONLY+ ^JJ
impact ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
? ^Y+QM+CLP++++ ^?
The ^DET+AT+SING+DEF+++ ^AT
impact ^N+CM+SING++++ ^NN1
depends ^VL+Z+++++ ^VVZ
both ^R++++++ ^RR
benefits ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
risks ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
side-effects ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
toxicity ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
consequences ^N+CM+PLUR+NOM+++ ^NN2
of ^I++++++ ^IO
withholding ^J+ING+ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Thus ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
even ^R++++++ ^RR
an ^D+AT+SING+INDEF+++ ^AT1
effective ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
might ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
withheld ^VL+EN+PSV+AGLS+++ ^VVN
when ^C+SRD+WH+CLS+++ ^CS
a ^D+AT+SING+INDEF+++ ^AT1
patient ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
prognosis ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
already ^R++++++ ^RR
good ^J++PRDV++++ ^JJ
without ^I++++++ ^IW
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
especially ^R++++++ ^RR
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
accompanied ^VL+EN+PSV+BY+++ ^VVN
by ^I++++++ ^II
important ^J++ATRB++++ ^JJ
side-effects ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
toxicity ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
We ^P+PER+PLUR+1+S++ ^PPIS2
summarize ^VL+BF+++++ ^VV0
our ^D+PER+PLUR+1+GEN++ ^APPGE
approach ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
evaluating ^VL+ING++COMP+PREP++ ^VVG
and ^C+CRD+PHRS++++ ^CC
applying ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
articles ^N+CM+PLUR++++ ^NN2
addressing ^VL+ING++REL+SUBJ++ ^VVG
therapeutic ^J++ATRB++++ ^JJ
effectiveness ^N+CM+PLUR+NOM+++ ^NN1
in ^I++++++ ^II
Table ^N+CM+SING++++ ^NN1
1 ^M+CARD+SING+ONE+++ ^MC1
. ^Y+PER+CLP++++ ^.
Housestaff ^VL+BF+++++ ^VV0
and ^C+CRD+++++ ^CC
practising ^J+ING+ATRB++++ ^JJ
physicians ^N+CM+PLUR+NOM+++ ^NN2
alike ^R++++++ ^RR
need ^VL+BF+++++ ^VV0
an ^D+AT+SING+INDEF+++ ^AT1
approach ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
is ^VL+Z++COP+++ ^VBZ
both ^R++++++ ^RR
efficient ^J++PRDV++++ ^JJ
and ^C+CRD+PHRS++++ ^CC
comprehensive ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
We ^P+PER+PLUR+1+S++ ^PPIS2
have ^VL+BF+++++ ^VH0
therefore ^R++++SPLT++ ^RR
labelled ^VL+EN+PRF++++ ^VVN
validity ^N+CM+SING+NOM++PMOD+ ^NN1
criteria ^N+CM+PLUR++++ ^NN2
as ^C+SRD+++++ ^CSA
" ^Y+QUO+++++ ^"
primary ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
-- ^N+CM+SING++++ ^NN1
those ^P+DEM+PLUR++++ ^DD2
few ^D++PLUR++PRO+A+ ^DA2
that ^C+SRD+THT+REL+++ ^CST
can ^VM+++++POS+ ^VM
quickly ^R++++SPLT++ ^RR
be ^VA+INF++++BE+ ^VBI
applied ^VL+EN+PSV+BY+++ ^VVN
by ^I++++++ ^II
readers ^N+CM+PLUR+NOM+++ ^NN2
with ^I++++++ ^IW
limited ^J+EN+ATRB++++ ^JJ
time ^N+CM+SING+++PMOD+ ^NNT1
-- ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
secondary ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
-- ^N+CM+SING++++ ^NN1
those ^P+DEM+PLUR++++ ^DD2
which ^D++WH++++ ^DDQ
, ^Y+COM+++++ ^,
though ^C+SRD++++CONC+ ^CS
still ^R++++++ ^RR
important ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
can ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
reserved ^VL+EN+PSV+AGLS+++ ^VVN
for ^I++++++ ^IF
articles ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
pass ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
initial ^J++ATRB++++ ^JJ
guides ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
for ^I++++++ ^IF
readers ^N+CM+PLUR+NOM+++ ^NN2
who ^P++WH++++ ^PNQS
have ^VL+BF+++++ ^VH0
both ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
need ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
time ^N+CM+SING+++TIME+ ^NNT1
for ^I++++++ ^IF
a ^D+AT+SING+INDEF+++ ^AT1
deeper ^J++ATRB+ER+++ ^JJR
review ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
III ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Will ^VM+++++PRDN+ ^VM
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
help ^VL+INF+++++ ^VVI
me ^P+PER+SING+1+O++ ^PPIO1
in ^I++++++ ^II
caring ^VL+ING++COMP+PREP++MULTI1 ^VVG
for ^I++PPVB++++MULTI2 ^IF
my ^D+PER+SING+1+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
? ^Y+QM+CLP++++ ^?
<h> ^FU++++++ ^NULL
Are ^VL+++COP+++ ^VBR
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
article ^N+CM+SING++++ ^NN1
valid ^J++PRDV++++ ^JJ
? ^Y+QM+CLP++++ ^?
<h> ^FU+++++PMOD+ ^NULL
A. ^ERROR+PR+SING++++ ^NP1
Primary ^J++ATRB++++ ^JJ
Guides ^N+CM+PLUR+++PMOD+ ^NN2
<h> ^FU++++++ ^NULL
1 ^M+CARD+SING+ONE+++ ^MC1
. ^Y+PER+CLP++++ ^.
Was ^VL+ED++COP+++ ^VBDZ
the ^DET+AT+SING+DEF+++ ^AT
assignment ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
randomized ^VL+ED+++++ ^VVD
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
During ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
1970s ^M+CARD+PLUR+MORE+++ ^MC2
and ^C+CRD+++++ ^CC
early ^J++ATRB++++ ^JJ
1980s ^M+CARD+PLUR+MORE+++ ^MC2
surgeons ^N+CM+PLUR++++ ^NN2
increasing ^VL+ING++REL+SUBJ++ ^VVG
undertook ^VL+ED+++++ ^VVD
bypass ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
anastomosis ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
branch ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
external ^J++ATRB++++ ^JJ
carotid ^J++ATRB++++ ^JJ
artery ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
superficial ^J++PRDV++++ ^JJ
temporal ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
to ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
branch ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
internal ^J++ATRB++++ ^JJ
carotid ^J++ATRB++++ ^JJ
artery ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
middle ^J++PRDV++++ ^JJ
cerebral ^J++PRDV++++ ^JJ
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
They ^P+PER+PLUR+3+S++ ^PPHS2
believed ^VL+ED++++THDEL+ ^VVD
it ^P+IM++3+++ ^PPH1
prevented ^VL+ED+++++ ^VVD
strokes ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
whose ^D++WH+REL+GEN++ ^DDQGE
symptomatic ^J++ATRB++++ ^JJ
cerebrovascular ^J++ATRB++++ ^JJ
disease ^N+CM+SING++++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
otherwise ^R++++++ ^RR
surgically ^R++++++ ^RR
inaccessible ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
conviction ^N+CM+SING+NOM+++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
based ^VL+EN+PSV+AGLS+++ ^VVN
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
comparison ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
clinical ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
among ^I++++++ ^II
non-randomized ^J+EN+ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
cohorts ^N+CM+PLUR++++ ^NN2
" ^Y+QUO+++++ ^"
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
, ^Y+COM+++++ ^,
for ^I++++++ ^IF
whatever ^P++WH+++EVER+ ^DDQV
reason ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
had ^VL+ED+++++ ^VHD
and ^C+CRD+PHRS++++ ^CC
had ^VL+ED+++++ ^VHD
not ^XX++++++ ^XX
undergone ^VL+EN+PRF++++ ^VVN
this ^D+DEM+SING++++ ^DD1
operation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
former ^D++++PRO+A+ ^DA
appeared ^VL+ED++COP+++ ^VVD
to ^TO+++COMP+VERB++ ^TO
fare ^VL+INF+++++ ^VVI
much ^R++++++ ^RR
better ^R+++ER+++ ^RRR
than ^C+SRD+++++ ^CSN
the ^DET+AT+SING+DEF+++ ^AT
latter ^D++++PRO+A+ ^DA
. ^Y+PER+CLP++++ ^.
To ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
surprise ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
many ^D++PLUR++PRO+A+ ^DA2
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
indignation ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
few ^D++PLUR++PRO+A+ ^DA2
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
large ^J++ATRB++++ ^JJ
multi-center ^N+CM+SING+NOM+++ ^NN1
randomized ^VL+ED+++++ ^VVD
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
patients ^N+CM+PLUR++++ ^NN2
were ^VA+ED++++BE+ ^VBDR
allocated ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
receive ^VL+INF+++++ ^VVI
or ^C+CRD+PHRS++++ ^CC
forego ^VL+INF+++++ ^VVI
this ^D+DEM+SING++++ ^DD1
operation ^N+CM+SING+NOM+++ ^NN1
using ^VL+ING++REL+SUBJ++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
process ^N+CM+PLUR+NOM+++ ^NN1
analogous ^J++PRDV++++ ^JJ
to ^I++++++ ^II
flipping ^VL+ING++COMP+PREP++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
coin ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
demonstrated ^VL+ED+++++ ^VVD
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
only ^J++ATRB++++ ^JJ
effect ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
surgery ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
to ^TO+++COMP+VERB++ ^TO
make ^VL+INF+++++ ^VVI
patients ^N+CM+PLUR++++ ^NN2
worse ^R+++ER+++ ^RRR
off ^R+PART+PHRV++++ ^RP
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
immediate ^J++ATRB++++ ^JJ
post-surgical ^J++ATRB++++ ^JJ
period ^N+CM+SING++++ ^NN1
; ^Y+SCOL+CLP++++ ^;
long-term ^J++ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
unaffected ^J+EN+PRDV++++ ^JJ
&lsqb; ^Y+PAR+LEFT++++ ^(
6 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Other ^D++ATRB++++ ^JJ
surprises ^N+CM+PLUR++++ ^NN2
generated ^VL+EN++CLS+++ ^VVN
by ^I++++++ ^II
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
contradicted ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
less ^R+++ER++DEG+ ^RGR
rigorous ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
include ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
demonstration ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
steroids ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
increase ^VL+INF+++++ ^VVI
( ^Y+PAR+LEFT++++ ^(
rather ^C+SRD+++++MULTI1 ^CS
than ^C_+SRD+++++MULTI2 ^CS
reduce ^VL+INF+++++ ^VVI
) ^Y+PAR+RIGHT++++ ^)
mortality ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
sepsis ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
7 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
that ^D+DEM+SING++++ ^DD1
steroid ^J++ATRB++++ ^JJ
injections ^N+CM+PLUR+NOM+++ ^NN2
do ^VA+BF++++DO+ ^VD0
not ^XX++++++ ^XX
ameliorate ^VL+INF+++++ ^VVI
facet-joint ^J++ATRB++++ ^JJ
back ^N+CM+SING+++PMOD+ ^NN1
pain ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
8 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
that ^D+DEM+SING++++ ^DD1
plasmapheresis ^N+CM+SING++++ ^NN1
does ^VA+Z++++DO+ ^VDZ
not ^XX++++++ ^XX
benefit ^VL+INF+++++ ^VVI
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
polymyositis ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
9 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Such ^D++++PRO+A+ ^DA
surprises ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
occur ^VL+INF+++++ ^VVI
when ^R++WH++++ ^RRQ
treatments ^N+CM+PLUR+NOM+++ ^NN2
are ^VA+++++BE+ ^VBR
assigned ^VL+EN+PSV+BY+++ ^VVN
by ^I++++++ ^II
random ^J++ATRB++++ ^JJ
allocation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
rather ^C+SRD+++++MULTI1 ^CS
than ^C_+SRD+++++MULTI2 ^CS
by ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
conscious ^J++ATRB++++ ^JJ
decisions ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
clinicians ^N+CM+PLUR+NOM+++ ^NN2
and ^C+CRD+++++ ^CC
patients ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
In ^R++++++MULTI1 ^RR
short ^R_++++++MULTI2 ^RR
, ^Y+COM+++++ ^,
clinical ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
result ^VL+BF+++++ ^VV0
from ^I++++++ ^II
many ^D++PLUR++PRO+A+ ^DA2
causes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
just ^R++++++ ^RR
one ^M+CARD+SING+ONE+++ ^MC1
of ^I++++++ ^IO
them ^P+PER+PLUR+3+O++ ^PPHO2
: ^Y+COL+CLP++++ ^:
underlying ^J+ING+ATRB++++ ^JJ
severity ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
illness ^N+CM+PLUR+NOM+++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
presence ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
comorbid ^J++ATRB++++ ^JJ
conditions ^N+CM+PLUR+NOM+++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
host ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
other ^D++ATRB++++ ^JJ
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
unknown ^J+EN+PRDV++++ ^JJ
as ^C+CRD+PHRS++++MULTI1 ^II
well ^C_+CRD+PHRS++++MULTI2 ^II
as ^C_+CRD+PHRS++++MULTI3 ^II
known ^J+EN+PRDV++++ ^JJ
) ^Y+PAR+RIGHT++++ ^)
often ^R++++++ ^RR
swamp ^VL+BF+++++ ^VV0
any ^D+AT+PLUR+INDEF+++ ^DD
effect ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Because ^C+SRD++++CAUS+ ^CS
these ^D+DEM+PLUR++++ ^DD2
other ^D++ATRB++++ ^JJ
features ^N+CM+PLUR++++ ^NN2
also ^R++++++ ^RR
influence ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
clinician ^N+CM+SING+NOM+++ ^NN1
's ^GE++++++ ^GE
decision ^N+CM+SING++++ ^NN1
to ^TO+++COMP+NOUN++ ^TO
offer ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
at ^I++++++ ^II
issue ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
nonrandomized ^VL+ED+++++ ^VVD
studies ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
efficacy ^N+CM+SING+NOM+++ ^NN1
are ^VA+++++BE+ ^VBR
inevitably ^R++++SPLT++ ^RR
limited ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
their ^D+PER+PLUR+3+GEN++ ^APPGE
ability ^N+CM+SING+NOM+++ ^NN1
to ^TO+++COMP+NOUN++ ^TO
distinguish ^VL+INF+++++ ^VVI
useful ^J++PRDV++++ ^JJ
from ^I++++++ ^II
useless ^J++ATRB++++ ^JJ
or ^C+CRD+++++ ^CC
even ^R++++++ ^RR
harmful ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
As ^C+SRD+++++ ^CSA
confirmation ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
fact ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
it ^P+IM++3+++ ^PPH1
turns ^VL+Z+++++MULTI1 ^VVZ
out ^R+PART+PHRV++++MULTI2 ^RP
that ^C+SRD+THT+REL+++ ^CST
studies ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
allocated ^VL+EN+PSV+BY+++ ^VVN
by ^I++++++ ^II
any ^D+AT+PLUR+INDEF+++ ^DD
method ^N+CM+SING++++ ^NN1
other ^D++SING++++MULTI1 ^II
than ^I++++++MULTI2 ^II
randomization ^N+CM+SING+NOM+++ ^NN1
tend ^VL+BF+++++ ^VV0
to ^TO+++COMP+VERB++ ^TO
show ^R+G+WH++++ ^VVI
larger ^J++ATRB+ER+++ ^JJR
( ^Y+PAR+LEFT++++ ^(
and ^C+CRD+++++ ^CC
frequently ^R++++++ ^RR
" ^Y+QUO+++++ ^"
false-positive ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
) ^Y+PAR+RIGHT++++ ^)
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effects ^N+CM+PLUR++++ ^NN2
than ^C+SRD+++++ ^CSN
do ^VL+BF+++++ ^VD0
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
&lsqb; ^Y+PAR+LEFT++++ ^(
10 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
11 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
12 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
13 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
beauty ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
randomization ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
that ^C+SRD+THT+COMP+VERB++ ^CST
it ^P+IM++3+++ ^PPH1
assures ^VL+Z+++++ ^VVZ
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
sample ^N+CM+SING+++PMOD+ ^NN1
size ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
sufficiently ^R++++++ ^RR
large ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
that ^C+SRD+THT+COMP+VERB++ ^CST
both ^D++DOUB+++B+ ^DB2
known ^VL+EN+++++ ^VVN
and ^C+CRD+++++ ^CC
unknown ^J+EN+ATRB++++ ^JJ
determinants ^N+CM+PLUR+NOM+++ ^NN2
of ^I++++++ ^IO
outcome ^N+CM+SING++++ ^NN1
are ^VA+++++BE+ ^VBR
evenly ^R++++SPLT++ ^RR
distributed ^VL+EN+PSV+AGLS+++ ^VVN
between ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
What ^P++WH+QUE+++ ^DDQ
can ^VM+++++POS+ ^VM
the ^DET+AT+SING+DEF+++ ^AT
clinician ^N+CM+SING+NOM+++ ^NN1
do ^VL+ING+++++ ^VDI
if ^C+SRD++++CND+ ^CS
no ^P+++INDEF+++MULTI1 ^PN1
one ^P_+++INDEF+++MULTI2 ^PN1
has ^VL+Z+++++ ^VHZ
done ^VL+EN+PRF++++ ^VDN
a ^D+AT+SING+INDEF+++ ^AT1
randomized ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
therapeutic ^J++ATRB++++ ^JJ
question ^N+CM+SING+NOM+++ ^NN1
she ^P+PER+SING+3+S++ ^PPHS1
faces ^VL+Z+++++ ^VVZ
? ^Y+QM+CLP++++ ^?
She ^P+PER+SING+3+S++ ^PPHS1
still ^R++++++ ^RR
has ^VM+Z++++NEC+MULTI1 ^VHZ
to ^VM_++++++MULTI2 ^TO
make ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
decision ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
so ^R++++++ ^RR
must ^VM+++++NEC+ ^VM
rely ^VL+INF+++++MULTI1 ^VVI
on ^I++PPVB++++MULTI2 ^II
weaker ^J++ATRB+ER+++ ^JJR
studies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
later ^J++ATRB+ER+++ ^JJR
article ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
devoted ^J+EN+PRDV++++ ^JJ
to ^I++++++ ^II
deciding ^VL+ING++COMP+PREP++ ^VVG
whether ^C+SRD+WH+CLS+++ ^CSW
a ^D+AT+SING+INDEF+++ ^AT1
therapy ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
an ^D+AT+SING+INDEF+++ ^AT1
exposure ^N+CM+SING++++ ^NN1
causes ^VL+Z+++++ ^VVZ
harm ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
a ^D+AT+SING+INDEF+++ ^AT1
situation ^N+CM+SING+NOM+++ ^NN1
when ^C+SRD+WH+CLS+++ ^CS
randomization ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
usually ^R++++++ ^RR
not ^XX++++++ ^XX
possible ^J++PRDV++++ ^JJ
) ^Y+PAR+RIGHT++++ ^)
we ^P+PER+PLUR+1+S++ ^PPIS2
deal ^VL+BF+++++ ^VV0
with ^I++++++ ^IW
how ^R+G+WH++SPLT++ ^RRQ
to ^TO++++++ ^TO
assess ^VL+INF+++++ ^VVI
weaker ^J++ATRB+ER+++ ^JJR
study ^N+CM+SING+++PMOD+ ^NN1
designs ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
For ^I++++++ ^IF
now ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
should ^VM+++++NEC+ ^VM
bear ^VL+INF+++++ ^VVI
in ^I++++++ ^II
mind ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
non-randomized ^J+EN+ATRB++++ ^JJ
studies ^N+CM+PLUR++++ ^NN2
provide ^VL+BF+++++ ^VV0
much ^R++++++ ^RR
weaker ^J++ATRB+ER+++ ^JJR
evidence ^N+CM+SING+NOM+++ ^NN1
than ^C+SRD+++++ ^CSN
do ^VL+BF+++++ ^VD0
randomized ^J+EN+ATRB++++ ^JJ
trials. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
2 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Were ^VL+ED++COP+++ ^VBDR
all ^D+++++B+ ^DB
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH+QUE+++ ^PNQS
entered ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
properly ^R++++++ ^RR
accounted ^VL+EN++CLS+++ ^VVN
for ^I++++++ ^IF
and ^C+CRD+++++ ^CC
attributed ^VL+EN++CLS+++ ^VVN
at ^I++++++ ^II
its ^D+IMPR++3+GEN++ ^APPGE
conclusion ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
This ^D+DEM+SING++++ ^DD1
guide ^N+CM+SING++++ ^NN1
has ^VL+Z+++++ ^VHZ
two ^M+CARD+SING+MORE+++ ^MC
components ^N+CM+PLUR++++ ^NN2
: ^Y+COL+CLP++++ ^:
was ^VL+ED++COP+++ ^VBDZ
followup ^N+CM+SING++++ ^NN1
complete ^VL+BF+++++ ^VV0
? ^Y+QM+CLP++++ ^?
and ^C+CRD++CLS+++ ^CC
, ^Y+COM+++++ ^,
were ^VL+ED++COP+++ ^VBDR
patients ^N+CM+PLUR++++ ^NN2
analyzed ^VL+ED+++++ ^VVD
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
groups ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
which ^D++WH+QUE+++ ^DDQ
they ^P+PER+PLUR+3+S++ ^PPHS2
were ^VA+ED++++BE+ ^VBDR
randomized ^VL+EN+PSV+AGLS+++ ^VVN
? ^Y+QM+CLP++++ ^?
<h> ^FU++++++ ^NULL
a ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
Was ^VL+ED++COP+++ ^VBDZ
followup ^N+CM+SING++++ ^NN1
complete ^VL+BF+++++ ^VV0
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
Every ^D+AT+SING+INDEF+++ ^AT1
patient ^N+CM+SING++++ ^NN1
who ^P++WH++++ ^PNQS
entered ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
should ^VM+++++NEC+ ^VM
be ^VA+INF++++BE+ ^VBI
accounted ^VL+EN+PSV+AGLS+++ ^VVN
for ^I++++++ ^IF
at ^I++++++ ^II
its ^D+IMPR++3+GEN++ ^APPGE
conclusion ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
this ^P+DEM+SING++++ ^DD1
is ^VA+Z++++BE+ ^VBZ
not ^XX++++++ ^XX
done ^VL+EN+PSV+AGLS+++ ^VDN
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
substantial ^J++ATRB++++ ^JJ
numbers ^N+CM+PLUR+NOM+++ ^NN2
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
are ^VA+++++BE+ ^VBR
reported ^VL+EN+PSV+AGLS+++ ^VVN
as ^C+SRD+++++ ^CSA
" ^Y+QUO+++++ ^"
lost ^VL+EN+++++ ^VVN
to ^TO++++++ ^TO
followup ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
the ^DET+AT+SING+DEF+++ ^AT
validity ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
open ^J++PRDV++++ ^JJ
to ^I++++++ ^II
question ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
greater ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
subjects ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
are ^VA+++++BE+ ^VBR
lost ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
more ^R+++ER+++ ^RRR
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
subject ^I++++++MULTI1 ^II
to ^I_++++++MULTI2 ^II
bias ^N+CM+SING++++ ^NN1
because ^C+SRD++++CAUS+ ^CS
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
are ^VA+++++BE+ ^VBR
lost ^VL+EN+PSV+AGLS+++ ^VVN
often ^R++++++ ^RR
have ^VL+BF+++++ ^VH0
different ^J++ATRB++++ ^JJ
prognoses ^N+CM+PLUR++++ ^NN2
from ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
are ^VA+++++BE+ ^VBR
retained ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
and ^C+CRD+PHRS++++ ^CC
may ^VM+++++POS+ ^VM
disappear ^VL+INF+++++ ^VVI
because ^C+SRD++++CAUS+ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
suffer ^VL+BF+++++ ^VV0
adverse ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
even ^R++++++ ^RR
death ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
or ^C+CRD+++++ ^CC
because ^C+SRD++++CAUS+ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
are ^VA+++++BE+ ^VBR
doing ^VL+ING+PRG++++ ^VDG
well ^R++++++ ^RR
( ^Y+PAR+LEFT++++ ^(
and ^C+CRD+++++ ^CC
so ^R++++++ ^RR
did ^VA+ED++++DO+ ^VDD
not ^XX++++++ ^XX
return ^VL+INF+++++ ^VVI
to ^I++++++ ^II
clinic ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
be ^VA+INF++++BE+ ^VBI
assessed ^VL+EN+PSV+AGLS+++ ^VVN
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Readers ^N+CM+PLUR+NOM+++ ^NN2
can ^VM+++++POS+ ^VM
decide ^VL+INF+++++ ^VVI
for ^I++++++ ^IF
themselves ^P+PER+PLUR+3+X++ ^PPX2
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
loss ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
follow-up ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
excessive ^J++PRDV++++ ^JJ
by ^I++++++ ^II
assuming ^VL+ING++COMP+PREP++ ^VVG
, ^Y+COM+++++ ^,
in ^I++++++ ^II
positive ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
that ^C+SRD+THT+COMP+VERB++ ^CST
all ^D+++++B+ ^DB
patients ^N+CM+PLUR++++ ^NN2
lost ^VL+EN++CLS+++ ^VVN
from ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
did ^VL+ED+++++ ^VDD
badly ^R++++++ ^RR
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
all ^D+++++B+ ^DB
lost ^VL+EN++CLS+++ ^VVN
from ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
did ^VL+ED+++++ ^VDD
well ^R++++++ ^RR
, ^Y+COM+++++ ^,
and ^C+CRD+PHRS+CLS+++ ^CC
then ^R+++++TIME+ ^RT
recalculating ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
outcomes ^N+CM+PLUR++++ ^NN2
under ^I++++++ ^II
these ^D+DEM+PLUR++++ ^DD2
assumptions ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
conclusions ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
do ^VA+BF++++DO+ ^VD0
not ^XX++++++ ^XX
change ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
loss ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
follow-up ^N+CM+SING++++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
not ^XX++++++ ^XX
excessive ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
conclusions ^N+CM+PLUR++++ ^NN2
would ^VM+++++PRDN+ ^VM
change ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
strength ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
inference ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
weakened ^VL+EN+PSV+AGLS+++ ^VVN
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
less ^D+++ER+PRO+A+ ^DAR
confidence ^N+CM+SING+NOM+++ ^NN1
can ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
placed ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
results ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
extent ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
which ^D++WH+QUE+++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
inference ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
weakened ^VL+EN+PSV+AGLS+++ ^VVN
will ^VM+++++PRDN+ ^VM
depend ^VL+INF+++++ ^VVI
on ^I++++++ ^II
how ^R+G+WH+QUE+++ ^RGQ
likely ^R++++++ ^RR
it ^P+IM++3+++ ^PPH1
is ^VL+Z++COP+++ ^VBZ
that ^D+DEM+SING++++ ^DD1
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
lost ^VL+ED+++++ ^VVD
to ^TO++++++ ^TO
followup ^VL+INF+++++ ^VVI
all ^D+++++B+ ^DB
did ^VL+ED+++++ ^VDD
badly ^R++++++ ^RR
, ^Y+COM+++++ ^,
while ^C+SRD++++CONC+ ^CS
control ^N+CM+SING+++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
lost ^VL+ED+++++ ^VVD
to ^TO++++++ ^TO
followup ^VL+INF+++++ ^VVI
all ^D+++++B+ ^DB
did ^VL+ED+++++ ^VDD
well. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
b ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
Were ^VL+ED++COP+++ ^VBDR
patients ^N+CM+PLUR++++ ^NN2
analyzed ^VL+ED+++++ ^VVD
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
groups ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
which ^D++WH+QUE+++ ^DDQ
they ^P+PER+PLUR+3+S++ ^PPHS2
were ^VA+ED++++BE+ ^VBDR
randomized ^VL+EN+PSV+AGLS+++ ^VVN
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
As ^C+SRD+++++ ^CSA
in ^I++++++ ^II
routine ^N+CM+SING+++PMOD+ ^NN1
practice ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
patients ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
sometimes ^R+++++TIME+ ^RT
forget ^VL+BF+++++ ^VV0
to ^TO+++COMP+VERB++ ^TO
take ^VL+INF+++++ ^VVI
their ^D+PER+PLUR+3+GEN++ ^APPGE
medicine ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
even ^R++++++ ^RR
refuse ^VL+BF+++++ ^VV0
their ^D+PER+PLUR+3+GEN++ ^APPGE
treatment ^N+CM+SING+NOM+++ ^NN1
altogether ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
Readers ^N+CM+PLUR+NOM+++ ^NN2
might ^VM+++++POS+ ^VM
, ^Y+COM+++++ ^,
on ^I++++++ ^II
first ^M+ORD+++++ ^MD
blush ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
agree ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
such ^D++++PRO+A+ ^DA
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
never ^R++++++ ^RR
actually ^R++++++ ^RR
received ^VL+ED+++++ ^VVD
their ^D+PER+PLUR+3+GEN++ ^APPGE
assigned ^J+EN+ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
should ^VM+++++NEC+ ^VM
be ^VA+INF++++BE+ ^VBI
excluded ^VL+EN+PSV+AGLS+++ ^VVN
from ^I++++++ ^II
analyses ^N+CM+PLUR++++ ^NN2
for ^I++++++ ^IF
efficacy ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Not ^XX++++++ ^XX
so ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
reasons ^N+CM+PLUR+++PMOD+ ^NN2
people ^N+CM+NEUT++++ ^NN
do ^VA+BF++++DO+ ^VD0
n't ^XX++++CONT++ ^XX
take ^VL+INF+++++ ^VVI
their ^D+PER+PLUR+3+GEN++ ^APPGE
medication ^N+CM+SING+NOM+++ ^NN1
are ^VA+++++BE+ ^VBR
often ^R++++SPLT++ ^RR
related ^VL+EN+PSV+AGLS+++ ^VVN
to ^I++++++ ^II
prognosis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
non-compliant ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
fared ^VL+EN+PRF++++ ^VVN
worse ^R+++ER+++ ^RRR
than ^C+SRD+++++ ^CSN
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
took ^VL+ED+++++ ^VVD
their ^D+PER+PLUR+3+GEN++ ^APPGE
medication ^N+CM+SING+NOM+++ ^NN1
as ^C+SRD+++++ ^CSA
instructed ^VL+EN++CLS+ADVL++ ^VVN
, ^Y+COM+++++ ^,
even ^R++++++ ^RR
after ^I++++++ ^II
taking ^VL+ING++COMP+PREP++ ^VVG
into ^I++++++ ^II
account ^N+CM+SING++++ ^NN1
all ^R++++++ ^RR
known ^VL+EN++CLS+++ ^VVN
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
even ^C+SRD+++++MULTI1 ^CS
when ^C_+SRD+WH+CLS+++MULTI2 ^CS
their ^D+PER+PLUR+3+GEN++ ^APPGE
medications ^N+CM+PLUR+NOM+++ ^NN2
were ^VL+ED++COP+++ ^VBDR
placebos ^N+CM+PLUR++++ ^NN2
! ^Y+EXCL+CLP++++ ^!
&lsqb; ^Y+PAR+LEFT++++ ^(
14 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
15 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
16 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
17 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
18 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
19 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
Excluding ^I++++++ ^II
non-compliant ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
from ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
analysis ^N+CM+SING++++ ^NN1
leaves ^VL+Z+++++ ^VVZ
behind ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
may ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
destined ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
have ^VL+INF+++++ ^VHI
a ^D+AT+SING+INDEF+++ ^AT1
better ^J++ATRB+ER+++ ^JJR
outcome ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
destroys ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
unbiased ^J+EN+ATRB++++ ^JJ
comparison ^N+CM+SING++++ ^NN1
provided ^VL+EN++CLS+++ ^VVN
by ^I++++++ ^II
randomization ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
situation ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
similar ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
surgical ^J++ATRB++++ ^JJ
therapies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Some ^D+AT+PLUR+INDEF+++ ^DD
patients ^N+CM+PLUR++++ ^NN2
randomized ^VL+ED+++++ ^VVD
to ^I++++++ ^II
surgery ^N+CM+SING+NOM+++ ^NN1
never ^R++++++ ^RR
have ^VL+BF+++++ ^VH0
the ^DET+AT+SING+DEF+++ ^AT
operation ^N+CM+SING+NOM+++ ^NN1
because ^C+SRD++++CAUS+ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
are ^VL+++COP+++ ^VBR
too ^R+++++DEG+ ^RG
sick ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
suffer ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
outcome ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
interest ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
stroke ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
before ^C+SRD+++++ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
get ^VL+BF+++++MULTI1 ^VV0
to ^I++PPVB++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
operating ^N+ING+SING+++PMOD+ ^NN1
room ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
investigators ^N+CM+PLUR++++ ^NN2
include ^VL+BF+++++ ^VV0
such ^D++++PRO+A+ ^DA
patients ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
who ^P++WH+REL+SUB++ ^PNQS
are ^VA+++++BE+ ^VBR
destined ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
do ^VL+ING+++++ ^VDI
badly ^R++++++ ^RR
, ^Y+COM+++++ ^,
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
arm ^N+CM+SING++++ ^NN1
but ^C+CRD++++ADVS+ ^CCB
not ^XX++++++ ^XX
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
surgical ^J++ATRB++++ ^JJ
arm ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
even ^R++++++ ^RR
a ^D+AT+SING+INDEF+++ ^AT1
useless ^J++ATRB++++ ^JJ
surgical ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
appear ^VL+INF++COP+++ ^VVI
to ^TO+++COMP+VERB++ ^TO
be ^VL+INF++COP+++ ^VBI
effective ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
However ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
apparent ^J++ATRB++++ ^JJ
effectiveness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
surgery ^N+CM+SING+NOM+++ ^NN1
will ^VM+++++PRDN+ ^VM
come ^VL+INF+++++ ^VVI
not ^XX++++++ ^XX
from ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
benefit ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
have ^VL+BF+++++ ^VH0
surgery ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
the ^DET+AT+SING+DEF+++ ^AT
systematic ^J++ATRB++++ ^JJ
exclusion ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
those ^P+DEM+PLUR++++ ^DD2
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
poorest ^J++ATRB+EST+++ ^JJT
prognosis ^N+CM+SING++++ ^NN1
from ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
surgical ^J++ATRB++++ ^JJ
group ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
This ^D+DEM+SING++++ ^DD1
principle ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
attributing ^VL+ING++COMP+PREP++ ^VVG
all ^D+++++B+ ^DB
patients ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
group ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
which ^D++WH++++ ^DDQ
they ^P+PER+PLUR+3+S++ ^PPHS2
were ^VL+ED++COP+++ ^VBDR
randomized ^J+EN+ATRB++++ ^JJ
results ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
intention-to-treat ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
analysis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
strategy ^N+CM+SING++++ ^NN1
preserves ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
value ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
randomization ^N+CM+SING+NOM+++ ^NN1
: ^Y+COL+CLP++++ ^:
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
we ^P+PER+PLUR+1+S++ ^PPIS2
know ^VL+BF+++++ ^VV0
about ^I+STRN+++++ ^II
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
those ^P+DEM+PLUR++++ ^DD2
we ^P+PER+PLUR+1+S++ ^PPIS2
do ^VA+BF++++DO+ ^VD0
n't ^XX++++CONT++ ^XX
know ^VL+INF+++++ ^VVI
about ^I+STRN+++++ ^II
, ^Y+COM+++++ ^,
will ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
, ^Y+COM+++++ ^,
on ^I++++++ ^II
average ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
equally ^R+CJ+++++ ^RR
distributed ^VL+EN++CLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
two ^M+CARD+SING+MORE+++ ^MC
groups ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
we ^P+PER+PLUR+1+S++ ^PPIS2
see ^VL+BF+++++ ^VV0
will ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
just ^R++++++ ^RR
that ^C+SRD+THT+COMP+VERB++ ^CST
due ^I++++++MULTI1 ^II
to ^I_++++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
assigned ^VL+EN++CLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
B. ^ERROR+PR+SING++++ ^NP1
Secondary ^J++ATRB++++ ^JJ
Guides ^N+CM+PLUR+++PMOD+ ^NN2
<p> ^FU++++++ ^NULL
Patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
know ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
they ^P+PER+PLUR+3+S++ ^PPHS2
are ^VL+++COP+++ ^VBR
on ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
new ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
experimental ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
are ^VL+++COP+++ ^VBR
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
have ^VL+INF+++++ ^VHI
an ^D+AT+SING+INDEF+++ ^AT1
opinion ^N+CM+SING++++ ^NN1
about ^I++++++ ^II
its ^D+IMPR++3+GEN++ ^APPGE
efficacy ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
as ^C+SRD+++++ ^CSA
are ^VL+++COP+++ ^VBR
their ^D+PER+PLUR+3+GEN++ ^APPGE
clinicians ^N+CM+PLUR+NOM+++ ^NN2
or ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
study ^N+CM+SING+++PMOD+ ^NN1
personnel ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
are ^VA+++++BE+ ^VBR
measuring ^VL+ING+PRG++++ ^VVG
responses ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
These ^D+DEM+PLUR++++ ^DD2
opinions ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
whether ^C+SRD+WH+REL+OBJ++ ^CSW
optimistic ^J++PRDV++++ ^JJ
or ^C+CRD+PHRS++++ ^CC
pessimistic ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
can ^VM+++++POS+ ^VM
systematically ^R++++SPLT++ ^RR
distort ^VL+INF+++++ ^VVI
both ^D++DOUB+++B+ ^DB2
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
aspects ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
reporting ^N+ING+SING++++ ^NN1
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
outcomes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
thereby ^R++++++ ^RR
reducing ^VL+ING++REL+SUBJ++ ^VVG
our ^D+PER+PLUR+1+GEN++ ^APPGE
confidence ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
results ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
In ^R++++++MULTI1 ^RR
addition ^R_++++++MULTI2 ^RR
, ^Y+COM+++++ ^,
unblinded ^J+EN+ATRB++++ ^JJ
study ^N+CM+SING+++PMOD+ ^NN1
personnel ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
are ^VA+++++BE+ ^VBR
measuring ^VL+ING+PRG++++ ^VVG
outcomes ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
provide ^VL+INF+++++ ^VVI
different ^J++ATRB++++ ^JJ
interpretations ^N+CM+PLUR+NOM+++ ^NN2
of ^I++++++ ^IO
marginal ^J++ATRB++++ ^JJ
findings ^N+ING+PLUR++++ ^NN2
or ^C+CRD+++++ ^CC
differential ^J++ATRB++++ ^JJ
encouragement ^N+CM+SING+NOM+++ ^NN1
during ^I++++++ ^II
performance ^N+CM+SING+NOM++PMOD+ ^NN1
tests ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
either ^C++DOUB++++ ^RR
one ^M+CARD+SING+ONE+++ ^MC1
of ^I++++++ ^IO
which ^D++WH++++ ^DDQ
can ^VM+++++POS+ ^VM
distort ^VL+INF+++++ ^VVI
their ^D+PER+PLUR+3+GEN++ ^APPGE
results ^N+CM+PLUR++++ ^NN2
&lsqb; ^Y+PAR+LEFT++++ ^(
20 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
best ^J++ATRB+EST+++ ^JJT
way ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
avoiding ^VL+ING++COMP+PREP++ ^VVG
all ^D+++++B+ ^DB
this ^D+DEM+SING++++ ^DD1
bias ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
double-blinding ^J+ING+PRDV++++ ^JJ
( ^Y+PAR+LEFT++++ ^(
sometimes ^R+++++TIME+ ^RT
referred ^VL+EN+++++ ^VVN
to ^I++++++ ^II
as ^R+++++DEG+ ^RG
double-masking ^J+ING+PRDV++++ ^JJ
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
which ^D++WH++++ ^DDQ
is ^VA+Z++++BE+ ^VBZ
achieved ^VL+EN+PSV+BY+++ ^VVN
in ^I++++++ ^II
drug ^N+CM+SING+++PMOD+ ^NN1
trials ^N+CM+PLUR++++ ^NN2
by ^I++++++ ^II
administering ^VL+ING++COMP+PREP++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
placebo ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
indistinguishable ^J++PRDV++++ ^JJ
from ^I++++++ ^II
active ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
appearance ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
taste ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
texture ^N+CM+SING++++ ^NN1
but ^C+CRD++++ADVS+ ^CCB
lacking ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
putative ^J++ATRB++++ ^JJ
active ^J++ATRB++++ ^JJ
ingredient ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
you ^P+PER++2+++ ^PPY
read ^VL+BF+++++ ^VV0
reports ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
treatments ^N+CM+PLUR+NOM+++ ^NN2
( ^Y+PAR+LEFT++++ ^(
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
trials ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
surgical ^J++ATRB++++ ^JJ
therapies ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
patients ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
treating ^VL+ING++COMP+VERB++ ^VVG
clinicians ^N+CM+PLUR+NOM+++ ^NN2
can ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
be ^VA+INF++++BE+ ^VBI
kept ^VL+EN+PSV+AGLS+++ ^VVN
blind ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
should ^VM+++++NEC+ ^VM
note ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
investigators ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
minimized ^VL+EN+PRF++++ ^VVN
bias ^N+CM+SING++++ ^NN1
by ^I++++++ ^II
blinding ^VL+ING++COMP+PREP++ ^VVG
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
assess ^VL+BF+++++ ^VV0
clinical ^J++ATRB++++ ^JJ
outcomes. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
4 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Were ^VL+ED++COP+++ ^VBDR
the ^DET+AT+SING+DEF+++ ^AT
groups ^N+CM+PLUR++++ ^NN2
similar ^J++PRDV++++ ^JJ
at ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
start ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
For ^I++++++ ^IF
reassurance ^N+CM+SING+NOM+++ ^NN1
about ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
study ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
validity ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
readers ^N+CM+PLUR+NOM+++ ^NN2
would ^VM+++++PRDN+ ^VM
like ^VL+INF+++++ ^VVI
to ^TO+++COMP+VERB++ ^TO
be ^VA+INF++++BE+ ^VBI
informed ^VL+EN+PSV+AGLS+++ ^VVN
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
were ^VL+ED++COP+++ ^VBDR
similar ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
all ^D+++++B+ ^DB
the ^DET+AT+SING+DEF+++ ^AT
factors ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
determine ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
clinical ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
interest ^N+CM+SING++++ ^NN1
save ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
: ^Y+COL+CLP++++ ^:
whether ^C+SRD+WH++++ ^CSW
they ^P+PER+PLUR+3+S++ ^PPHS2
received ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
experimental ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Investigators ^N+CM+PLUR++++ ^NN2
provide ^VL+BF+++++ ^VV0
this ^D+DEM+SING++++ ^DD1
reassurance ^N+CM+SING+NOM+++ ^NN1
when ^C+SRD+WH+CLS+++ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
display ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
" ^Y+QUO+++++ ^"
entry ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
or ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
baseline ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
prognostic ^J++ATRB++++ ^JJ
features ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Although ^C+SRD++++CONC+ ^CS
we ^P+PER+PLUR+1+S++ ^PPIS2
never ^R++++++ ^RR
will ^VM+++++PRDN+ ^VM
know ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
similarity ^N+CM+SING+NOM+++ ^NN1
exists ^VL+Z+++++ ^VVZ
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
unknown ^J+EN+ATRB++++ ^JJ
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
are ^VA+++++BE+ ^VBR
reassured ^VL+EN+PSV+AGLS+++ ^VVN
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
known ^J+EN+ATRB++++ ^JJ
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
are ^VA+++++BE+ ^VBR
nicely ^R++++SPLT++ ^RR
balanced ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
Randomization ^N+CM+SING+NOM+++ ^NN1
does ^VA+Z++++DO+ ^VDZ
n't ^XX++++CONT++ ^XX
always ^R++++SPLT++ ^RR
produce ^VL+INF+++++ ^VVI
groups ^N+CM+PLUR++++ ^NN2
balanced ^VL+EN++CLS+++ ^VVN
for ^I++++++ ^IF
known ^J+EN+ATRB++++ ^JJ
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
groups ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
small ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
chance ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
place ^VL+INF+++++ ^VVI
those ^P+DEM+PLUR++++ ^DD2
with ^I++++++ ^IW
apparently ^R++++++ ^RR
better ^J++ATRB+ER+++ ^JJR
prognoses ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
group ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
As ^C+SRD+++++ ^CSA
sample ^N+CM+SING+++PMOD+ ^NN1
size ^N+CM+SING+++PMOD+ ^NN1
increases ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
this ^P+DEM+SING++++ ^DD1
is ^VL+Z++COP+++ ^VBZ
less ^R+++ER++DEG+ ^RGR
and ^C+CRD+PHRS++++ ^CC
less ^R+++ER++DEG+ ^RGR
likely ^J++PRDV++++ ^JJ
( ^Y+PAR+LEFT++++ ^(
this ^P+DEM+SING++++ ^DD1
is ^VL+Z++COP+++ ^VBZ
analogous ^J++PRDV++++ ^JJ
to ^I++++++ ^II
multiple ^J++ATRB++++ ^JJ
coin ^N+CM+SING++++ ^NN1
flips ^VL+Z+++++ ^VVZ
: ^Y+COL+CLP++++ ^:
one ^P+++INDEF+++ ^PN1
would ^VM+++++PRDN+ ^VM
n't ^XX++++CONT++ ^XX
be ^VL+INF++COP+++ ^VBI
too ^R+++++DEG+ ^RG
surprised ^J+EN+PRDV++++ ^JJ
to ^TO++++++ ^TO
see ^VL+INF+++++ ^VVI
seven ^M+CARD+SING+MORE+++ ^MC
heads ^N+CM+PLUR++++ ^NN2
out ^I++++++MULTI1 ^II
of ^I_++++++MULTI2 ^II
ten ^M+CARD+SING+MORE+++ ^MC
coin ^N+CM+SING++++ ^NN1
flips ^VL+Z+++++ ^VVZ
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
one ^P+++INDEF+++ ^PN1
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
very ^R+++++DEG+ ^RG
surprised ^J+EN+PRDV++++ ^JJ
to ^TO++++++ ^TO
see ^VL+INF+++++ ^VVI
seventy ^M+CARD+SING+MORE+++ ^MC
heads ^N+CM+PLUR++++ ^NN2
out ^I++++++MULTI1 ^II
of ^I_++++++MULTI2 ^II
one ^M+CARD+SING+ONE+++ ^MC1
hundred ^M+CARD+SING+MORE++PMOD+ ^NNO
coin ^N+CM+SING++++ ^NN1
flips ^VL+Z+++++ ^VVZ
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
issue ^N+CM+SING++++ ^NN1
here ^R+++++LOC+ ^RL
is ^VL+Z++COP+++ ^VBZ
not ^XX++++++ ^XX
whether ^C+SRD+WH++++ ^CSW
there ^P+EX+++++ ^EX
are ^VL+++COP+++ ^VBR
statistically ^R++++++ ^RR
significant ^J++ATRB++++ ^JJ
differences ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++ ^II
known ^J+EN+ATRB++++ ^JJ
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
between ^I++++++ ^II
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
randomized ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
one ^P+++INDEF+++ ^PN1
knows ^VL+Z+++++ ^VVZ
in ^I++++++ ^II
advance ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
any ^D+AT+PLUR+INDEF+++ ^DD
differences ^N+CM+PLUR+NOM+++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
did ^VA+ED++++DO+ ^VDD
occur ^VL+INF+++++ ^VVI
happened ^VL+EN+++++ ^VVN
by ^I++++++ ^II
chance ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
but ^C+CRD++++ADVS+ ^CCB
rather ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
magnitude ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
these ^D+DEM+PLUR++++ ^DD2
differences ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
are ^VL+++COP+++ ^VBR
large ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
validity ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
compromised ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
stronger ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
relationship ^N+CM+SING+NOM+++ ^NN1
between ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
prognostic ^J++ATRB++++ ^JJ
factors ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
outcome ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
smaller ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
more ^R+++ER+++ ^RRR
the ^DET+AT+SING+DEF+++ ^AT
differences ^N+CM+PLUR+NOM+++ ^NN2
between ^I++++++ ^II
groups ^N+CM+PLUR++++ ^NN2
will ^VM+++++PRDN+ ^VM
weaken ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
strength ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
any ^D+AT+PLUR+INDEF+++ ^DD
inference ^N+CM+SING+NOM+++ ^NN1
about ^I++++++ ^II
efficacy ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
All ^D+++++B+ ^DB
is ^VA+Z++++BE+ ^VBZ
not ^XX++++++ ^XX
lost ^VL+EN+PSV+AGLS+++ ^VVN
if ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
not ^XX++++++ ^XX
similar ^J++PRDV++++ ^JJ
at ^I++++++ ^II
baseline ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Statistical ^J++ATRB++++ ^JJ
techniques ^N+CM+PLUR++++ ^NN2
permit ^VL+BF+++++ ^VV0
adjustment ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
result ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
baseline ^N+CM+SING+++PMOD+ ^NN1
differences ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
Accordingly ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
readers ^N+CM+PLUR+NOM+++ ^NN2
should ^VM+++++NEC+ ^VM
look ^VL+INF+++++MULTI1 ^VVI
for ^I++PPVB++++MULTI2 ^IF
documentation ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
similarity ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
relevant ^J++ATRB++++ ^JJ
baseline ^N+CM+SING+++PMOD+ ^NN1
characteristics ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
substantial ^J++ATRB++++ ^JJ
differences ^N+CM+PLUR+NOM+++ ^NN2
exist ^VL+BF+++++ ^VV0
should ^VM+++++NEC+ ^VM
note ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
investigators ^N+CM+PLUR++++ ^NN2
conducted ^VL+ED+++++ ^VVD
an ^D+AT+SING+INDEF+++ ^AT1
analysis ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
adjusted ^VL+ED+++++ ^VVD
for ^I++++++ ^IF
those ^D+DEM+PLUR++++ ^DD2
differences ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
both ^D++DOUB+++B+ ^DB2
unadjusted ^J+EN+ATRB++++ ^JJ
and ^C+CRD+PHRS++++ ^CC
adjusted ^J+EN+ATRB++++ ^JJ
analyses ^N+CM+PLUR++++ ^NN2
reach ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
same ^D++++PRO+A+ ^DA
conclusion ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
readers ^N+CM+PLUR+NOM+++ ^NN2
justifiably ^R++++++ ^RR
gain ^VL+BF+++++ ^VV0
confidence ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
validity ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
result. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
5 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Aside ^I++++++MULTI1 ^II
from ^I_++++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
experimental ^J++ATRB++++ ^JJ
intervention ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
were ^VL+ED++COP+++ ^VBDR
the ^DET+AT+SING+DEF+++ ^AT
groups ^N+CM+PLUR++++ ^NN2
treated ^VL+EN++CLS+++ ^VVN
equally ^R++++++ ^RR
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
Care ^VL+BF+++++ ^VV0
for ^I++++++ ^IF
experimental ^J++ATRB++++ ^JJ
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
can ^VM+++++POS+ ^VM
differ ^VL+INF+++++ ^VVI
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
ways ^N+CM+PLUR++++ ^NN2
besides ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
test ^N+CM+SING+++PMOD+ ^NN1
therapy ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
differences ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++ ^II
care ^N+CM+SING++++ ^NN1
other ^D++SING++++MULTI1 ^II
than ^I++++++MULTI2 ^II
that ^P+DEM+SING++++ ^DD1
under ^I++++++ ^II
study ^N+CM+SING++++ ^NN1
can ^VM+++++POS+ ^VM
weaken ^VL+INF+++++ ^VVI
distort ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
one ^M+CARD+SING+ONE+++ ^MC1
group ^N+CM+SING++++ ^NN1
received ^VL+ED+++++ ^VVD
closer ^J++ATRB+ER+++ ^JJR
followup ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
events ^N+CM+PLUR++++ ^NN2
might ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
more ^R+++ER++DEG+ ^RGR
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
be ^VA+INF++++BE+ ^VBI
reported ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
patients ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
treated ^VL+EN+PSV+AGLS+++ ^VVN
more ^R+++ER++DEG+ ^RGR
intensively ^R++++++ ^RR
with ^I++++++ ^IW
non-study ^J++ATRB++++ ^JJ
therapies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
For ^R+++++APP+MULTI1 ^REX
example ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
in ^I++++++ ^II
trials ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
new ^J++ATRB++++ ^JJ
forms ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
therapy ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
resistant ^J++ATRB++++ ^JJ
rheumatoid ^J++ATRB++++ ^JJ
arthritis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
ancillary ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
with ^I++++++ ^IW
systemic ^J++ATRB++++ ^JJ
steroids ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
extremely ^R++++++ ^RR
effective ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
relieving ^J+ING+ATRB++++ ^JJ
symptoms ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+SUB+CND+ ^CS
administered ^VL+EN++CLS+ADVL++ ^VVN
more ^R+++ER++DEG+ ^RGR
frequently ^R++++++ ^RR
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
than ^C+SRD+++++ ^CSN
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
could ^VM+++++POS+ ^VM
obscure ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
experimental ^J++ATRB++++ ^JJ
drug ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
true ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
unless ^C+SRD++++CND+ ^CS
exacerbation ^N+CM+SING+NOM+++ ^NN1
requiring ^VL+ING++REL+SUBJ+THDEL+ ^VVG
steroids ^N+CM+PLUR++++ ^NN2
were ^VL+ED++COP+++ ^VBDR
itself ^P+IMPR+SING+3+X++ ^PPX1
counted ^VL+EN++CLS+++ ^VVN
as ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
outcome ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Interventions ^N+CM+PLUR+NOM+++ ^NN2
other ^D++SING++++MULTI1 ^II
than ^I++++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
under ^I++++++ ^II
study ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
when ^C+SRD+WH+CLS+++ ^CS
differentially ^R++++++ ^RR
applied ^VL+EN++CLS+ADVL++ ^VVN
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
often ^R++++++ ^RR
are ^VA+++++BE+ ^VBR
called ^VL+EN+PSV+AGLS+++ ^VVN
" ^Y+QUO+++++ ^"
cointerventions ^N+CM+PLUR+NOM+++ ^NN2
" ^Y+QUO+++++ ^"
. ^Y+PER+CLP++++ ^.
Cointervention ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
a ^D+AT+SING+INDEF+++ ^AT1
more ^R+++ER++DEG+ ^RGR
serious ^J++ATRB++++ ^JJ
problem ^N+CM+SING++++ ^NN1
when ^C+SRD+WH+CLS+++ ^CS
double-blinding ^N+ING+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
absent ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
use ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
very ^R+++++DEG+ ^RG
effective ^J++ATRB++++ ^JJ
non-study ^J++ATRB++++ ^JJ
treatments ^N+CM+PLUR+NOM+++ ^NN2
is ^VA+Z++++BE+ ^VBZ
permitted ^VL+EN+PSV+AGLS+++ ^VVN
at ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
physicians ^FU++++++ ^ERROR
' ^GE++++++ ^GE
discretion ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Clinicians ^N+PR+PLUR+NOM++PMOD+ ^NP1
gain ^N+CM+SING++++ ^NN1
greatest ^J++ATRB+EST+++ ^JJT
confidence ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
when ^R++WH++++ ^RRQ
permissible ^J++ATRB++++ ^JJ
cointerventions ^N+CM+PLUR+NOM+++ ^NN2
are ^VA+++++BE+ ^VBR
described ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
methods ^N+CM+PLUR+++PMOD+ ^NN2
section ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
documented ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
be ^VL+INF++COP+++ ^VBI
infrequent ^J++ATRB++++ ^JJ
occurrences ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
foregoing ^J+ING+ATRB++++ ^JJ
five ^M+CARD+SING+MORE+++ ^MC
guides ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
two ^M+CARD+SING+MORE+++ ^MC
primary ^J++PRDV++++ ^JJ
and ^C+CRD+++++ ^CC
three ^M+CARD+SING+MORE+++ ^MC
secondary ^J++PRDV++++ ^JJ
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
applied ^VL+EN+++++ ^VVN
in ^I++++++ ^II
sequence ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
will ^VM+++++PRDN+ ^VM
help ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
reader ^N+CM+SING++++ ^NN1
determine ^VL+BF+++++ ^VV0
whether ^C+SRD+WH+CLS+++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
an ^D+AT+SING+INDEF+++ ^AT1
article ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
therapy ^N+CM+SING++++ ^NN1
are ^VL+++COP+++ ^VBR
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
be ^VL+INF++COP+++ ^VBI
valid ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
valid ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
reader ^N+CM+SING++++ ^NN1
can ^VM+++++POS+ ^VM
proceed ^VL+INF+++++ ^VVI
to ^TO++++++ ^TO
consider ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
magnitude ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
applicability ^N+CM+SING+NOM+++ ^NN1
to ^I++++++ ^II
her ^D+PER+SING+3+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Scenario ^N+CM+SING+++PMOD+ ^NN1
Resolution ^N+CM+SING+NOM++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
Readers ^N+CM+PLUR+NOM+++ ^NN2
may ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
interested ^J+EN+PRDV++++ ^JJ
in ^I++++++ ^II
how ^R+G+WH++++ ^RGQ
well ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
plasmapheresis ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
lupus ^N+CM+SING+++PMOD+ ^NN1
nephritis ^N+CM+SING++++ ^NN1
met ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
tests ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
validity ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
With ^I++++++MULTI1 ^II
respect ^I_++++++MULTI2 ^II
to ^I_++++++MULTI3 ^II
primary ^J++ATRB++++ ^JJ
criteria ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
randomization ^N+CM+SING+NOM+++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
rigorously ^R++++SPLT++ ^RR
conducted ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
as ^C+SRD+++++ ^CSA
treatment ^N+CM+SING+NOM+++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
assigned ^VL+EN+PSV+AGLS+++ ^VVN
through ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
phone ^N+CM+SING+++PMOD+ ^NN1
call ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
Methods ^N+CM+PLUR+++PMOD+ ^NN2
Center ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
One ^M+CARD+SING+ONE+++ ^MC1
patient ^N+CM+SING++++ ^NN1
assigned ^VL+EN++CLS+++ ^VVN
to ^I++++++ ^II
standard ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
lost ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
followup ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
all ^D+++++B+ ^DB
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
were ^VA+ED++++BE+ ^VBDR
analyzed ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
group ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
which ^D++WH++++ ^DDQ
they ^P+PER+PLUR+3+S++ ^PPHS2
had ^VL+ED+++++ ^VHD
been ^VA+EN+PRF+++BE+ ^VBN
assigned ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
With ^I++++++MULTI1 ^II
respect ^I_++++++MULTI2 ^II
to ^I_++++++MULTI3 ^II
secondary ^J++ATRB++++ ^JJ
criteria ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
not ^XX++++++ ^XX
blinded ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
two ^M+CARD+SING+MORE+++ ^MC
groups ^N+CM+PLUR++++ ^NN2
were ^VL+ED++COP+++ ^VBDR
comparable ^J++PRDV++++ ^JJ
at ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
start ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
provide ^VL+BF+++++ ^VV0
little ^J++ATRB++++ ^JJ
information ^N+CM+SING+NOM+++ ^NN1
about ^I++++++ ^II
comparability ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
other ^D++ATRB++++ ^JJ
treatments ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
introductory ^J++ATRB++++ ^JJ
paper ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
described ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
concept ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
strength ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
inference ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
final ^J++ATRB++++ ^JJ
assessment ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
validity ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
never ^R++++++ ^RR
a ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
yes ^UH++++++ ^UH
" ^Y+QUO+++++ ^"
or ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
no ^D+AT++DEF+++ ^AT
" ^Y+QUO+++++ ^"
decision ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
must ^VM+++++NEC+ ^VM
, ^Y+COM+++++ ^,
to ^I++++++ ^II
some ^D+AT+PLUR+INDEF+++ ^DD
extent ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
be ^VL+INF++COP+++ ^VBI
subjective ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
We ^P+PER+PLUR+1+S++ ^PPIS2
judge ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
methods ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
trial ^N+CM+SING++++ ^NN1
were ^VL+ED++COP+++ ^VBDR
, ^Y+COM+++++ ^,
overall ^R++++++ ^RR
, ^Y+COM+++++ ^,
strong ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
provide ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
valid ^J++ATRB++++ ^JJ
start ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
deciding ^VL+ING++COMP+PREP++ ^VVG
whether ^C+SRD+WH+CLS+++MULTI1 ^CSW
or ^C_+SRD+WH++++MULTI2 ^CSW
not ^C_+SRD+WH++++MULTI3 ^CSW
to ^TO++++++ ^TO
administer ^VL+INF+++++ ^VVI
plasmapheresis ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
our ^D+PER+PLUR+1+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
severe ^J++ATRB++++ ^JJ
lupus ^N+CM+SING+++PMOD+ ^NN1
nephritis ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
II ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
What ^P++WH+QUE+++ ^DDQ
were ^VL+ED++COP+++ ^VBDR
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
Clinical ^J++ATRB++++ ^JJ
Scenario ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
You ^P+PER++2+++ ^PPY
are ^VL+++COP+++ ^VBR
a ^D+AT+SING+INDEF+++ ^AT1
general ^J++ATRB++++ ^JJ
internist ^N+CM+SING+NOM+++ ^NN1
who ^P++WH++++ ^PNQS
is ^VA+Z++++BE+ ^VBZ
asked ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO+++COMP+VERB++ ^TO
see ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
65 ^M+CARD+SING+MORE+++ ^MC
year-old ^J++ATRB+++ONLY+ ^JJ
man ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
controlled ^J+EN+ATRB++++ ^JJ
hypertension ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
six-month ^J++ATRB+++ONLY+ ^JJ
history ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM+++ ^NN1
resistant ^J++PRDV++++ ^JJ
to ^I++++++ ^II
cardioversion ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Although ^C+SRD++++CONC+ ^CS
he ^P+PER+SING+3+S++ ^PPHS1
has ^VL+Z+++++ ^VHZ
no ^D+AT++DEF+++ ^AT
evidence ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
valvular ^J++ATRB++++ ^JJ
or ^C+CRD+PHRS++++ ^CC
coronary ^J++ATRB++++ ^JJ
heart ^N+CM+SING+++PMOD+ ^NN1
disease ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
family ^N+CM+SING+++PMOD+ ^NN1
physician ^N+CM+SING+NOM+++ ^NN1
who ^P++WH++++ ^PNQS
referred ^VL+ED+++++ ^VVD
him ^P+PER+SING+3+O++ ^PPHO1
to ^I++++++ ^II
you ^P+PER++2+++ ^PPY
wants ^VL+Z+++++ ^VVZ
your ^D+PER++2+GEN++ ^APPGE
advice ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
whether ^C+SRD+WH++++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
benefits ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
long-term ^J++ATRB++++ ^JJ
anticoagulants ^N+CM+PLUR+NOM+++ ^NN2
( ^Y+PAR+LEFT++++ ^(
to ^TO++++++ ^TO
reduce ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
embolic ^J++ATRB++++ ^JJ
stroke ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
outweigh ^VL+BF+++++ ^VV0
their ^D+PER+PLUR+3+GEN++ ^APPGE
risks ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
of ^I++++++ ^IO
hemorrhage ^N+CM+SING+NOM+++ ^NN1
from ^I++++++ ^II
anticoagulant ^J++ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
patient ^J++ATRB++++ ^JJ
shares ^N+CM+PLUR++++ ^NN2
these ^D+DEM+PLUR++++ ^DD2
concerns ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
does ^VA+Z++++DO+ ^VDZ
n't ^XX++++CONT++ ^XX
want ^VL+INF+++++ ^VVI
to ^TO+++COMP+VERB++ ^TO
receive ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
treatment ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
would ^VM+++++PRDN+ ^VM
do ^VL+ING+++++ ^VDI
more ^D+++ER+PRO+A+ ^DAR
harm ^N+CM+SING++++ ^NN1
than ^C+SRD+++++ ^CSN
good ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
know ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
there ^P+EX+++++ ^EX
have ^VL+BF+++++ ^VH0
been ^VA+EN+PRF+++BE+ ^VBN
randomized ^VL+EN+PSV+AGLS+++ ^VVN
trials ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
warfarin ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
non-valvular ^J++ATRB++++ ^JJ
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
decide ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
you ^P+PER++2+++ ^PPY
'd ^VM+ED+++CONT+NEC+MULTI1 ^VM
better ^VM_+++ER++NEC+MULTI2 ^RRR
review ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
of ^I++++++ ^IO
them ^P+PER+PLUR+3+O++ ^PPHO2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
Search ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
ideal ^J++ATRB++++ ^JJ
article ^N+CM+SING++++ ^NN1
addressing ^VL+ING++REL+SUBJ++ ^VVG
this ^D+DEM+SING++++ ^DD1
clinical ^J++ATRB++++ ^JJ
problem ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
include ^VL+INF+++++ ^VVI
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
non-valvular ^J++ATRB++++ ^JJ
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
would ^VM+++++PRDN+ ^VM
compare ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
warfarin ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
control ^N+CM+SING+++PMOD+ ^NN1
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
ideally ^R++++++ ^RR
a ^D+AT+SING+INDEF+++ ^AT1
placebo ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
emboli ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
including ^I++++++ ^II
embolic ^J++ATRB++++ ^JJ
stroke ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
also ^R++++++ ^RR
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
complications ^N+CM+PLUR+NOM+++ ^NN2
of ^I++++++ ^IO
anticoagulation ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Randomized ^N+PR+SING++++ ^NP1
, ^Y+COM+++++ ^,
double-blind ^J++ATRB++++ ^JJ
studies ^N+CM+PLUR++++ ^NN2
would ^VM+++++PRDN+ ^VM
provide ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
strongest ^J++ATRB+EST+++ ^JJT
evidence ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
software ^N+CM+SING+++PMOD+ ^NN1
program ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
Grateful ^J++PRDV++++ ^JJ
Med ^J++PRDV++++ ^JJ
" ^Y+QUO+++++ ^"
you ^P+PER++2+++ ^PPY
select ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
Medical ^J++ATRB++++ ^JJ
subject ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
MeSH ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
heading ^VL+ING++COMP+VERB++ ^VVG
that ^C+SRD+THT+REL+++ ^CST
identifies ^VL+Z+++++ ^VVZ
your ^D+PER++2+GEN++ ^APPGE
population ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
another ^D++SING++PRO++ ^DD1
that ^C+SRD+THT+REL+++ ^CST
specifies ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
intervention ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
warfarin ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
third ^M+ORD+++++ ^MD
that ^P+DEM+SING++++ ^DD1
specifies ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
outcome ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
interest ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
stroke ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
( ^Y+PAR+LEFT++++ ^(
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
software ^N+CM+SING++++ ^NN1
automatically ^R++++++ ^RR
converts ^VL+Z+++++ ^VVZ
to ^TO++++++ ^TO
" ^Y+QUO+++++ ^"
explode ^VL+INF+++++ ^VVI
cerebrovascular ^J++ATRB++++ ^JJ
disorders ^N+CM+PLUR+NOM+++ ^NN2
" ^Y+QUO+++++ ^"
meaning ^VL+ING++COMP+VERB++ ^VVG
that ^C+SRD+THT+COMP+VERB++ ^CST
all ^D+++++B+ ^DB
articles ^N+CM+PLUR++++ ^NN2
indexed ^VL+EN++CLS+++ ^VVN
under ^I++++++ ^II
cerebrovascular ^J++ATRB++++ ^JJ
disorders ^N+CM+PLUR+NOM+++ ^NN2
or ^C+CRD+++++ ^CC
its ^D+IMPR++3+GEN++ ^APPGE
subheadings ^N+ING+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
potential ^J++ATRB++++ ^JJ
targets ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
search ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
while ^C+SRD++++CONC+ ^CS
restricting ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
search ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
English-language ^J++ATRB++++ ^JJ
studies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
To ^TO++++++ ^TO
ensure ^VL+INF+++++ ^VVI
that ^P+DEM+SING++++ ^DD1
, ^Y+COM+++++ ^,
at ^R++++++MULTI1 ^RR
least ^R_++++++MULTI2 ^RR
on ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
first ^M+ORD+++++ ^MD
pass ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
identify ^VL+BF+++++ ^VV0
only ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
highest ^J++ATRB+EST+++ ^JJT
quality ^N+CM+SING+NOM++PMOD+ ^NN1
studies ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
include ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
methodological ^J++ATRB++++ ^JJ
term ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
randomized ^VL+ED+++++ ^VVD
controlled ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
PT ^FO++++++ ^FO
) ^Y+PAR+RIGHT++++ ^)
" ^Y+QUO+++++ ^"
( ^Y+PAR+LEFT++++ ^(
PT ^N+CM+SING++++ ^NN1
stands ^VL+Z+++++MULTI1 ^VVZ
for ^I++PPVB++++MULTI2 ^IF
publication ^N+CM+SING+NOM++PMOD+ ^NN1
type ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
search ^N+CM+SING++++ ^NN1
yields ^VL+Z+++++ ^VVZ
nine ^M+CARD+SING+MORE+++ ^MC
articles ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Three ^M+CARD+SING+MORE+++ ^MC
are ^VL+++COP+++ ^VBR
editorials ^N+CM+PLUR+NOM+++ ^NN2
or ^C+CRD+++++ ^CC
commentaries ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
one ^P+++INDEF+++ ^PN1
addresses ^VL+Z+++++ ^VVZ
prognosis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
one ^P+++INDEF+++ ^PN1
focuses ^VL+Z+++++ ^VVZ
on ^I++++++ ^II
quality ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
life ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
anticoagulants ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
decide ^VL+BF+++++ ^VV0
to ^TO+++COMP+VERB++ ^TO
read ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
most ^R+++EST++DEG+ ^RGT
recent ^J++PRDV++++ ^JJ
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
four ^M+CARD+SING+MORE+++ ^MC
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
&lsqb; ^Y+PAR+LEFT++++ ^(
21 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Reading ^VL+ING++CLS+ADVL++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
find ^VL+BF++++THDEL+ ^VV0
it ^P+IM++3+++ ^PPH1
meets ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
validity ^N+CM+SING+NOM++PMOD+ ^NN1
criteria ^N+CM+PLUR++++ ^NN2
you ^P+PER++2+++ ^PPY
learned ^VL+ED+++++ ^VVD
about ^R+PART+PHRV++++ ^RP
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
prior ^J++ATRB++++ ^JJ
article ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
&lsqb; ^Y+PAR+LEFT++++ ^(
22 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
To ^TO++++++ ^TO
answer ^VL+INF+++++ ^VVI
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
referring ^VL+ING++COMP+VERB++ ^VVG
physician ^N+CM+SING+NOM+++ ^NN1
's ^GE++++++ ^GE
concerns ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
need ^VM+BF++++NEC+MULTI1 ^VV0
to ^VM_++++++MULTI2 ^TO
delve ^VL+INF+++++ ^VVI
further ^R+++ER+++ ^RRR
into ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
relation ^N+CM+SING+NOM+++ ^NN1
between ^I++++++ ^II
benefits ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
risks. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
1 ^M+CARD+SING+ONE+++ ^MC1
. ^Y+PER+CLP++++ ^.
How ^R+G+WH+QUE+++ ^RGQ
large ^J++PRDV++++ ^JJ
was ^VL+ED++COP+++ ^VBDZ
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
Most ^R+++EST++DEG+ ^RGT
frequently ^R++++++ ^RR
, ^Y+COM+++++ ^,
randomized ^VL+ED+++++ ^VVD
clinical ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
carefully ^R++++++ ^RR
monitor ^VL+BF+++++ ^VV0
how ^R+G+WH++++ ^RGQ
often ^R++++++ ^RR
patients ^N+CM+PLUR++++ ^NN2
experience ^VL+BF+++++ ^VV0
some ^D+AT+PLUR+INDEF+++ ^DD
adverse ^J++ATRB++++ ^JJ
event ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
outcome ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Examples ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
these ^D+DEM+PLUR++++ ^DD2
" ^Y+QUO+++++ ^"
dichotomous ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
outcomes ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
" ^Y+QUO+++++ ^"
yes ^UH++++++ ^UH
" ^Y+QUO+++++ ^"
or ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
no ^D+AT++DEF+++ ^AT
" ^Y+QUO+++++ ^"
outcomes ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
either ^C++DOUB++++ ^RR
happen ^VL+BF+++++ ^VV0
or ^C+CRD+PHRS++++ ^CC
do ^VA+BF++++DO+ ^VD0
n't ^XX++++CONT++ ^XX
happen ^VL+INF+++++ ^VVI
) ^Y+PAR+RIGHT++++ ^)
include ^VL+BF+++++ ^VV0
cancer ^N+CM+SING+++PMOD+ ^NN1
recurrence ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
death ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Patients ^N+CM+PLUR++++ ^NN2
either ^C++DOUB++++ ^RR
do ^VL+BF+++++ ^VD0
or ^C+CRD+PHRS++++ ^CC
do ^VA+BF++++DO+ ^VD0
not ^XX++++++ ^XX
suffer ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
event ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
reports ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
proportion ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
develop ^VL+BF+++++ ^VV0
such ^D++++PRO+A+ ^DA
events ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Consider ^VL+BF+++++ ^VV0
, ^Y+COM+++++ ^,
for ^R+++++APP+MULTI1 ^REX
example ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
study ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
20% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
0.20 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
died ^VL+ED+++++ ^VVD
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
only ^R++++++ ^RR
15% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
0.15 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
of ^I++++++ ^IO
those ^P+DEM+PLUR++++ ^DD2
receiving ^VL+ING++COMP+VERB++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
died ^VL+ED+++++ ^VVD
. ^Y+PER+CLP++++ ^.
How ^R+G+WH+QUE+++ ^RRQ
might ^VM+++++POS+ ^VM
these ^D+DEM+PLUR++++ ^DD2
results ^N+CM+PLUR++++ ^NN2
be ^VA+INF++++BE+ ^VBI
expressed ^VL+EN+PSV+AGLS+++ ^VVN
? ^Y+QM+CLP++++ ^?
Table ^N+CM+SING++++ ^NN1
2 ^M+CARD+SING+MORE+++ ^MC
provides ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
summary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
ways ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
presenting ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
effects ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Table ^N+CM+SING++++ ^NN1
2 ^M+CARD+SING+MORE+++ ^MC
: ^Y+COL+CLP++++ ^:
Measures ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
effects ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
therapy ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
Risk ^VL+BF+++++ ^VV0
without ^I++++++ ^IW
therapy ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
Baseline ^N+CM+SING+++PMOD+ ^NN1
risk ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
20/100=0.20 ^M+F+++++ ^FU
or ^C+CRD+++++ ^CC
20% ^N++++U+PMOD+ ^NNU
<p> ^FU++++++ ^NULL
Risk ^VL+BF+++++ ^VV0
with ^I++++++ ^IW
therapy ^N+CM+SING++++ ^NN1
: ^Y+COL+CLP++++ ^:
Y ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
15/100=0.15 ^M+F+++++ ^FU
or ^C+CRD+++++ ^CC
15% ^N++++U+PMOD+ ^NNU
<p> ^FU++++++ ^NULL
Absolute ^J++ATRB++++ ^JJ
Risk ^N+CM+SING+++PMOD+ ^NN1
Reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
Risk ^VL+BF+++++ ^VV0
Difference ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
- ^Y+DSH+++++ ^-
Y ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
0.20-0.15=0.05 ^FO++++++ ^FO
<p> ^FU++++++ ^NULL
Relative ^J++ATRB++++ ^JJ
Risk ^N+CM+SING++++ ^NN1
: ^Y+COL+CLP++++ ^:
Y/X ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
0.15/0.20 ^M+F+++++ ^MF
= ^FO++++++ ^FO
0.75 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
Relative ^J++ATRB++++ ^JJ
Risk ^N+CM+SING+++PMOD+ ^NN1
Reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
RRR ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
: ^Y+COL+CLP++++ ^:
&lsqb; ^Y+PAR+LEFT++++ ^(
1-Y/X ^M++++++ ^FU
&rsqb; ^Y+PAR+RIGHT++++ ^)
x ^ZZ++SING++++ ^ZZ1
100 ^M+CARD+SING+MORE+++ ^MC
or ^C+CRD+++++ ^CC
&lsqb; ^Y+PAR+LEFT++++ ^(
( ^Y+PAR+LEFT++++ ^(
X-Y ^FO++++++ ^FO
) ^Y+PAR+RIGHT++++ ^)
/ ^FO++++++ ^FO
X ^ZZ++SING++++ ^ZZ1
&rsqb; ^Y+PAR+RIGHT++++ ^)
x ^ZZ++SING++++ ^ZZ1
100 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
&lsqb; ^Y+PAR+LEFT++++ ^(
1-0.75 ^M+CARD+++HYPH++ ^MCMC
&rsqb; ^Y+PAR+RIGHT++++ ^)
x100=25% ^FO++++++ ^FO
&lsqb; ^Y+PAR+LEFT++++ ^(
0.05/0.20 ^M+T+++++ ^MF
&rsqb; ^Y+PAR+RIGHT++++ ^)
x100=25% ^FO++++++ ^FO
<p> ^FU++++++ ^NULL
95% ^N++++U+PMOD+ ^NNU
Confidence ^N+CM+SING+NOM++PMOD+ ^NN1
Interval ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING+++PMOD+ ^NP1
<p> ^FU++++++ ^NULL
-38% ^FO++++++ ^FO
to ^I++++++ ^II
+59% ^FO++++++ ^FO
<p> ^FU++++++ ^NULL
One ^M+CARD+SING+ONE+++ ^MC1
way ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
as ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
absolute ^J++ATRB++++ ^JJ
difference ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
known ^VL+EN+++++ ^VVN
as ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
risk ^N+CM+SING+++PMOD+ ^NN1
difference ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
between ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
proportion ^N+CM+SING+NOM+++ ^NN1
who ^P++WH++++ ^PNQS
died ^VL+ED+++++ ^VVD
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
X ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
proportion ^N+CM+SING+NOM+++ ^NN1
who ^P++WH++++ ^PNQS
died ^VL+ED+++++ ^VVD
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
Y ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
X ^ZZ++SING++++ ^ZZ1
- ^Y+DSH+++++ ^-
Y ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
0.20 ^M+CARD+SING+MORE+++ ^MC
- ^Y+DSH+++++ ^-
0.15 ^M+CARD+SING+MORE+++ ^MC
= ^FO++++++ ^FO
0.05 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Another ^D++SING++++ ^DD1
way ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
express ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
impact ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM+++ ^NN1
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
as ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING++++ ^NN1
: ^Y+COL+CLP++++ ^:
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
events ^N+CM+PLUR++++ ^NN2
among ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
relative ^I++++++MULTI1 ^II
to ^I_++++++MULTI2 ^II
that ^P+DEM+SING++++ ^DD1
among ^I++++++ ^II
controls ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
Y/X ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
0.15 ^M+CARD+SING+MORE+++ ^MC
/ ^FO++++++ ^FO
0.20 ^M+CARD+SING+MORE+++ ^MC
= ^FO++++++ ^FO
0.75 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
most ^R+++EST++DEG+ ^RGT
commonly ^R++++++ ^RR
reported ^VL+EN+++++ ^VVN
measure ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
dichotomous ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effects ^N+CM+PLUR++++ ^NN2
is ^VL+Z++COP+++ ^VBZ
the ^DET+AT+SING+DEF+++ ^AT
complement ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
is ^VA+Z++++BE+ ^VBZ
called ^VL+EN+PSV+AGLS+++ ^VVN
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
RRR ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
It ^P+IM++3+++ ^PPH1
is ^VA+Z++++BE+ ^VBZ
expressed ^VL+EN+PSV+AGLS+++ ^VVN
as ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
per ^N++++U+PMOD+MULTI1 ^NNU
cent ^N_++++U++MULTI2 ^NNU
: ^Y+COL+CLP++++ ^:
( ^Y+PAR+LEFT++++ ^(
1 ^M+CARD+SING+ONE+++ ^MC1
- ^Y+DSH+++++ ^-
Y/X ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
x ^ZZ++SING++++ ^ZZ1
100% ^N++++U++ ^NNU
= ^FO++++++ ^FO
( ^Y+PAR+LEFT++++ ^(
1 ^M+CARD+SING+ONE+++ ^MC1
- ^Y+DSH+++++ ^-
0.75 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
x ^ZZ++SING++++ ^ZZ1
100% ^N++++U++ ^NNU
= ^FO++++++ ^FO
25% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
A ^ZZ++SING++++ ^ZZ1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
25% ^N++++U++ ^NNU
means ^VL+Z+++++ ^VVZ
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
reduced ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
by ^I++++++ ^II
25% ^N++++U++ ^NNU
relative ^I++++++MULTI1 ^II
to ^I_++++++MULTI2 ^II
that ^P+DEM+SING++++ ^DD1
occurring ^VL+ING++COMP+VERB++ ^VVG
among ^I++++++ ^II
control ^N+CM+SING+++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
; ^Y+SCOL+CLP++++ ^;
the ^DET+AT+SING+DEF+++ ^AT
greater ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
more ^R+++ER++DEG+ ^RGR
effective ^J++ATRB++++ ^JJ
the ^DET+AT+SING+DEF+++ ^AT
therapy. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
2 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
How ^R+G+WH+QUE+++ ^RGQ
precise ^J++PRDV++++ ^JJ
was ^VL+ED++COP+++ ^VBDZ
the ^DET+AT+SING+DEF+++ ^AT
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
can ^VM+++++POS+ ^VM
never ^R++++SPLT++ ^RR
be ^VA+INF++++BE+ ^VBI
known ^VL+EN+PSV+AGLS+++ ^VVN
; ^Y+SCOL+CLP++++ ^;
all ^D+++++B+ ^DB
we ^P+PER+PLUR+1+S++ ^PPIS2
have ^VL+BF+++++ ^VH0
is ^VL+Z++COP+++ ^VBZ
the ^DET+AT+SING+DEF+++ ^AT
estimate ^N+CM+SING+NOM+++ ^NN1
provided ^VL+EN++CLS+++ ^VVN
by ^I++++++ ^II
rigorous ^J++ATRB++++ ^JJ
controlled ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
best ^J++ATRB+EST+++ ^JJT
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
that ^C+SRD+THT+COMP+VERB++ ^CST
observed ^VL+ED+++++ ^VVD
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
estimate ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
called ^VL+EN+PSV+AGLS+++ ^VVN
a ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
" ^Y+QUO+++++ ^"
in ^I++++++MULTI1 ^BCL
order ^N+CM+SING++++MULTI2 ^BCL
to ^TO+INF+++++MULTI3 ^TO
remind ^VL+INF+++++ ^VVI
us ^P+PER+PLUR+1+O++ ^PPIO2
that ^C+SRD+THT+COMP+VERB++ ^CST
, ^Y+COM+++++ ^,
although ^C+SRD++++CONC+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
value ^N+CM+SING++++ ^NN1
lies ^VL+Z+++++ ^VVZ
somewhere ^R+++++LOC+ ^RL
in ^I++++++ ^II
its ^D+IMPR++3+GEN++ ^APPGE
neighbourhood ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
it ^P+IM++3+++EXT ^PPH1
is ^VL+Z++COP+++ ^VBZ
unlikely ^J++PRDV++++ ^JJ
to ^TO++++ADJ++EXT ^TO
be ^VL+INF++COP+++ ^VBI
precisely ^R++++++ ^RR
correct ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
Investigators ^N+CM+PLUR++++ ^NN2
tell ^VL+BF+++++ ^VV0
us ^P+PER+PLUR+1+O++ ^PPIO2
the ^DET+AT+SING+DEF+++ ^AT
neighbourhood ^N+CM+SING+NOM+++ ^NN1
within ^I++++++ ^II
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
effect ^N+CM+SING++++ ^NN1
likely ^J++ATRB++++ ^JJ
lies ^N+CM+PLUR++++ ^NN2
by ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
statistical ^J++ATRB++++ ^JJ
strategy ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
calculating ^VL+ING++COMP+PREP++ ^VVG
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
&lsqb; ^Y+PAR+LEFT++++ ^(
23 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
We ^P+PER+PLUR+1+S++ ^PPIS2
usually ^R++++++ ^RR
( ^Y+PAR+LEFT++++ ^(
though ^C+SRD++++CONC+ ^CS
arbitrarily ^R++++++ ^RR
) ^Y+PAR+RIGHT++++ ^)
use ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
which ^D++WH++++ ^DDQ
can ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
simply ^R++++SPLT++ ^RR
interpreted ^VL+EN+PSV+AGLS+++ ^VVN
as ^C+SRD+++++ ^CSA
defining ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
range ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
includes ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM++PMOD+ ^NN1
95% ^N++++U++ ^NNU
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
time ^N+CM+SING+++TIME+ ^NNT1
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
'll ^VM++++CONT+PRDN+ ^VM
seldom ^R++++SPLT++ ^RR
find ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
toward ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
extremes ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
interval ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
you ^P+PER++2+++ ^PPY
'll ^VM++++CONT+PRDN+ ^VM
find ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
beyond ^I++++++ ^II
these ^D+DEM+PLUR++++ ^DD2
extremes ^N+CM+PLUR++++ ^NN2
only ^R++++++ ^RR
5% ^N++++U++ ^NNU
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
time ^N+CM+SING+++TIME+ ^NNT1
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
property ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
relates ^VL+Z+++++ ^VVZ
closely ^R++++++ ^RR
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
conventional ^J++ATRB++++ ^JJ
level ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
" ^Y+QUO+++++ ^"
statistical ^J++ATRB++++ ^JJ
significance ^N+CM+SING+NOM+++ ^NN1
" ^Y+QUO+++++ ^"
of ^I++++++ ^IO
p ^ZZ++SING++++ ^ZZ1
&lt; ^FO++++++ ^FO
0.05 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
We ^P+PER+PLUR+1+S++ ^PPIS2
illustrate ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
use ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
following ^J+ING+ATRB++++ ^JJ
examples ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
randomized ^VL+ED+++++ ^VVD
100 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
each ^D++SING++++ ^DD1
to ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
control ^N+CM+SING+++PMOD+ ^NN1
groups ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
there ^P+EX+++++ ^EX
were ^VL+ED++COP+++ ^VBDR
20 ^M+CARD+SING+MORE+++ ^MC
deaths ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
15 ^M+CARD+SING+MORE+++ ^MC
deaths ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
would ^VM+++++PRDN+ ^VM
calculate ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
25% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
X ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
20/100 ^M+F+++++ ^MF
or ^C+CRD+++++ ^CC
0.20 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
Y ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
15/100 ^M+F+++++ ^MF
or ^C+CRD+++++ ^CC
0.15 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
1-Y/X ^M+F+++++ ^FU
= ^FO++++++ ^FO
&lsqb; ^Y+PAR+LEFT++++ ^(
1-0.75 ^M+CARD+++HYPH++ ^MCMC
&rsqb; ^Y+PAR+RIGHT++++ ^)
x100 ^FO++++++ ^FO
= ^FO++++++ ^FO
25% ^N++++U++ ^NNU
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
might ^VM+++++POS+ ^VM
guess ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
might ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
much ^R++++++ ^RR
smaller ^J++ATRB+ER+++ ^JJR
or ^C+CRD+++++ ^CC
much ^R++++++ ^RR
greater ^J++ATRB+ER+++ ^JJR
than ^C+SRD+++++ ^CSN
this ^D+DEM+SING++++ ^DD1
25% ^N++++U++ ^NNU
, ^Y+COM+++++ ^,
based ^VL+EN++CLS+++ ^VVN
on ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
difference ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
just ^R++++++ ^RR
5 ^M+CARD+SING+MORE+++ ^MC
deaths ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
fact ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
surmise ^VL+BF+++++ ^VV0
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
might ^VM+++++POS+ ^VM
provide ^VL+INF+++++ ^VVI
no ^D+AT++DEF+++ ^AT
benefit ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
an ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
0% ^N++++U++ ^NNU
) ^Y+PAR+RIGHT++++ ^)
or ^C+CRD+++++ ^CC
even ^R++++++ ^RR
harm ^VL+BF+++++ ^VV0
( ^Y+PAR+LEFT++++ ^(
a ^D+AT+SING+INDEF+++ ^AT1
negative ^J++ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
And ^C+CRD++CLS+++ ^CC
you ^P+PER++2+++ ^PPY
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
right ^J++ATRB++++ ^JJ
-- ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
fact ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
these ^D+DEM+PLUR++++ ^DD2
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
consistent ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
both ^R++++++ ^RR
an ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
- ^Y+DSH+++++ ^-
38% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
patients ^N+CM+PLUR++++ ^NN2
given ^VL+EN++CLS+++ ^VVN
the ^DET+AT+SING+DEF+++ ^AT
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
might ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
38% ^N++++U++ ^NNU
more ^D+++ER+PRO+A+ ^DAR
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
die ^VL+INF+++++ ^VVI
than ^C+SRD+++++ ^CSN
control ^N+CM+SING+++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
an ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
nearly ^R++++++ ^RR
59% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
patients ^N+CM+PLUR++++ ^NN2
subsequently ^R++++++ ^RR
receiving ^VL+ING++REL+SUBJ++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
might ^VM+++++POS+ ^VM
have ^VL+INF+++++ ^VHI
a ^D+AT+SING+INDEF+++ ^AT1
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
dying ^VL+ING++COMP+PREP++ ^VVG
less ^D+++ER+PRO+A+ ^DAR
than ^C+SRD+++++ ^CSN
60% ^N++++U++ ^NNU
that ^P+DEM+SING++++ ^DD1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
are ^VA+++++BE+ ^VBR
not ^XX++++++ ^XX
treated ^VL+EN+PSV+AGLS+++ ^VVN
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
other ^D++ATRB++++ ^JJ
words ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
on ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
RRR ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
-38% ^FO++++++ ^FO
to ^I++++++ ^II
59% ^N++++U++ ^NNU
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
really ^R++++++ ^RR
has ^VL+Z+++++ ^VHZ
n't ^XX++++CONT++ ^XX
helped ^VL+EN+PRF++++ ^VVN
us ^P+PER+PLUR+1+O++ ^PPIO2
decide ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
to ^TO++++++ ^TO
offer ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
What ^P++WH+QUE+++ ^DDQ
sort ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
study ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
more ^R+++ER++DEG+ ^RGR
helpful ^J++PRDV++++ ^JJ
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
What ^P++WH++++ ^DDQ
if ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
enrolled ^VL+ED+++++ ^VVD
, ^Y+COM+++++ ^,
not ^XX++++++ ^XX
100 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
per ^I++++++ ^II
group ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
1,000 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
per ^I++++++ ^II
group ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
observed ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
same ^D++++PRO+A+ ^DA
event ^N+CM+SING+++PMOD+ ^NN1
rates ^N+CM+PLUR++++ ^NN2
as ^C+SRD+++++ ^CSA
before ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
so ^C+SRD+++++MULTI1 ^CS
that ^C_+SRD+THT+REL+++MULTI2 ^CS
there ^P+EX+++++ ^EX
were ^VL+ED++COP+++ ^VBDR
200 ^M+CARD+SING+MORE+++ ^MC
deaths ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
X ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
200/1,000 ^M+F+++++ ^MF
= ^FO++++++ ^FO
0.20 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
150 ^M+CARD+SING+MORE+++ ^MC
deaths ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
Y ^ZZ++SING++++ ^ZZ1
= ^FO++++++ ^FO
150/1,000 ^M+F+++++ ^MF
= ^FO++++++ ^FO
0.15 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Again ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
25% ^N++++U++ ^NNU
( ^Y+PAR+LEFT++++ ^(
1-Y/X ^M+F+++++ ^FU
= ^FO++++++ ^FO
1 ^M+CARD+SING+ONE+++ ^MC1
- ^Y+DSH+++++ ^-
&lsqb; ^Y+PAR+LEFT++++ ^(
0.15/0.20 ^M+T+++++ ^MF
&rsqb; ^Y+PAR+RIGHT++++ ^)
x ^ZZ++SING++++ ^ZZ1
100 ^M+CARD+SING+MORE+++ ^MC
= ^FO++++++ ^FO
25% ^N++++U++ ^NNU
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
larger ^J++ATRB+ER+++ ^JJR
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
might ^VM+++++POS+ ^VM
think ^VL+INF+++++ ^VVI
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
reduction ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
risk ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
much ^R++++++ ^RR
closer ^J++PRDV+ER+++ ^JJR
to ^I++++++ ^II
25% ^N++++U++ ^NNU
and ^C+CRD+++++ ^CC
, ^Y+COM+++++ ^,
again ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
right ^J++PRDV++++ ^JJ
; ^Y+SCOL+CLP++++ ^;
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
for ^I++++++ ^IF
this ^D+DEM+SING++++ ^DD1
set ^N+EN+SING++++ ^NN1
of ^I++++++ ^IO
results ^N+CM+PLUR++++ ^NN2
is ^VL+Z++COP+++ ^VBZ
all ^D+++++B+ ^DB
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
positive ^J++ATRB++++ ^JJ
side ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
zero ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
runs ^VL+Z+++++ ^VVZ
from ^I++++++ ^II
9% ^N++++U++ ^NNU
to ^I++++++ ^II
41% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
What ^P++WH++++ ^DDQ
these ^D+DEM+PLUR++++ ^DD2
examples ^N+CM+PLUR++++ ^NN2
show ^R+G+WH++++ ^VV0
is ^VL+Z++COP+++ ^VBZ
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
larger ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
sample ^N+CM+SING+++PMOD+ ^NN1
size ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
larger ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
outcome ^N+CM+SING+++PMOD+ ^NN1
events ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
greater ^J++ATRB+ER+++ ^JJR
our ^D+PER+PLUR+1+GEN++ ^APPGE
confidence ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
or ^C+CRD+++++ ^CC
any ^D+AT+PLUR+INDEF+++ ^DD
other ^D++ATRB++++ ^JJ
measure ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
efficacy ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
close ^J++PRDV++++ ^JJ
to ^I++++++ ^II
what ^P++WH++++ ^DDQ
we ^P+PER+PLUR+1+S++ ^PPIS2
have ^VL+BF+++++ ^VH0
observed ^VL+EN+PRF++++ ^VVN
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
second ^M+ORD+++++ ^MD
example ^N+CM+SING++++ ^NN1
above ^R+++++LOC+ ^RL
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
lowest ^J++ATRB+EST+++ ^JJT
plausible ^J++ATRB++++ ^JJ
value ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
was ^VL+ED++COP+++ ^VBDZ
9% ^N++++U++ ^NNU
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
highest ^J++ATRB+EST+++ ^JJT
value ^N+CM+SING+++PMOD+ ^NN1
41% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM++PMOD+ ^NN1
-- ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
case ^N+CM+SING+++PMOD+ ^NN1
25% ^N++++U+PMOD+ ^NNU
-- ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
the ^DET+AT+SING+DEF+++ ^AT
one ^M+CARD+SING+ONE+++ ^MC1
value ^N+CM+SING++++ ^NN1
most ^R+++EST++DEG+ ^RGT
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
represent ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
As ^C+SRD+++++ ^CSA
one ^P+++INDEF+++ ^PN1
considers ^VL+Z+++++ ^VVZ
values ^N+CM+PLUR++++ ^NN2
farther ^R+++ER+++ ^RRR
and ^C+CRD+PHRS++++ ^CC
farther ^R+++ER+++ ^RRR
from ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
they ^P+PER+PLUR+3+S++ ^PPHS2
become ^VL+BF++COP+++ ^VV0
less ^D+++ER+PRO+A+ ^DAR
and ^C+CRD+++++ ^CC
less ^R+++ER++DEG+ ^RGR
consistent ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
observed ^J+EN+ATRB++++ ^JJ
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
By ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
time ^N+CM+SING+++TIME+ ^NNT1
one ^P+++INDEF+++ ^PN1
crosses ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
or ^C+CRD+PHRS++++ ^CC
lower ^J++ATRB+ER+++ ^JJR
boundaries ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
values ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
extremely ^R++++++ ^RR
unlikely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
represent ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
, ^Y+COM+++++ ^,
given ^VL+EN++CLS+++ ^VVN
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
observed ^J+EN+ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Figure ^VL+BF+++++ ^VV0
1 ^M+CARD+SING+ONE+++ ^MC1
represents ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
around ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
25% ^N++++U++ ^NNU
in ^I++++++ ^II
these ^D+DEM+PLUR++++ ^DD2
two ^M+CARD+SING+MORE+++ ^MC
examples ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
0 ^M+CARD+SING+MORE+++ ^MC
representing ^VL+ING++COMP+VERB++ ^VVG
no ^D+AT++DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
both ^D++DOUB+++B+ ^DB2
scenarios ^N+CM+PLUR++++ ^NN2
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
25% ^N++++U++ ^NNU
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
far ^R++++++ ^RR
narrower ^J++PRDV+ER+++ ^JJR
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
second ^M+ORD+++++ ^MD
scenario ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
Figure ^VL+BF+++++ ^VV0
1 ^M+CARD+SING+ONE+++ ^MC1
: ^Y+COL+CLP++++ ^:
Confidence ^N+CM+SING+NOM++PMOD+ ^NN1
Intervals ^N+CM+PLUR+NOM+++ ^NN2
Around ^I++++++ ^II
Relative ^J++ATRB++++ ^JJ
Risk ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
It ^P+IM++3+++ ^PPH1
is ^VL+Z++COP+++ ^VBZ
evident ^J++ATRB++++ ^JJ
that ^C+SRD+THT+COMP+ADJ++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
larger ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
sample ^N+CM+SING+++PMOD+ ^NN1
size ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
narrower ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
When ^R++WH+QUE+++ ^RRQ
is ^VL+Z++COP+++ ^VBZ
the ^DET+AT+SING+DEF+++ ^AT
sample ^N+CM+SING+++PMOD+ ^NN1
size ^N+CM+SING++++ ^NN1
big ^J++PRDV++++ ^JJ
enough ^R++++++ ^RR
&lsqb; ^Y+PAR+LEFT++++ ^(
24 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
? ^Y+QM+CLP++++ ^?
In ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
positive ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
study ^N+CM+SING+++PMOD+ ^NN1
-- ^N+CM+SING++++ ^NN1
a ^D+AT+SING+INDEF+++ ^AT1
study ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
conclude ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
effective ^J++ATRB++++ ^JJ
-- ^J++ATRB++++ ^JJ
one ^P+++INDEF+++ ^PN1
can ^VM+++++POS+ ^VM
look ^VL+INF+++++MULTI1 ^VVI
at ^I++PPVB++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
second ^M+ORD+++++ ^MD
example ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
this ^D+DEM+SING++++ ^DD1
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
+9% ^FO++++++ ^FO
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
this ^D+DEM+SING++++ ^DD1
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
the ^DET+AT+SING+DEF+++ ^AT
lowest ^R+++EST+++ ^RRT
that ^P+DEM+SING++++ ^DD1
is ^VL+Z++COP+++ ^VBZ
consistent ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
results ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
still ^R++++++ ^RR
important ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
" ^Y+QUO+++++ ^"
clinically ^R++++++ ^RR
significant ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
" ^Y+QUO+++++ ^"
( ^Y+PAR+LEFT++++ ^(
that ^P+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
it ^P+IM++3+++ ^PPH1
is ^VL+Z++COP+++ ^VBZ
large ^J++PRDV++++ ^JJ
enough ^R++++++ ^RR
for ^I++++++ ^IF
you ^P+PER++2+++ ^PPY
to ^TO++++++ ^TO
want ^VL+INF+++++ ^VVI
to ^TO+++COMP+VERB++ ^TO
offer ^VL+INF+++++ ^VVI
it ^P+IM++3+++ ^PPH1
to ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
investigators ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
enrolled ^VL+EN+PRF++++ ^VVN
sufficient ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
, ^Y+COM+++++ ^,
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
hand ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
do ^VA+BF++++DO+ ^VD0
not ^XX++++++ ^XX
consider ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
9% ^N++++U++ ^NNU
clinically ^R++++++ ^RR
significant ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
can ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
be ^VA+INF++++BE+ ^VBI
considered ^VL+EN+PSV+AGLS+++ ^VVN
definitive ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
even ^C+SRD++++CONC+MULTI1 ^CS
if ^C_+SRD++++CND+MULTI2 ^CS
its ^D+IMPR++3+GEN++ ^APPGE
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
statistically ^R++++++ ^RR
significant ^J++PRDV++++ ^JJ
( ^Y+PAR+LEFT++++ ^(
that ^P+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
they ^P+PER+PLUR+3+S++ ^PPHS2
exclude ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
0 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Keep ^VL+BF++COP+++ ^VV0
in ^I++++++ ^II
mind ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
probability ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
value ^N+CM+SING++++ ^NN1
being ^VL+ING++COP+SUBJ++ ^VBG
less ^R+++ER+++ ^RRR
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
only ^R++++++ ^RR
2.5% ^FO++++++ ^FO
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
that ^C+SRD+THT+COMP+VERB++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
different ^J++ATRB++++ ^JJ
criterion ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
a ^D+AT+SING+INDEF+++ ^AT1
90% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
for ^R+++++APP+MULTI1 ^REX
instance ^R_+++++APP+MULTI2 ^REX
) ^Y+PAR+RIGHT++++ ^)
might ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
as ^C+SRD+++++ ^CSA
or ^C+CRD+++++ ^CC
more ^R+++ER++DEG+ ^RGR
appropriate ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
also ^R++++++ ^RR
helps ^VL+Z+++++ ^VVZ
us ^P+PER+PLUR+1+O++ ^PPIO2
interpret ^VL+INF+++++ ^VVI
" ^Y+QUO+++++ ^"
negative ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
studies ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
concluded ^VL+EN+PRF++++ ^VVN
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
experimental ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
no ^D+AT++DEF+++ ^AT
better ^J++ATRB+ER+++ ^JJR
than ^C+SRD+++++ ^CSN
control ^N+CM+SING+++PMOD+ ^NN1
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
All ^D+++++B+ ^DB
we ^P+PER+PLUR+1+S++ ^PPIS2
need ^VM++++++ ^VM
do ^VL+ING+++++ ^VDI
is ^VL+Z++COP+++ ^VBZ
look ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
at ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
would ^VM+++++PRDN+ ^VM
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
true ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
be ^VL+INF++COP+++ ^VBI
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
has ^VL+Z+++++ ^VHZ
failed ^VL+EN+PRF++++ ^VVN
to ^TO+++COMP+VERB++ ^TO
exclude ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
important ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
first ^M+ORD+++++ ^MD
example ^N+CM+SING++++ ^NN1
we ^P+PER+PLUR+1+S++ ^PPIS2
presented ^VL+ED+++++ ^VVD
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
section ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
a ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
of ^I++++++ ^IO
59% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
Clearly ^R++++++ ^RR
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
this ^P+DEM+SING++++ ^DD1
represented ^VL+ED+++++ ^VVD
the ^DET+AT+SING+DEF+++ ^AT
truth ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
benefit ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
substantial ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
we ^P+PER+PLUR+1+S++ ^PPIS2
would ^VM+++++PRDN+ ^VM
conclude ^VL+INF+++++ ^VVI
that ^D+DEM+SING++++ ^DD1
, ^Y+COM+++++ ^,
although ^C+SRD++++CONC+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
investigators ^N+CM+PLUR++++ ^NN2
had ^VL+ED+++++ ^VHD
failed ^VL+EN+PRF++++ ^VVN
to ^TO+++COMP+VERB++ ^TO
prove ^VL+INF+++++ ^VVI
that ^D+DEM+SING++++ ^DD1
experimental ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
better ^R+++ER+++ ^RRR
than ^C+SRD+++++ ^CSN
placebo ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
they ^P+PER+PLUR+3+S++ ^PPHS2
also ^R++++++ ^RR
had ^VL+ED+++++ ^VHD
failed ^VL+EN+PRF++++ ^VVN
to ^TO+++COMP+VERB++ ^TO
prove ^VL+INF+++++ ^VVI
that ^C+SRD+THT+COMP+VERB++ ^CST
it ^P+IM++3+++ ^PPH1
was ^VL+ED++COP+++ ^VBDZ
not ^XX++++++ ^XX
; ^Y+SCOL+CLP++++ ^;
they ^P+PER+PLUR+3+S++ ^PPHS2
could ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
exclude ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
large ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
positive ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Once ^R++++++MULTI1 ^RR
again ^R_++++++MULTI2 ^RR
the ^DET+AT+SING+DEF+++ ^AT
clinician ^N+CM+SING+NOM+++ ^NN1
must ^VM+++++NEC+ ^VM
bear ^VL+INF+++++ ^VVI
in ^I++++++ ^II
mind ^N+CM+SING++++ ^NN1
the ^DET+AT+SING+DEF+++ ^AT
privoso ^N+CM+SING++++ ^NN1
about ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
arbitrariness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
choice ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
95% ^N++++U+PMOD+ ^NNU
boundaries ^N+CM+PLUR++++ ^NN2
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
reasonable ^J++ATRB++++ ^JJ
alternative ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
90% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
would ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
somewhat ^R++++++ ^RR
narrower ^J++PRDV+ER+++ ^JJR
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
What ^P++WH+QUE+++ ^DDQ
can ^VM+++++POS+ ^VM
the ^DET+AT+SING+DEF+++ ^AT
clinician ^N+CM+SING+NOM+++ ^NN1
do ^VL+ING+++++ ^VDI
if ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
around ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
is ^VA+Z++++BE+ ^VBZ
not ^XX++++++ ^XX
reported ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
There ^P+EX+++++ ^EX
are ^VL+++COP+++ ^VBR
three ^M+CARD+SING+MORE+++ ^MC
approaches ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
we ^P+PER+PLUR+1+S++ ^PPIS2
present ^VL+BF+++++ ^VV0
them ^P+PER+PLUR+3+O++ ^PPHO2
in ^I++++++ ^II
order ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
increasing ^J+ING+ATRB++++ ^JJ
complexity ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
easiest ^J++ATRB+EST+++ ^JJT
approach ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
to ^TO+++COMP+VERB++ ^TO
examine ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
p-value ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
p-value ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
exactly ^R++++++ ^RR
0.05 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
bound ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
limit ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
has ^VM+Z++++NEC+MULTI1 ^VHZ
to ^VM_++++++MULTI2 ^TO
lie ^VL+INF+++++ ^VVI
exactly ^R++++++ ^RR
at ^I++++++ ^II
zero ^M+CARD+SING+MORE+++ ^MC
( ^Y+PAR+LEFT++++ ^(
a ^D+AT+SING+INDEF+++ ^AT1
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
1 ^M+CARD+SING+ONE+++ ^MC1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
you ^P+PER++2+++ ^PPY
can ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
exclude ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
possibility ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+COMP+NOUN++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
has ^VL+Z+++++ ^VHZ
no ^D+AT++DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
As ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
p-value ^N+CM+SING++++ ^NN1
decreases ^VL+Z+++++ ^VVZ
below ^R+++++DEG+ ^RG
0.05 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
bound ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
limit ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
rises ^VL+Z+++++ ^VVZ
above ^I++++++ ^II
zero ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
A ^D+AT+SING+INDEF+++ ^AT1
second ^M+ORD+++++ ^MD
approach ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
involving ^VL+ING++REL+SUBJ++ ^VVG
some ^D+AT+PLUR+INDEF+++ ^DD
quick ^J++ATRB++++ ^JJ
mental ^J++ATRB++++ ^JJ
arithmetic ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
pencil ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
paper ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
can ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
used ^VL+EN+PSV+AGLS+++ ^VVN
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
includes ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
value ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
standard ^J++ATRB++++ ^JJ
error ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
( ^Y+PAR+LEFT++++ ^(
or ^C+CRD+++++ ^CC
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
This ^P+DEM+SING++++ ^DD1
is ^VL+Z++COP+++ ^VBZ
because ^C+SRD++++CAUS+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
and ^C+CRD+PHRS++++ ^CC
lower ^J++ATRB+ER+++ ^JJR
boundaries ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
a ^D+AT+SING+INDEF+++ ^AT1
RRR ^N+PR+SING++++ ^NP1
are ^VL+++COP+++ ^VBR
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
plus ^I++++++ ^II
and ^C+CRD+++++ ^CC
minus ^N+CM+SING++++ ^NN1
twice ^R++++++ ^RR
this ^D+DEM+SING++++ ^DD1
standard ^J++ATRB++++ ^JJ
error ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
third ^M+ORD+++++ ^MD
approach ^N+CM+SING++++ ^NN1
involves ^VL+Z+++++ ^VVZ
calculating ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
yourself ^P+PER+SING+2+X++ ^PPX1
&lsqb; ^Y+PAR+LEFT++++ ^(
5 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
or ^C+CRD+++++ ^CC
asking ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
help ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
someone ^P+++INDEF+++ ^PN1
else ^R++++SPLT++ ^RR
( ^Y+PAR+LEFT++++ ^(
a ^D+AT+SING+INDEF+++ ^AT1
statistician ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
for ^R++++SPLT+APP+MULTI1 ^REX
instance ^R_++++SPLT+APP+MULTI2 ^REX
) ^Y+PAR+RIGHT++++ ^)
to ^TO++++++ ^TO
do ^VL+ING+++++ ^VDI
so ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
Once ^C+SRD+++++ ^CS
you ^P+PER++2+++ ^PPY
obtain ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
know ^VL+BF+++++ ^VV0
how ^C+SRD+WH+CLS+++ ^RGQ
high ^J++ATRB++++ ^JJ
and ^C+CRD+++++ ^CC
low ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
might ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
( ^Y+PAR+LEFT++++ ^(
that ^P+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
know ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
precision ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
estimate ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
can ^VM+++++POS+ ^VM
interpret ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
as ^C+SRD+++++ ^CSA
described ^VL+EN++CLS+ADVL++ ^VVN
above ^R+++++LOC+ ^RL
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Not ^XX++++++ ^XX
all ^D+++++B+ ^DB
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
dichotomous ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
nor ^C+CRD++++ADVS+ ^CC
should ^VM+++++NEC+ ^VM
they ^P+PER+PLUR+3+S++ ^PPHS2
. ^Y+PER+CLP++++ ^.
For ^R+++++APP+MULTI1 ^REX
example ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
new ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
chronic ^J++ATRB++++ ^JJ
lung ^N+CM+SING+++PMOD+ ^NN1
disease ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
focus ^VL+INF+++++ ^VVI
on ^I++++++ ^II
increasing ^VL+ING++COMP+PREP++ ^VVG
their ^D+PER+PLUR+3+GEN++ ^APPGE
exercise ^N+CM+SING+++PMOD+ ^NN1
capacity ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Thus ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
study ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
respiratory ^J++ATRB++++ ^JJ
muscle ^N+CM+SING+++PMOD+ ^NN1
training ^N+ING+SING++++ ^NN1
for ^I++++++ ^IF
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
chronic ^J++ATRB++++ ^JJ
airflow ^N+CM+SING+++PMOD+ ^NN1
limitation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
one ^M+CARD+SING+ONE+++ ^MC1
primary ^J++ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
measured ^VL+ED+++++ ^VVD
how ^R+G+WH++++ ^RGQ
far ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
could ^VM+++++POS+ ^VM
walk ^VL+INF+++++ ^VVI
in ^I++++++ ^II
six ^M+CARD+SING+MORE+++ ^MC
minutes ^N+CM+PLUR+++TIME+ ^NNT2
in ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
enclosed ^J+EN+ATRB++++ ^JJ
corridor ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
25 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
six-minute ^J++ATRB+++ONLY+ ^JJ
walk ^N+CM+SING++++ ^NN1
improved ^VL+EN++CLS+++ ^VVN
from ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
average ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
406 ^M+CARD+SING+MORE+++ ^MC
to ^I++++++ ^II
416 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
up ^I++++++ ^II
10 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
experimental ^J++ATRB++++ ^JJ
group ^N+CM+SING++++ ^NN1
receiving ^VL+ING++REL+SUBJ++ ^VVG
respiratory ^J++ATRB++++ ^JJ
muscle ^N+CM+SING+++PMOD+ ^NN1
training ^N+ING+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
from ^I++++++ ^II
409 ^M+CARD+SING+MORE+++ ^MC
to ^I++++++ ^II
429 ^M+CARD+SING+MORE+++ ^MC
( ^Y+PAR+LEFT++++ ^(
up ^I++++++ ^II
20 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
improvement ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
six-minute ^J++ATRB+++ONLY+ ^JJ
walk ^N+CM+SING++++ ^NN1
due ^I++++++MULTI1 ^II
to ^I_++++++MULTI2 ^II
respiratory ^J++ATRB++++ ^JJ
muscle ^N+CM+SING+++PMOD+ ^NN1
training ^N+ING+SING++++ ^NN1
therefore ^R++++++ ^RR
was ^VL+ED++COP+++ ^VBDZ
negative ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
at ^I++++++ ^II
-10 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
or ^C+CRD+++++ ^CC
a ^D+AT+SING+INDEF+++ ^AT1
10 ^M+CARD+SING+MORE+++ ^MC
meter ^N+CM+SING+++PMOD+ ^NN1
difference ^N+CM+SING+NOM+++ ^NN1
in ^I++++++MULTI1 ^II
favour ^I_++++++MULTI2 ^II
of ^I_++++++MULTI3 ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
group ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Here ^R+++++LOC+ ^RL
too ^R++++++ ^RR
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
should ^VM+++++NEC+ ^VM
look ^VL+INF+++++MULTI1 ^VVI
for ^I++PPVB++++MULTI2 ^IF
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
around ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
difference ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
changes ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
exercise ^N+CM+SING+++PMOD+ ^NN1
capacity ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
consider ^VL+BF+++++ ^VV0
their ^D+PER+PLUR+3+GEN++ ^APPGE
implications ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
investigators ^N+CM+PLUR++++ ^NN2
tell ^VL+BF+++++ ^VV0
us ^P+PER+PLUR+1+O++ ^PPIO2
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
95% ^N++++U+PMOD+ ^NNU
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
- ^Y+DSH+++++ ^-
26 ^M+CARD+SING+MORE+++ ^MC
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
consistent ^J++PRDV++++ ^JJ
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
difference ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
26 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
in ^I++++++MULTI1 ^II
favour ^I_++++++MULTI2 ^II
of ^I_++++++MULTI3 ^II
the ^DET+AT+SING+DEF+++ ^AT
control ^N+CM+SING+++PMOD+ ^NN1
treatment ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
+5 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Even ^R++++++ ^RR
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
best ^J++PRDV+EST+++ ^JJT
of ^I++++++ ^IO
circumstances ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
adding ^VL+ING++REL+SUBJ++ ^VVG
5 ^M+CARD+SING+MORE+++ ^MC
meters ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
400 ^M+CARD+SING+MORE+++ ^MC
recorded ^VL+ED+++++ ^VVD
at ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
start ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
not ^XX++++++ ^XX
be ^VL+INF++COP+++ ^VBI
important ^J++PRDV++++ ^JJ
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
this ^D+DEM+SING++++ ^DD1
result ^N+CM+SING++++ ^NN1
effectively ^R++++++ ^RR
excludes ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
clinically ^R++++++ ^RR
significant ^J++ATRB++++ ^JJ
benefit ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
respiratory ^J++ATRB++++ ^JJ
muscle ^N+CM+SING+++PMOD+ ^NN1
training ^N+ING+SING++++ ^NN1
as ^C+SRD+++++ ^CSA
applied ^VL+EN++CLS+ADVL++ ^VVN
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
study ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Having ^VL+ING++COMP+VERB++ ^VHG
determined ^VL+EN+PRF++++ ^VVN
the ^DET+AT+SING+DEF+++ ^AT
magnitude ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
precision ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
readers ^N+CM+PLUR+NOM+++ ^NN2
now ^R+++++TIME+ ^RT
can ^VM+++++POS+ ^VM
turn ^VL+INF+++++MULTI1 ^VVI
to ^I++PPVB++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
final ^J++ATRB++++ ^JJ
question ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
how ^P+G+WH+COMP+NOUN++ ^RRQ
to ^TO++++++ ^TO
apply ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
results ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
their ^D+PER+PLUR+3+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
clinical ^J++ATRB++++ ^JJ
practice ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU++++++ ^NULL
Will ^VM+++++PRDN+ ^VM
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
help ^VL+INF+++++ ^VVI
me ^P+PER+SING+1+O++ ^PPIO1
in ^I++++++ ^II
caring ^VL+ING++COMP+PREP++MULTI1 ^VVG
for ^I++PPVB++++MULTI2 ^IF
my ^D+PER+SING+1+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
? ^Y+QM+CLP++++ ^?
<h> ^FU++++++ ^NULL
1 ^M+CARD+SING+ONE+++ ^MC1
. ^Y+PER+CLP++++ ^.
Can ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
be ^VA+INF++++BE+ ^VBI
applied ^VL+EN+PSV+AGLS+++ ^VVN
to ^I++++++ ^II
my ^D+PER+SING+1+GEN++ ^APPGE
patient ^N+CM+SING+++PMOD+ ^NN1
care ^N+CM+SING++++ ^NN1
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
first ^M+ORD+++++ ^MD
issue ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
address ^VL+INF+++++ ^VVI
is ^VL+Z++COP+++ ^VBZ
how ^C+SRD+WH+CLS+++ ^RRQ
confident ^J++PRDV++++ ^JJ
you ^P+PER++2+++ ^PPY
are ^VL+++COP+++ ^VBR
that ^C+SRD+THT+COMP+VERB++ ^CST
you ^P+PER++2+++ ^PPY
can ^VM+++++POS+ ^VM
apply ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
particular ^J++ATRB++++ ^JJ
patient ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
patients ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
practice ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
have ^VL+INF+++++ ^VHI
been ^VA+EN+PRF+++BE+ ^VBN
enroled ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
had ^VL+ED+++++ ^VHD
she ^P+PER+SING+3+S++ ^PPHS1
been ^VL+EN+PRF+COP+++ ^VBN
there ^R+++++LOC+ ^RL
-- ^N+CM+SING++++ ^NN1
that ^P+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
she ^P+PER+SING+3+S++ ^PPHS1
meets ^VL+Z+++++ ^VVZ
all ^D+++++B+ ^DB
the ^DET+AT+SING+DEF+++ ^AT
inclusion ^N+CM+SING+++PMOD+ ^NN1
criteria ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
does ^VA+Z++++DO+ ^VDZ
n't ^XX++++CONT++ ^XX
violate ^VL+INF+++++ ^VVI
any ^D+AT+PLUR+INDEF+PRO++ ^DD
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
exclusion ^N+CM+SING+++PMOD+ ^NN1
criteria ^N+CM+PLUR+++PMOD+ ^NN2
-- ^N+CM+SING++++ ^NN1
there ^P+EX+++++ ^EX
is ^VL+Z++COP+++ ^VBZ
little ^D++SING++PRO+A+ ^DA1
question ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
applicable ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
this ^P+DEM+SING++++ ^DD1
is ^VL+Z++COP+++ ^VBZ
not ^XX++++++ ^XX
the ^DET+AT+SING+DEF+++ ^AT
case ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
she ^P+PER+SING+3+S++ ^PPHS1
would ^VM+++++PRDN+ ^VM
not ^XX++++++ ^XX
have ^VL+INF+++++ ^VHI
been ^VL+EN+PRF+COP+++ ^VBN
eligible ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
judgement ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
required ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING+++PMOD+ ^NN1
result ^N+CM+SING++++ ^NN1
probably ^R++++++ ^RR
applies ^VL+Z+++++ ^VVZ
even ^C+SRD++++CONC+MULTI1 ^CS
if ^C_+SRD++++CND+MULTI2 ^CS
, ^Y+COM+++++ ^,
for ^R+++++APP+MULTI1 ^REX
example ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
she ^P+PER+SING+3+S++ ^PPHS1
was ^VL+ED++COP+++ ^VBDZ
2 ^M+CARD+SING+MORE+++ ^MC
years ^N+CM+PLUR+++TIME+ ^NNT2
too ^R+++++DEG+ ^RG
old ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
had ^VL+ED+++++ ^VHD
more ^D+++ER+PRO+A+ ^DAR
severe ^J++ATRB++++ ^JJ
disease ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
had ^VL+ED+++++ ^VHD
previously ^R++++SPLT++ ^RR
been ^VA+EN+PRF+++BE+ ^VBN
treated ^VL+EN+PSV+AGLS+++ ^VVN
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
competing ^J+ING+ATRB++++ ^JJ
therapy ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
had ^VL+ED+++++ ^VHD
a ^D+AT+SING+INDEF+++ ^AT1
comorbid ^J++ATRB++++ ^JJ
condition ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
better ^J++ATRB+ER+++ ^JJR
approach ^N+CM+SING++++ ^NN1
than ^C+SRD+++++ ^CSN
rigidly ^R++++++ ^RR
applying ^VL+ING++REL+SUBJ++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
inclusion ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
exclusion ^N+CM+SING+++PMOD+ ^NN1
criteria ^N+CM+PLUR++++ ^NN2
is ^VL+Z++COP+++ ^VBZ
to ^TO+++COMP+VERB++ ^TO
ask ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
there ^P+EX+++++ ^EX
is ^VL+Z++COP+++ ^VBZ
some ^D+AT+PLUR+INDEF+++ ^DD
compelling ^J+ING+ATRB++++ ^JJ
reason ^N+CM+SING++++ ^NN1
why ^R++WH++++ ^RRQ
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
should ^VM+++++NEC+ ^VM
not ^XX++++++ ^XX
be ^VA+INF++++BE+ ^VBI
applied ^VL+EN+PSV+AGLS+++ ^VVN
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
compelling ^J+ING+ATRB++++ ^JJ
reason ^N+CM+SING++++ ^NN1
usually ^R++++++ ^RR
wo ^VM+++++PRDN+ ^VM
n't ^XX++++CONT++ ^XX
be ^VA+INF++++BE+ ^VBI
found ^VL+EN+PSV+AGLS+++ ^VVN
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
most ^R+++EST++DEG+ ^RGT
often ^R++++++ ^RR
you ^P+PER++2+++ ^PPY
can ^VM+++++POS+ ^VM
generalize ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
confidence ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
A ^D+AT+SING+INDEF+++ ^AT1
final ^J++ATRB++++ ^JJ
issue ^N+CM+SING++++ ^NN1
arises ^VL+Z+++++ ^VVZ
when ^R++WH++++ ^RRQ
our ^D+PER+PLUR+1+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
fits ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
features ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
subgroup ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
pateints ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING+++PMOD+ ^NN1
report ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
articles ^N+CM+PLUR++++ ^NN2
reporting ^VL+ING++REL+SUBJ++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
trial ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
especially ^R++++++ ^RR
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
does ^VA+Z++++DO+ ^VDZ
n't ^XX++++CONT++ ^XX
appear ^VL+INF++COP+++ ^VVI
to ^TO+++COMP+VERB++ ^TO
be ^VL+INF++COP+++ ^VBI
efficacious ^J++PRDV++++ ^JJ
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
average ^J++ATRB++++ ^JJ
patient ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
have ^VL+INF+++++ ^VHI
examined ^VL+EN+PRF++++ ^VVN
a ^D+AT+SING+INDEF+++ ^AT1
large ^J++ATRB++++ ^JJ
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
subgroups ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
at ^I++++++ ^II
different ^J++ATRB++++ ^JJ
stages ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
their ^D+PER+PLUR+3+GEN++ ^APPGE
illness ^N+CM+PLUR+NOM+++ ^NN1
, ^Y+COM+++++ ^,
with ^I++++++ ^IW
different ^J++ATRB++++ ^JJ
comorbid ^J++ATRB++++ ^JJ
conditions ^N+CM+PLUR+NOM+++ ^NN2
, ^Y+COM+++++ ^,
with ^I++++++ ^IW
different ^J++ATRB++++ ^JJ
ages ^N+CM+PLUR++++ ^NN2
at ^I++++++ ^II
entry ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
like ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
Quite ^R+++++DEG+ ^RG
often ^R++++++ ^RR
these ^P+DEM+PLUR++++ ^DD2
subgroup ^VL+BF+++++ ^VV0
analyses ^N+CM+PLUR++++ ^NN2
were ^VA+ED++++BE+ ^VBDR
not ^XX++++++ ^XX
planned ^VL+EN+PSV+AGLS+++ ^VVN
ahead ^I++++++MULTI1 ^II
of ^I_++++++MULTI2 ^II
time ^N+CM+SING+++TIME+ ^NNT1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
data ^N+CM+NEUT++++ ^NN
are ^VL+++COP+++ ^VBR
simply ^R++++++ ^RR
" ^Y+QUO+++++ ^"
dredged ^VL+ED+++++ ^VVD
" ^Y+QUO+++++ ^"
to ^TO++++++ ^TO
see ^VL+INF++++THDEL+ ^VVI
what ^C+SRD+WH+CLS+++ ^DDQ
might ^VM+++++POS+ ^VM
turn ^VL+INF+++++MULTI1 ^VVI
up ^R+PART+PHRV++++MULTI2 ^RP
. ^Y+PER+CLP++++ ^.
Investigators ^N+CM+PLUR++++ ^NN2
may ^VM+++++POS+ ^VM
sometimes ^R++++SPLT+TIME+ ^RT
over-interpret ^VL+INF+++++ ^VVI
these ^D+DEM+PLUR++++ ^DD2
" ^Y+QUO+++++ ^"
data-dependent ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
analyses ^N+CM+PLUR++++ ^NN2
as ^C+SRD+++++ ^CSA
demonstrating ^VL+ING++REL+SUBJ++ ^VVG
that ^C+SRD+THT+COMP+VERB++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
really ^R++++++ ^RR
has ^VL+Z+++++ ^VHZ
a ^D+AT+SING+INDEF+++ ^AT1
different ^J++ATRB++++ ^JJ
effect ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
subgroup ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
patients ^N+CM+PLUR+++PMOD+ ^NN2
-- ^N+CM+SING++++ ^NN1
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
are ^VL+++COP+++ ^VBR
older ^J++PRDV+ER+++ ^JJR
or ^C+CRD+PHRS++++ ^CC
sicker ^J++PRDV+ER+++ ^JJR
, ^Y+COM+++++ ^,
for ^R+++++APP+MULTI1 ^REX
instance ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
may ^VM+++++POS+ ^VM
be ^VA+INF++++BE+ ^VBI
held ^VL+EN+PSV+AGLS+++MULTI1 ^VVN
up ^R+PART+PHRV++++MULTI2 ^RP
as ^C+SRD+++++ ^CSA
benefitting ^VL+ING++COMP+VERB++ ^VVG
substantially ^R++++++ ^RR
more ^R+++ER+++ ^RRR
or ^C+CRD+++++ ^CC
less ^D+++ER+PRO+A+ ^DAR
than ^C+SRD+++++ ^CSN
other ^D++ATRB++++ ^JJ
subgroups ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
You ^P+PER++2+++ ^PPY
can ^VM+++++POS+ ^VM
find ^VL+INF+++++ ^VVI
guides ^N+CM+PLUR++++ ^NN2
for ^I++++++ ^IF
deciding ^VL+ING++COMP+PREP++ ^VVG
whether ^C+SRD+WH+CLS+++ ^CSW
to ^TO++++++ ^TO
believe ^VL+INF++++THDEL+ ^VVI
these ^P+DEM+PLUR++++ ^DD2
subgroup ^VL+BF+++++ ^VV0
analyses ^N+CM+PLUR++++ ^NN2
&lsqb; ^Y+PAR+LEFT++++ ^(
26 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
we ^P+PER+PLUR+1+S++ ^PPIS2
'll ^VM++++CONT+PRDN+ ^VM
summarize ^VL+INF+++++ ^VVI
them ^P+PER+PLUR+3+O++ ^PPHO2
for ^I++++++ ^IF
you ^P+PER++2+++ ^PPY
here ^R+++++LOC+ ^RL
: ^Y+COL+CLP++++ ^:
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
really ^R++++++ ^RR
likely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
benefit ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
subgroup ^N+CM+SING++++ ^NN1
more ^R+++ER+++ ^RRR
or ^C+CRD+++++ ^CC
less ^D+++ER+PRO+A+ ^DAR
than ^C+SRD+++++ ^CSN
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
if ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
difference ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
effects ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
subgroups ^N+CM+PLUR++++ ^NN2
is ^VL+Z++COP+++ ^VBZ
large ^J++PRDV++++ ^JJ
; ^Y+SCOL+CLP++++ ^;
is ^VL+Z++COP+++ ^VBZ
very ^R+++++DEG+ ^RG
unlikely ^J++PRDV++++ ^JJ
to ^TO+++COMP+ADJ++ ^TO
occur ^VL+INF+++++ ^VVI
by ^I++++++ ^II
chance ^N+CM+SING++++ ^NN1
; ^Y+SCOL+CLP++++ ^;
results ^N+CM+PLUR++++ ^NN2
from ^I++++++ ^II
an ^D+AT+SING+INDEF+++ ^AT1
analysis ^N+CM+SING++++ ^NN1
specified ^VL+EN++CLS+++ ^VVN
as ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
hypothesis ^N+CM+SING++++ ^NN1
before ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
study ^N+CM+SING++++ ^NN1
began ^VL+ED+++++ ^VVD
; ^Y+SCOL+CLP++++ ^;
was ^VL+ED++COP+++ ^VBDZ
one ^M+CARD+SING+ONE+++ ^MC1
of ^I++++++ ^IO
only ^R++++++ ^RR
a ^D+AT+SING+INDEF+++ ^AT1
very ^R+++++DEG+ ^RG
few ^D++PLUR++PRO+A+ ^DA2
subgroup ^N+CM+SING++++ ^NN1
analyses ^VL+Z+++++ ^VVZ
that ^C+SRD+THT+REL+++ ^CST
were ^VA+ED++++BE+ ^VBDR
carried ^VL+EN+PSV+AGLS+++MULTI1 ^VVN
out ^R+PART+PHRV++++MULTI2 ^RP
; ^Y+SCOL+CLP++++ ^;
and ^C+CRD++CLS+++ ^CC
is ^VA+Z++++BE+ ^VBZ
replicated ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
other ^D++ATRB++++ ^JJ
studies ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
To ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
extent ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
subgroup ^N+CM+SING+++PMOD+ ^NN1
analysis ^N+CM+SING++++ ^NN1
fails ^VL+Z+++++ ^VVZ
these ^D+DEM+PLUR++++ ^DD2
criteria ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
clinicians ^N+CM+PLUR+NOM+++ ^NN2
should ^VM+++++NEC+ ^VM
be ^VL+INF++COP+++ ^VBI
increasingly ^R++++++ ^RR
sceptical ^J++PRDV++++ ^JJ
about ^I++++++ ^II
applying ^VL+ING++COMP+PREP++ ^VVG
them ^P+PER+PLUR+3+O++ ^PPHO2
to ^I++++++ ^II
their ^D+PER+PLUR+3+GEN++ ^APPGE
patients. ^ERROR++++U+PMOD+ ^NNU
<h> ^FU++++++ ^NULL
2 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Were ^VA+ED++++BE+ ^VBDR
all ^D+++++B+ ^DB
clinically ^R++++SPLT++ ^RR
important ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
considered ^VL+EN+PSV+AGLS+++ ^VVN
? ^Y+QM+CLP++++ ^?
<p> ^FU++++++ ^NULL
Treatments ^N+CM+PLUR+NOM+++ ^NN2
are ^VA+++++BE+ ^VBR
indicated ^VL+EN+PSV+AGLS+++ ^VVN
when ^C+SRD+WH+CLS+++ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
provide ^VL+BF+++++ ^VV0
important ^J++ATRB++++ ^JJ
benefits ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Demonstrating ^VL+ING++COMP+VERB++ ^VVG
that ^C+SRD+THT+COMP+VERB++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
bronchodilator ^N+CM+SING++++ ^NN1
produces ^VL+Z+++++ ^VVZ
small ^J++ATRB++++ ^JJ
increments ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++ ^II
forced ^J+EN+ATRB++++ ^JJ
expired ^J+EN+ATRB++++ ^JJ
volume ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
chronic ^J++ATRB++++ ^JJ
airflow ^N+CM+SING+++PMOD+ ^NN1
limitation ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
that ^C+SRD+THT+COMP+VERB++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
vasodilator ^N+CM+SING++++ ^NN1
improves ^VL+Z+++++ ^VVZ
cardiac ^J++ATRB++++ ^JJ
output ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
heart ^N+CM+SING+++PMOD+ ^NN1
failure ^N+CM+SING+++PMOD+ ^NN1
patients ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
or ^C+CRD++CLS+++ ^CC
that ^C+SRD+THT+COMP+VERB++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
lipid-lowering ^J+ING+ATRB++++ ^JJ
agent ^N+CM+SING++++ ^NN1
improves ^VL+Z+++++ ^VVZ
lipid ^J++ATRB++++ ^JJ
profiles ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
does ^VA+Z++++DO+ ^VDZ
not ^XX++++++ ^XX
necessarily ^R++++SPLT++ ^RR
provide ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
sufficient ^J++ATRB++++ ^JJ
reason ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
administering ^VL+ING++COMP+PREP++ ^VVG
these ^D+DEM+PLUR++++ ^DD2
drugs ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
What ^P++WH++++ ^DDQ
is ^VA+Z++++BE+ ^VBZ
required ^VL+EN+PSV+AGLS+++ ^VVN
is ^VL+Z++COP+++ ^VBZ
evidence ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+COMP+NOUN++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
treatments ^N+CM+PLUR+NOM+++ ^NN2
improve ^VL+BF+++++ ^VV0
outcomes ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
are ^VL+++COP+++ ^VBR
important ^J++PRDV++++ ^JJ
to ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
reducing ^VL+ING++COMP+PREP++ ^VVG
shortness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
breath ^N+CM+SING++++ ^NN1
during ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
activities ^N+CM+PLUR+NOM+++ ^NN2
required ^VL+EN++CLS+++ ^VVN
for ^I++++++ ^IF
daily ^J++ATRB++++ ^JJ
living ^N+ING+SING++++ ^NN1
, ^Y+COM+++++ ^,
avoiding ^VL+ING++REL+SUBJ++ ^VVG
hospitalization ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
heart ^N+CM+SING+++PMOD+ ^NN1
failure ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
decreasing ^VL+ING++REL+SUBJ++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
We ^P+PER+PLUR+1+S++ ^PPIS2
can ^VM+++++POS+ ^VM
consider ^VL+INF+++++ ^VVI
forced ^J+EN+ATRB++++ ^JJ
expired ^J+EN+ATRB++++ ^JJ
volume ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
second ^N+CM+SING+++TIME+ ^NNT1
, ^Y+COM+++++ ^,
cardiac ^J++ATRB++++ ^JJ
output ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
lipid ^J++ATRB++++ ^JJ
profile ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
substitute ^N+CM+SING+++PMOD+ ^NN1
endpoints ^N+CM+PLUR++++ ^NN2
" ^Y+QUO+++++ ^"
. ^Y+PER+CLP++++ ^.
That ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
authors ^N+CM+PLUR++++ ^NN2
have ^VL+BF+++++ ^VH0
substituted ^VL+EN+PRF++++ ^VVN
these ^D+DEM+PLUR++++ ^DD2
physiologic ^J++ATRB++++ ^JJ
measures ^N+CM+PLUR++++ ^NN2
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
important ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
shortness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
breath ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
hospitalization ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
usually ^R++++++ ^RR
because ^C+SRD++++CAUS+ ^CS
to ^TO++++++ ^TO
confirm ^VL+INF+++++ ^VVI
benefit ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
latter ^D++++PRO+A+ ^DA
they ^P+PER+PLUR+3+S++ ^PPHS2
would ^VM+++++PRDN+ ^VM
have ^VL+INF+++++ ^VHI
had ^VM+EN+PRF+++NEC+MULTI1 ^VHN
to ^VM_++++++MULTI2 ^TO
enroll ^VL+INF+++++ ^VVI
many ^D++PLUR++PRO+A+ ^DA2
more ^D+++ER+PRO+A+ ^DAR
patients ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
followed ^VL+ED+++++ ^VVD
them ^P+PER+PLUR+3+O++ ^PPHO2
for ^I++++++ ^IF
far ^R+++++DEG+ ^RG
longer ^J++ATRB+ER+++ ^JJR
periods ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
time ^N+CM+SING+++TIME+ ^NNT1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
A ^D+AT+SING+INDEF+++ ^AT1
dramatic ^J++ATRB++++ ^JJ
recent ^J++ATRB++++ ^JJ
example ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
danger ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
substitute ^J++ATRB++++ ^JJ
endpoints ^N+CM+PLUR++++ ^NN2
was ^VA+ED++++BE+ ^VBDZ
found ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
evaluation ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
usefulness ^N+CM+PLUR+NOM+++ ^NN1
of ^I++++++ ^IO
antiarrhythmic ^J++ATRB++++ ^JJ
drugs ^N+CM+PLUR++++ ^NN2
following ^VL+ING++REL+SUBJ++ ^VVG
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Because ^C+SRD++++CAUS+ ^CS
such ^D++++PRO+A+ ^DA
drugs ^N+CM+PLUR++++ ^NN2
had ^VL+ED+++++ ^VHD
been ^VA+EN+PRF+++BE+ ^VBN
shown ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO+++COMP+VERB++ ^TO
reduce ^VL+INF+++++ ^VVI
abnormal ^J++ATRB++++ ^JJ
ventricular ^J++ATRB++++ ^JJ
depolarizations ^N+CM+PLUR+NOM+++ ^NN2
( ^Y+PAR+LEFT++++ ^(
the ^DET+AT+SING+DEF+++ ^AT
substitute ^J++ATRB++++ ^JJ
endpoints ^N+CM+PLUR++++ ^NN2
) ^Y+PAR+RIGHT++++ ^)
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
short ^J++ATRB++++ ^JJ
run ^N+EN+SING++++ ^NN1
, ^Y+COM+++++ ^,
it ^P+IM++3+++EXT ^PPH1
made ^VL+ED+++++ ^VVD
sense ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+CLS+VERB++EXT ^CST
they ^P+PER+PLUR+3+S++ ^PPHS2
should ^VM+++++NEC+ ^VM
reduce ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
occurrence ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
life-threatening ^J+ING+ATRB++++ ^JJ
arrhythmias ^N+CM+PLUR++++ ^NN2
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
long ^J++ATRB++++ ^JJ
run ^N+EN+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^D+AT+SING+INDEF+++ ^AT1
group ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
investigators ^N+CM+PLUR++++ ^NN2
performed ^VL+ED+++++ ^VVD
randomized ^J+EN+ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
three ^M+CARD+SING+MORE+++ ^MC
agents ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
encainide ^VL+BF+++++ ^VV0
, ^Y+COM+++++ ^,
flecainide ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
moricizine ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
previously ^R++++++ ^RR
shown ^VL+EN+++++ ^VVN
to ^TO+++COMP+VERB++ ^TO
be ^VL+INF++COP+++ ^VBI
effective ^J++PRDV++++ ^JJ
in ^I++++++ ^II
suppressing ^VL+ING++COMP+PREP++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
substitute ^J++ATRB++++ ^JJ
endpoint ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
abnormal ^J++ATRB++++ ^JJ
ventricular ^J++ATRB++++ ^JJ
depolarizations ^N+CM+PLUR+NOM+++ ^NN2
in ^I++++++MULTI1 ^BCL
order ^N+CM+SING++++MULTI2 ^BCL
to ^TO+INF+++++MULTI3 ^TO
determine ^VL+INF+++++ ^VVI
whether ^C+SRD+WH+CLS+++ ^CSW
they ^P+PER+PLUR+3+S++ ^PPHS2
reduced ^VL+ED+++++ ^VVD
mortality ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
asymptomatic ^J++ATRB++++ ^JJ
or ^C+CRD+++++ ^CC
mildly ^R++++++ ^RR
symptomatic ^J++ATRB++++ ^JJ
arrhythmias ^N+CM+PLUR++++ ^NN2
following ^VL+ING++REL+SUBJ++ ^VVG
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
investigators ^N+CM+PLUR++++ ^NN2
had ^VM+ED++++NEC+MULTI1 ^VHD
to ^VM_++++++MULTI2 ^TO
stop ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
trials ^N+CM+PLUR++++ ^NN2
when ^C+SRD+WH+CLS+++ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
discovered ^VL+ED+++++ ^VVD
that ^D+DEM+SING++++ ^DD1
mortality ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
substantially ^R++++++ ^RR
higher ^J++PRDV+ER+++ ^JJR
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
receiving ^VL+ING++REL+SUBJ++ ^VVG
antiarrhythmic ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
than ^C+SRD+++++ ^CSN
in ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
receiving ^VL+ING++CLS+ADVL++ ^VVG
placebo ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
27 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
28 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Clinicians ^N+CM+PLUR+NOM+++ ^NN2
relying ^VL+ING++REL+SUBJ++MULTI1 ^VVG
on ^I++PPVB++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
substitute ^J++ATRB++++ ^JJ
endpoint ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
arrhythmia ^N+CM+SING+++PMOD+ ^NN1
suppression ^N+CM+SING++++ ^NN1
would ^VM+++++PRDN+ ^VM
have ^VL+INF+++++ ^VHI
continued ^VL+EN+PRF++++ ^VVN
to ^TO++++++ ^TO
administer ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
three ^M+CARD+SING+MORE+++ ^MC
drugs ^N+CM+PLUR++++ ^NN2
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
considerable ^J++ATRB++++ ^JJ
detriment ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
their ^D+PER+PLUR+3+GEN++ ^APPGE
patients ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
Even ^C+SRD+++++MULTI1 ^CS
when ^C_+SRD+WH+CLS+++MULTI2 ^CS
investigators ^N+CM+PLUR++++ ^NN2
report ^VL+BF+++++ ^VV0
favourable ^J++ATRB++++ ^JJ
effects ^N+CM+PLUR++++ ^NN2
ot ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM+++ ^NN1
on ^I++++++ ^II
one ^P+++INDEF+++ ^PN1
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
clinicians ^N+CM+PLUR+NOM+++ ^NN2
must ^VM+++++NEC+ ^VM
take ^VL+INF+++++ ^VVI
care ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
there ^P+EX+++++ ^EX
are ^VL+++COP+++ ^VBR
no ^D+AT++DEF+++ ^AT
deleterious ^J++ATRB++++ ^JJ
effects ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
other ^D++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
For ^R+++++APP+MULTI1 ^REX
instance ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
as ^C+SRD+++++ ^CSA
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
was ^VL+ED++COP+++ ^VBDZ
in ^I++++++ ^II
preparation ^N+CM+SING+NOM+++ ^NN1
the ^DET+AT+SING+DEF+++ ^AT
controversy ^N+CM+SING++++ ^NN1
continued ^VL+ED+++++ ^VVD
over ^R+PART+PHRV++++ ^RP
whether ^C+SRD+WH++++ ^CSW
reducing ^VL+ING++COMP+VERB++ ^VVG
lipids ^N+CM+PLUR++++ ^NN2
unexpectedly ^R++++++ ^RR
increases ^VL+Z+++++ ^VVZ
non-cardiovascular ^J++ATRB++++ ^JJ
causes ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
29 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Cancer ^N+CM+SING+++PMOD+ ^NN1
chemotherapy ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
lengthen ^VL+INF+++++ ^VVI
life ^N+CM+SING++++ ^NN1
but ^C+CRD++++ADVS+ ^CCB
decrease ^VL+BF+++++ ^VV0
its ^D+IMPR++3+GEN++ ^APPGE
quality ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Finally ^R++++++ ^RR
, ^Y+COM+++++ ^,
surgical ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
often ^R++++++ ^RR
document ^VL+BF+++++ ^VV0
prolonged ^J+EN+ATRB++++ ^JJ
life ^N+CM+SING++++ ^NN1
for ^I++++++ ^IF
those ^P+DEM+PLUR++++ ^DD2
who ^P++WH+REL+SUB++ ^PNQS
survive ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
operation ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
yielding ^VL+ING++COMP+VERB++ ^VVG
higher ^J++ATRB+ER+++ ^JJR
3-year ^J++ATRB+++ONLY+ ^JJ
survival ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
receiving ^VL+ING++COMP+VERB++ ^VVG
surgery ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
an ^D+AT+SING+INDEF+++ ^AT1
immediate ^J++ATRB++++ ^JJ
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
dying ^VL+ING++COMP+PREP++ ^VVG
during ^I++++++ ^II
or ^C+CRD+++++ ^CC
shortly ^R++++++ ^RR
after ^I++++++ ^II
surgery ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Accordingly ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
users ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
reports ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
surgical ^J++ATRB++++ ^JJ
trials ^N+CM+PLUR++++ ^NN2
should ^VM+++++NEC+ ^VM
look ^VL+INF+++++MULTI1 ^VVI
for ^I++PPVB++++MULTI2 ^IF
information ^N+CM+SING+NOM+++ ^NN1
on ^I++++++ ^II
immediate ^J++ATRB++++ ^JJ
and ^C+CRD+PHRS++++ ^CC
early ^J++ATRB++++ ^JJ
mortality ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
typically ^R++++++ ^RR
higher ^J++PRDV+ER+++ ^JJR
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
surgical ^J++ATRB++++ ^JJ
group ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
in ^I++++++MULTI1 ^II
addition ^I_++++++MULTI2 ^II
to ^I_++++++MULTI3 ^II
longer-term ^J++ATRB++++ ^JJ
results ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
article ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
generalizable ^J++PRDV++++ ^JJ
to ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
its ^D+IMPR++3+GEN++ ^APPGE
outcomes ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
important ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
next ^M+ORD+++++ ^MD
question ^N+CM+SING+NOM+++ ^NN1
concerns ^VL+Z+++++ ^VVZ
whether ^C+SRD+WH++++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
probable ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
benefits ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
worth ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
effort ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
you ^P+PER++2+++ ^PPY
and ^C+CRD+++++ ^CC
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
must ^VM+++++NEC+ ^VM
put ^VL+INF+++++ ^VVI
into ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
enterprise ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
A ^ZZ++SING++++ ^ZZ1
25% ^N++++U+PMOD+ ^NNU
reduction ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
sound ^VL+INF++COP+++ ^VVI
quite ^R+++++DEG+ ^RG
impressive ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
its ^D+IMPR++3+GEN++ ^APPGE
impact ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
your ^D+PER++2+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
practice ^N+CM+SING++++ ^NN1
may ^VM+++++POS+ ^VM
nevertheless ^R++++SPLT++ ^RR
be ^VL+INF++COP+++ ^VBI
minimal ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
notion ^N+CM+SING++++ ^NN1
is ^VA+Z++++BE+ ^VBZ
illustrated ^VL+EN+PSV+AGLS+++ ^VVN
using ^VL+ING++COMP+VERB++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
concept ^N+CM+SING++++ ^NN1
called ^VL+EN++CLS+++ ^VVN
" ^Y+QUO+++++ ^"
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
" ^Y+QUO+++++ ^"
( ^Y+PAR+LEFT++++ ^(
NNT ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
&lsqb; ^Y+PAR+LEFT++++ ^(
30 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
The ^DET+AT+SING+DEF+++ ^AT
impact ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
treatment ^N+CM+SING+NOM+++ ^NN1
is ^VA+Z++++BE+ ^VBZ
related ^VL+EN+PSV+AGLS+++ ^VVN
not ^XX++++++ ^XX
only ^R++++++ ^RR
to ^I++++++ ^II
its ^D+IMPR++3+GEN++ ^APPGE
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
also ^R++++++ ^RR
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
adverse ^J++ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
it ^P+IM++3+++ ^PPH1
is ^VA+Z++++BE+ ^VBZ
designed ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO+++COMP+VERB++ ^TO
prevent ^VL+INF+++++ ^VVI
. ^Y+PER+CLP++++ ^.
Beta ^N+CM+SING+++PMOD+ ^NN1
blockers ^N+CM+PLUR+NOM+++ ^NN2
reduce ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
following ^VL+ING++REL+SUBJ++ ^VVG
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
by ^I++++++ ^II
approximately ^R++++++ ^RR
25% ^N++++U++ ^NNU
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
this ^D+DEM+SING++++ ^DD1
RRR ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
consistent ^J++PRDV++++ ^JJ
across ^I++++++ ^II
subgroups ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
including ^I++++++ ^II
those ^P+DEM+PLUR++++ ^DD2
at ^I++++++ ^II
higher ^J++ATRB+ER+++ ^JJR
and ^C+CRD+PHRS++++ ^CC
lower ^J++ATRB+ER+++ ^JJR
" ^Y+QUO+++++ ^"
baseline ^N+CM+SING++++ ^NN1
" ^Y+QUO+++++ ^"
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
recurrence ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
death ^N+CM+SING++++ ^NN1
when ^C+SRD+WH+CLS+++ ^CS
they ^P+PER+PLUR+3+S++ ^PPHS2
are ^VL+++COP+++ ^VBR
untreated ^J+EN+PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
Table ^N+CM+SING++++ ^NN1
3 ^M+CARD+SING+MORE+++ ^MC
considers ^VL+Z+++++ ^VVZ
two ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
recent ^J++ATRB++++ ^JJ
myocardial ^J++ATRB++++ ^JJ
infarctions ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Table ^N+CM+SING++++ ^NN1
3 ^M+CARD+SING+MORE+++ ^MC
: ^Y+COL+CLP++++ ^:
Two ^M+CARD+SING+MORE+++ ^MC
men ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
contrasting ^J+ING+ATRB++++ ^JJ
prognoses ^N+CM+PLUR++++ ^NN2
following ^VL+ING++REL+SUBJ++ ^VVG
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
year ^N+CM+SING+++TIME+ ^NNT1
without ^I++++++ ^IW
therapy ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
baseline ^N+CM+SING+++PMOD+ ^NN1
risk ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
First ^M+ORD+++++ ^MD
, ^Y+COM+++++ ^,
consider ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
40 ^M+CARD+SING+MORE+++ ^MC
year ^N+CM+SING+++TIME+ ^NNT1
old ^J++ATRB++++ ^JJ
man ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
a ^D+AT+SING+INDEF+++ ^AT1
small ^J++ATRB++++ ^JJ
infarct ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
normal ^J++ATRB++++ ^JJ
exercise ^N+CM+SING+++PMOD+ ^NN1
capacity ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
no ^D+AT++DEF+++ ^AT
sign ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
ventricular ^J++ATRB++++ ^JJ
arrhythmia ^N+CM+SING++++ ^NN1
who ^P++WH++++ ^PNQS
is ^VL+Z++COP+++ ^VBZ
willing ^J+ING+PRDV++++ ^JJ
to ^TO++++++ ^TO
stop ^VL+INF+++++ ^VVI
smoking ^N+ING+SING++++ ^NN1
, ^Y+COM+++++ ^,
begin ^VL+BF+++++ ^VV0
exercising ^VL+ING++COMP+VERB++ ^VVG
, ^Y+COM+++++ ^,
lose ^VL+BF+++++ ^VV0
weight ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
take ^VL+BF+++++ ^VV0
aspirin ^N+CM+NEUT++++ ^NN
daily ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
This ^D+DEM+SING++++ ^DD1
individual ^N+CM+SING+NOM+++ ^NN1
's ^GE++++++ ^GE
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
first ^M+ORD+++++ ^MD
year ^N+CM+SING+++TIME+ ^NNT1
after ^I++++++ ^II
infarction ^N+CM+SING+NOM+++ ^NN1
may ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
as ^R+++++DEG+ ^RG
low ^J++ATRB++++ ^JJ
as ^C+SRD+++++ ^CSA
1% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
Beta ^N+CM+SING+++PMOD+ ^NN1
blockers ^N+CM+PLUR+NOM+++ ^NN2
would ^VM+++++PRDN+ ^VM
reduce ^VL+INF+++++ ^VVI
this ^D+DEM+SING++++ ^DD1
risk ^N+CM+SING++++ ^NN1
by ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
quarter ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
to ^I++++++ ^II
0.75% ^FO++++++ ^FO
, ^Y+COM+++++ ^,
for ^I++++++ ^IF
an ^D+AT+SING+INDEF+++ ^AT1
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
0.25% ^FO++++++ ^FO
or ^C+CRD+++++ ^CC
0.0025 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
inverse ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
that ^D+DEM+SING+++APP+MULTI1 ^REX
is ^R+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
1 ^M+CARD+SING+ONE+++ ^MC1
/ ^FO++++++ ^FO
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
equals ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
such ^D++++PRO+A+ ^DA
patients ^N+CM+PLUR++++ ^NN2
we ^P+PER+PLUR+1+S++ ^PPIS2
'd ^VM++++CONT+PRDN+ ^VM
have ^VM+INF++++NEC+MULTI1 ^VHI
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
in ^I++++++MULTI1 ^BCL
order ^N+CM+SING++++MULTI2 ^BCL
to ^TO+INF+++++MULTI3 ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
event ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
in ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
case ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
death ^N+CM+SING++++ ^NN1
following ^VL+ING++REL+SUBJ++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
mild ^J++ATRB++++ ^JJ
heart ^N+CM+SING+++PMOD+ ^NN1
attack ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
low ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
patient ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
case ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
would ^VM+++++PRDN+ ^VM
have ^VM+INF++++NEC+MULTI1 ^VHI
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
400 ^M+CARD+SING+MORE+++ ^MC
such ^D++++PRO+A+ ^DA
patients ^N+CM+PLUR++++ ^NN2
for ^I++++++ ^IF
one ^M+CARD+SING+ONE+++ ^MC1
year ^N+CM+SING+++TIME+ ^NNT1
to ^TO++++++ ^TO
save ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
single ^J++ATRB++++ ^JJ
life ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
1 ^M+CARD+SING+ONE+++ ^MC1
/ ^FO++++++ ^FO
0.0025 ^M+CARD+SING+MORE+++ ^MC
= ^FO++++++ ^FO
400 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
An ^D+AT+SING+INDEF+++ ^AT1
older ^J++ATRB+ER+++ ^JJR
man ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
limited ^J+EN+ATRB++++ ^JJ
exercise ^N+CM+SING+++PMOD+ ^NN1
capacity ^N+CM+SING+NOM+++ ^NN1
and ^C+CRD+++++ ^CC
frequent ^J++ATRB++++ ^JJ
ventricular ^J++ATRB++++ ^JJ
extrasystoles ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
continues ^VL+Z+++++ ^VVZ
to ^TO++++++ ^TO
smoke ^VL+INF+++++ ^VVI
following ^VL+ING++COMP+VERB++ ^VVG
his ^D+PER+SING+3+GEN++ ^APPGE
infarction ^N+CM+SING+NOM+++ ^NN1
may ^VM+++++POS+ ^VM
have ^VL+INF+++++ ^VHI
a ^D+AT+SING+INDEF+++ ^AT1
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
dying ^VL+ING++COMP+PREP++ ^VVG
in ^C+SRD+++++MULTI1 ^II
that ^C_+SRD+SING++++MULTI2 ^DD1
next ^M+ORD+++++ ^MD
year ^N+CM+SING+++TIME+ ^NNT1
as ^R+++++DEG+ ^RG
high ^J++ATRB++++ ^JJ
as ^C+SRD+++++ ^CSA
10% ^N++++U++ ^NNU
. ^Y+PER+CLP++++ ^.
A ^ZZ++SING++++ ^ZZ1
25% ^N++++U+PMOD+ ^NNU
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
death ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
such ^D++++PRO+A+ ^DA
a ^D+AT+SING+INDEF+++ ^AT1
high-risk ^J++ATRB++++ ^JJ
patient ^N+CM+SING++++ ^NN1
generates ^VL+Z+++++ ^VVZ
an ^D+AT+SING+INDEF+++ ^AT1
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
2.5% ^FO++++++ ^FO
or ^C+CRD+++++ ^CC
0.025 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
we ^P+PER+PLUR+1+S++ ^PPIS2
would ^VM+++++PRDN+ ^VM
have ^VM+INF++++NEC+MULTI1 ^VHI
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
only ^R++++++ ^RR
40 ^M+CARD+SING+MORE+++ ^MC
such ^D++++PRO+A+ ^DA
individuals ^N+CM+PLUR+NOM+++ ^NN2
for ^I++++++ ^IF
one ^M+CARD+SING+ONE+++ ^MC1
year ^N+CM+SING+++TIME+ ^NNT1
to ^TO++++++ ^TO
save ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
life ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
1 ^M+CARD+SING+ONE+++ ^MC1
/ ^FO++++++ ^FO
0.025 ^M+CARD+SING+MORE+++ ^MC
= ^FO++++++ ^FO
40 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
These ^D+DEM+PLUR++++ ^DD2
examples ^N+CM+PLUR++++ ^NN2
underscore ^VL+BF+++++ ^VV0
a ^D+AT+SING+INDEF+++ ^AT1
key ^J++ATRB++++ ^JJ
element ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
decision ^N+CM+SING++++ ^NN1
to ^TO+++COMP+NOUN++ ^TO
start ^VL+INF+++++ ^VVI
therapy ^N+CM+SING++++ ^NN1
: ^Y+COL+CLP++++ ^:
before ^I++++++ ^II
deciding ^VL+ING++COMP+PREP++ ^VVG
on ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
must ^VM+++++NEC+ ^VM
consider ^VL+INF+++++ ^VVI
our ^D+PER+PLUR+1+GEN++ ^APPGE
patient ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
adverse ^J++ATRB++++ ^JJ
event ^N+CM+SING++++ ^NN1
if ^C+SRD++++CND+ ^CS
left ^J++PRDV++++ ^JJ
untreated ^J+EN+PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
For ^I++++++ ^IF
any ^D+AT+PLUR+INDEF+++ ^DD
given ^J+EN+ATRB++++ ^JJ
RRR ^N+PR+SING++++ ^NP1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
higher ^J++ATRB+ER+++ ^JJR
the ^DET+AT+SING+DEF+++ ^AT
probability ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+COMP+NOUN++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
patient ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
experience ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
adverse ^J++ATRB++++ ^JJ
outcome ^N+CM+SING++++ ^NN1
if ^C+SRD++++CND+ ^CS
we ^P+PER+PLUR+1+S++ ^PPIS2
do ^VA+BF++++DO+ ^VD0
n't ^XX++++CONT++ ^XX
treat ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
more ^R+++ER++DEG+ ^RGR
likely ^R++++++ ^RR
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
benefit ^VL+INF+++++ ^VVI
from ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
fewer ^D+++ER+PRO+A+ ^DAR
such ^D++++PRO+A+ ^DA
patients ^N+CM+PLUR++++ ^NN2
we ^P+PER+PLUR+1+S++ ^PPIS2
need ^VM+BF++++NEC+MULTI1 ^VV0
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
event ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
Thus ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
both ^D++DOUB+++B+ ^DB2
patients ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
our ^D+PER+PLUR+1+GEN++ ^APPGE
own ^D++++PRO+A+ ^DA
clinical ^J++ATRB++++ ^JJ
efficiency ^N+CM+SING+++PMOD+ ^NN1
benefit ^N+CM+SING++++ ^NN1
when ^C+SRD+WH+CLS+++ ^CS
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
we ^P+PER+PLUR+1+S++ ^PPIS2
need ^VM+BF++++NEC+MULTI1 ^VV0
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
an ^D+AT+SING+INDEF+++ ^AT1
event ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
low ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
We ^P+PER+PLUR+1+S++ ^PPIS2
might ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
hesitate ^VL+INF+++++ ^VVI
to ^TO+++COMP+VERB++ ^TO
treat ^VL+INF+++++ ^VVI
even ^R++++++ ^RR
as ^R+++++DEG+ ^RG
many ^D++PLUR++PRO+A+ ^DA2
as ^C+SRD+++++ ^CSA
400 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
to ^TO++++++ ^TO
save ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
life ^N+CM+SING++++ ^NN1
if ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
treatment ^N+CM+SING+NOM+++ ^NN1
was ^VL+ED++COP+++ ^VBDZ
cheap ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
easy ^J++PRDV++++ ^JJ
to ^TO++++++ ^TO
apply ^VL+INF+++++ ^VVI
and ^C+CRD+PHRS++++ ^CC
comply ^VL+INF+++++ ^VVI
with ^I+STRN+++++ ^IW
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
safe ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
reality ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
treatments ^N+CM+PLUR+NOM+++ ^NN2
usually ^R++++++ ^RR
are ^VL+++COP+++ ^VBR
expensive ^J++PRDV++++ ^JJ
and ^C+CRD+++++ ^CC
they ^P+PER+PLUR+3+S++ ^PPHS2
carry ^VL+BF+++++ ^VV0
risks ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
these ^D+DEM+PLUR++++ ^DD2
risks ^N+CM+PLUR++++ ^NN2
or ^C+CRD+++++ ^CC
adverse ^J++ATRB++++ ^JJ
outcomes ^N+CM+PLUR++++ ^NN2
are ^VA+++++BE+ ^VBR
documented ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
trial ^N+CM+SING+++PMOD+ ^NN1
reports ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
users ^N+CM+PLUR++++ ^NN2
can ^VM+++++POS+ ^VM
apply ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
to ^TO++++++ ^TO
judge ^VL+INF+++++ ^VVI
both ^D++DOUB+++B+ ^DB2
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
benefits ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
costs ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
therapy ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
, ^Y+COM+++++ ^,
for ^R+++++APP+MULTI1 ^REX
instance ^R_+++++APP+MULTI2 ^REX
, ^Y+COM+++++ ^,
beta ^N+CM+SING+++PMOD+ ^NN1
blockers ^N+CM+PLUR+NOM+++ ^NN2
cause ^VL+BF+++++ ^VV0
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
fatigue ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
10% ^N++++U++ ^NNU
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
patients ^N+CM+PLUR++++ ^NN2
who ^P++WH++++ ^PNQS
use ^VL+BF+++++ ^VV0
them ^P+PER+PLUR+3+O++ ^PPHO2
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
NNT ^N+PR+SING++++ ^NP1
to ^TO++++++ ^TO
cause ^VL+INF+++++ ^VVI
fatigue ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
1/0.10 ^M+F+++++ ^MF
or ^C+CRD+++++ ^CC
10 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
This ^P+DEM+SING++++ ^DD1
is ^VA+Z++++BE+ ^VBZ
shown ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
Table ^N+CM+SING++++ ^NN1
4 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
where ^C+SRD+WH+CLS+++ ^CS
it ^P+IM++3+++ ^PPH1
is ^VA+Z++++BE+ ^VBZ
seen ^VL+EN+PSV+AGLS+++ ^VVN
that ^C+SRD+THT+COMP+VERB++ ^CST
a ^D+AT+SING+INDEF+++ ^AT1
policy ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
treating ^VL+ING++COMP+PREP++ ^VVG
low-risk ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
after ^I++++++ ^II
myocardial ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
NNT ^N+PR+SING++++ ^NP1
= ^FO++++++ ^FO
400 ^M+CARD+SING+MORE+++ ^MC
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
death ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
will ^VM+++++PRDN+ ^VM
result ^VL+INF+++++ ^VVI
in ^I++++++ ^II
40 ^M+CARD+SING+MORE+++ ^MC
being ^VA+ING++COMP+VERB+BE+ ^VBG
fatigued ^VL+EN+PSV+AGLS+++ ^VVN
for ^I++++++ ^IF
every ^D+AT+SING+INDEF+++ ^AT1
life ^N+CM+SING++++ ^NN1
saved ^VL+EN++CLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
On ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
hand ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
policy ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
treating ^VL+ING++COMP+PREP++ ^VVG
just ^R++++++ ^RR
high-risk ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
will ^VM+++++PRDN+ ^VM
result ^VL+INF+++++ ^VVI
in ^I++++++ ^II
4 ^M+CARD+SING+MORE+++ ^MC
being ^VA+ING++COMP+VERB+BE+ ^VBG
fatigued ^VL+EN+PSV+AGLS+++ ^VVN
for ^I++++++ ^IF
every ^D+AT+SING+INDEF+++ ^AT1
life ^N+CM+SING++++ ^NN1
saved ^VL+EN++CLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Table ^N+CM+SING++++ ^NN1
4 ^M+CARD+SING+MORE+++ ^MC
: ^Y+COL+CLP++++ ^:
Incorporating ^VL+ING++COMP+VERB++ ^VVG
side-effects ^N+CM+PLUR++++ ^NN2
into ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
Number ^N+CM+SING++++ ^NN1
Needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
be ^VA+INF++++BE+ ^VBI
Treated ^VL+EN+PSV+AGLS+++ ^VVN
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
year ^N+CM+SING+++TIME+ ^NNT1
without ^I++++++ ^IW
therapy ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
baseline ^N+CM+SING+++PMOD+ ^NN1
risk ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
1% ^N++++U++ ^NNU
or ^C+CRD+++++ ^CC
0.01 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
10% ^N++++U++ ^NNU
or ^C+CRD+++++ ^CC
0.10 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
And ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
death ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
propranolol ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
Y ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
0.01x0.75= ^FO++++++ ^FO
0.0075 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
0.10x0.75= ^FO++++++ ^FO
0.075 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
Then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
Absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
- ^Y+DSH+++++ ^-
Y ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
0.01-0.0075=0.0025 ^FO++++++ ^FO
<p> ^FU++++++ ^NULL
0.10-0.075=0.025 ^FO++++++ ^FO
<p> ^FU++++++ ^NULL
And ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
Number ^N+CM+SING++++ ^NN1
Needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
be ^VA+INF++++BE+ ^VBI
Treated ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
event ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
1/ ^M++++++ ^FO
( ^Y+PAR+LEFT++++ ^(
X ^ZZ++SING++++ ^ZZ1
- ^Y+DSH+++++ ^-
Y ^ZZ++SING++++ ^ZZ1
) ^Y+PAR+RIGHT++++ ^)
<p> ^FU++++++ ^NULL
1/0.0025 ^M+F+++++ ^MF
= ^FO++++++ ^FO
400 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
1/0.025 ^M+F+++++ ^MF
= ^FO++++++ ^FO
40 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
And ^C+CRD+++++ ^CC
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
incidence ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
fatigue ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
propranolol ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
<p> ^FU++++++ ^NULL
10% ^N++++U++ ^NNU
or ^C+CRD+++++ ^CC
0.10 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
Then ^R+++++TIME+ ^RT
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
fatigued ^J+EN+ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
per ^I++++++ ^II
life ^N+CM+SING++++ ^NN1
saved ^VL+EN++CLS+++ ^VVN
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
<p> ^FU++++++ ^NULL
400x0.1 ^FO++++++ ^FO
= ^FO++++++ ^FO
40 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
40x0.1 ^FO++++++ ^FO
= ^FO++++++ ^FO
4 ^M+CARD+SING+MORE+++ ^MC
<p> ^FU++++++ ^NULL
Clinicians ^N+CM+PLUR+NOM+++ ^NN2
do ^VL+BF+++++ ^VD0
n't ^XX++++CONT++ ^XX
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
treat ^VL+BF+++++ ^VV0
groups ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
uniformly ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
Rather ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
consider ^VL+BF+++++ ^VV0
individual ^J++ATRB++++ ^JJ
responses ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
tailor ^VL+BF+++++ ^VV0
our ^D+PER+PLUR+1+GEN++ ^APPGE
therapy ^N+CM+SING++++ ^NN1
accordingly ^R++++++ ^RR
. ^Y+PER+CLP++++ ^.
One ^M+CARD+SING+ONE+++ ^MC1
response ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
problem ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
common ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
relatively ^R++++++ ^RR
minor ^J++ATRB++++ ^JJ
side ^N+CM+SING+++PMOD+ ^NN1
effects ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
fatigue ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
to ^TO+++COMP+VERB++ ^TO
discontinue ^VL+INF+++++ ^VVI
therapy ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
suffering ^VL+ING++REL+SUBJ++ ^VVG
from ^I++++++ ^II
that ^D+DEM+SING++++ ^DD1
problem ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
we ^P+PER+PLUR+1+S++ ^PPIS2
think ^VL+BF+++++ ^VV0
of ^I++++++ ^IO
fatigued ^J+EN+ATRB++++ ^JJ
low-risk ^J++ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
as ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
group ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
would ^VM+++++PRDN+ ^VM
make ^VL+INF+++++ ^VVI
400 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
fatigued ^VL+ED+++++ ^VVD
to ^TO++++++ ^TO
save ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
life ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
a ^D+AT+SING+INDEF+++ ^AT1
trade-off ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
probably ^R++++++ ^RR
would ^VM+++++PRDN+ ^VM
n't ^XX++++CONT++ ^XX
be ^VL+INF++COP+++ ^VBI
worth ^I++++++ ^II
it ^P+IM++3+++ ^PPH1
. ^Y+PER+CLP++++ ^.
By ^I++++++ ^II
discontinuing ^VL+ING++COMP+PREP++ ^VVG
treatment ^N+CM+SING+NOM+++ ^NN1
in ^I++++++ ^II
these ^D+DEM+PLUR++++ ^DD2
people ^N+CM+NEUT++++ ^NN
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
can ^VM+++++POS+ ^VM
treat ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
remainder ^N+CM+SING+NOM+++ ^NN1
without ^I++++++ ^IW
making ^VL+ING++COMP+PREP++ ^VVG
anyone ^P+++INDEF+++ ^PN1
fatigued ^VL+ED+++++ ^VVD
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
We ^P+PER+PLUR+1+S++ ^PPIS2
can ^VM+++++POS+ ^VM
not ^XX++++++ ^XX
apply ^VL+INF+++++ ^VVI
this ^D+DEM+SING++++ ^DD1
approach ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
however ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
to ^I++++++ ^II
severe ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
episodic ^J++ATRB++++ ^JJ
events ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Examples ^N+CM+PLUR++++ ^NN2
include ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
bleeding ^VL+ING++COMP+PREP++ ^VVG
in ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
given ^VL+EN++CLS+++ ^VVN
anticoagulants ^N+CM+PLUR+NOM+++ ^NN2
, ^Y+COM+++++ ^,
thrombolytic ^J++ATRB++++ ^JJ
agents ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
aspirin ^N+CM+NEUT++++ ^NN
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
rare ^J++ATRB++++ ^JJ
but ^C+CRD+PHRS+++ADVS+ ^CCB
devastating ^J+ING+ATRB++++ ^JJ
drug ^N+CM+SING+++PMOD+ ^NN1
reactions ^N+CM+PLUR+NOM+++ ^NN2
. ^Y+PER+CLP++++ ^.
In ^I++++++ ^II
each ^D++SING++++ ^DD1
of ^I++++++ ^IO
these ^D+DEM+PLUR++++ ^DD2
examples ^N+CM+PLUR++++ ^NN2
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
adverse ^J++ATRB++++ ^JJ
events ^N+CM+PLUR++++ ^NN2
per ^I++++++ ^II
life ^N+CM+SING++++ ^NN1
saved ^VL+EN++CLS+++ ^VVN
( ^Y+PAR+LEFT++++ ^(
or ^C+CRD+++++ ^CC
, ^Y+COM+++++ ^,
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
events ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
rare ^J++ATRB++++ ^JJ
enough ^R++++++ ^RR
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
lives ^N+CM+PLUR++++ ^NN2
saved ^VL+EN++CLS+++ ^VVN
per ^I++++++ ^II
adverse ^J++ATRB++++ ^JJ
event ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
can ^VM+++++POS+ ^VM
provide ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
compelling ^J+ING+ATRB++++ ^JJ
picture ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
trade ^N+CM+SING+++PMOD+ ^NN1
offs ^N+CM+PLUR++++ ^NN2
associated ^VL+EN++CLS+++ ^VVN
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
intervention ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Resolution ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
Scenario ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
In ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
randomized ^J+EN+ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
warfarin ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
non-valvular ^J++ATRB++++ ^JJ
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM+++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
you ^P+PER++2+++ ^PPY
selected ^VL+EN++CLS+++ ^VVN
for ^I++++++ ^IF
reading ^N+ING+SING++++ ^NN1
, ^Y+COM+++++ ^,
260 ^M+CARD+SING+MORE+++ ^MC
patients ^N+CM+PLUR++++ ^NN2
received ^VL+ED+++++ ^VVD
warfarin ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
265 ^M+CARD+SING+MORE+++ ^MC
received ^J+EN+ATRB++++ ^JJ
placebo ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VA+++++BE+ ^VBR
summarized ^VL+EN+PSV+AGLS+++ ^VVN
in ^I++++++ ^II
Table ^N+CM+SING++++ ^NN1
5 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Table ^N+CM+SING++++ ^NN1
5 ^M+CARD+SING+MORE+++ ^MC
: ^Y+COL+CLP++++ ^:
Summary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
effect ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
warfarin ^N+CM+SING+++PMOD+ ^NN1
therapy ^N+CM+SING++++ ^NN1
on ^I++++++ ^II
patients ^N+CM+PLUR++++ ^NN2
with ^I++++++ ^IW
non-valvular ^J++ATRB++++ ^JJ
atrial ^J++ATRB++++ ^JJ
fibrillation ^N+CM+SING+NOM++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
stroke ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
one ^M+CARD+SING+ONE+++ ^MC1
year ^N+CM+SING+++TIME+ ^NNT1
without ^I++++++ ^IW
therapy ^N+CM+SING++++ ^NN1
( ^Y+PAR+LEFT++++ ^(
baseline ^N+CM+SING+++PMOD+ ^NN1
risk ^N+CM+SING++++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
: ^Y+COL+CLP++++ ^:
X ^ZZ++SING++++ ^ZZ1
<p> ^FU++++++ ^NULL
Over ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
next ^M+ORD+++++ ^MD
year-and-a-half ^M+F+++++ ^MF
, ^Y+COM+++++ ^,
just ^R++++++ ^RR
4 ^M+CARD+SING+MORE+++ ^MC
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
former ^D++++PRO+A+ ^DA
( ^Y+PAR+LEFT++++ ^(
0.9% ^FO++++++ ^FO
per ^I++++++ ^II
year ^N+CM+SING+++TIME+ ^NNT1
) ^Y+PAR+RIGHT++++ ^)
, ^Y+COM+++++ ^,
but ^C+CRD++++ADVS+ ^CCB
19 ^M+CARD+SING+MORE+++ ^MC
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
latter ^D++++PRO+A+ ^DA
( ^Y+PAR+LEFT++++ ^(
4.3% ^FO++++++ ^FO
per ^I++++++ ^II
year ^N+CM+SING+++TIME+ ^NNT1
) ^Y+PAR+RIGHT++++ ^)
suffered ^VL+ED+++++ ^VVD
cerebral ^J++ATRB++++ ^JJ
infarction ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Thus ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
relative ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
RRR ^N+PR+SING++++ ^NP1
) ^Y+PAR+RIGHT++++ ^)
is ^VL+Z++COP+++ ^VBZ
( ^Y+PAR+LEFT++++ ^(
0.043 ^M+CARD+SING+MORE+++ ^MC
- ^Y+DSH+++++ ^-
0.009 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
/0.043 ^M+F+++++ ^MF
= ^FO++++++ ^FO
79% ^N++++U++ ^NNU
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
absolute ^J++ATRB++++ ^JJ
risk ^N+CM+SING+++PMOD+ ^NN1
reduction ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
0.043-0.009 ^M+CARD+++HYPH++ ^MCMC
= ^FO++++++ ^FO
0.034 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
be ^VA+INF++++BE+ ^VBI
treated ^VL+EN+PSV+AGLS+++ ^VVN
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
one ^M+CARD+SING+ONE+++ ^MC1
stroke ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
1/0.034 ^M+F+++++ ^MF
= ^FO++++++ ^FO
29 ^M+CARD+SING+MORE+++ ^MC
( ^Y+PAR+LEFT++++ ^(
or ^C+CRD+++++ ^CC
approximately ^R++++++ ^RR
30 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Applying ^VL+ING++COMP+VERB++ ^VVG
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
intervals ^N+CM+PLUR+NOM+++ ^NN2
to ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
could ^VM+++++POS+ ^VM
be ^VL+INF++COP+++ ^VBI
( ^Y+PAR+LEFT++++ ^(
using ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
around ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
, ^Y+COM+++++ ^,
which ^D++WH++++ ^DDQ
was ^VL+ED++COP+++ ^VBDZ
0.52 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
as ^R+++++DEG+ ^RG
great ^J++PRDV++++ ^JJ
as ^C+SRD+++++ ^CSA
45 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
( ^Y+PAR+LEFT++++ ^(
using ^VL+ING++COMP+VERB++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
around ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
RRR ^N+PR+SING++++ ^NP1
, ^Y+COM+++++ ^,
which ^D++WH++++ ^DDQ
was ^VL+ED++COP+++ ^VBDZ
0.90 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
as ^R+++++DEG+ ^RG
few ^D++PLUR++PRO+A+ ^DA2
as ^C+SRD+++++ ^CSA
17 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Now ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
you ^P+PER++2+++ ^PPY
know ^VL+BF+++++ ^VV0
that ^D+DEM+SING++++ ^DD1
warfarin ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
a ^D+AT+SING+INDEF+++ ^AT1
potentially ^R++++++ ^RR
dangerous ^J++ATRB++++ ^JJ
drug ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD++CLS+++ ^CC
that ^C+SRD+THT+REL+++ ^CST
about ^R+++++DEG+ ^RG
1% ^N++++U++ ^NNU
of ^I++++++ ^IO
patients ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
treatment ^N+CM+SING+NOM+++ ^NN1
will ^VM+++++PRDN+ ^VM
suffer ^VL+INF+++++ ^VVI
clinically ^R++++++ ^RR
important ^J++PRDV++++ ^JJ
bleeding ^J+ING+PRDV++++ ^JJ
as ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
result ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
treatment ^N+CM+SING+NOM+++ ^NN1
each ^D++SING++++ ^DD1
year ^N+CM+SING+++TIME+ ^NNT1
&lsqb; ^Y+PAR+LEFT++++ ^(
31 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Therefore ^R+CJ+++++ ^RR
, ^Y+COM+++++ ^,
there ^P+EX+++++ ^EX
will ^VM+++++PRDN+ ^VM
be ^VL+INF++COP+++ ^VBI
one ^M+CARD+SING+ONE+++ ^MC1
bleed ^VL+BF+++++ ^VV0
in ^I++++++ ^II
every ^D+AT+SING+INDEF+++ ^AT1
100 ^M+CARD+SING+MORE+++ ^MC
treated ^J+EN+ATRB++++ ^JJ
patients ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
if ^C+SRD+WH+REL+OBJ+CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
number ^N+CM+SING++++ ^NN1
needed ^VM+ED++++NEC+MULTI1 ^VVD
to ^VM_++++++MULTI2 ^TO
treat ^VL+INF+++++ ^VVI
to ^TO++++++ ^TO
prevent ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
stroke ^N+CM+SING++++ ^NN1
is ^VL+Z++COP+++ ^VBZ
30 ^M+CARD+SING+MORE+++ ^MC
, ^Y+COM+++++ ^,
then ^R+++++TIME+ ^RT
for ^I++++++ ^IF
every ^D+AT+SING+INDEF+++ ^AT1
3 ^M+CARD+SING+MORE+++ ^MC
strokes ^N+CM+PLUR++++ ^NN2
prevented ^VL+ED+++++ ^VVD
, ^Y+COM+++++ ^,
one ^M+CARD+SING+ONE+++ ^MC1
major ^J++ATRB++++ ^JJ
episode ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
bleeding ^VL+ING++COMP+PREP++ ^VVG
would ^VM+++++PRDN+ ^VM
occur ^VL+INF+++++ ^VVI
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
lower ^J++ATRB+ER+++ ^JJR
boundary ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
confidence ^N+CM+SING+NOM++PMOD+ ^NN1
interval ^N+CM+SING+NOM+++ ^NN1
for ^I++++++ ^IF
the ^DET+AT+SING+DEF+++ ^AT
benefit ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
oral ^J++ATRB++++ ^JJ
anticoagulants ^N+CM+PLUR+NOM+++ ^NN2
represents ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
truth ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
NNT ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
45 ^M+CARD+SING+MORE+++ ^MC
and ^C+CRD+++++ ^CC
for ^I++++++ ^IF
every ^D+AT+SING+INDEF+++ ^AT1
two ^M+CARD+SING+MORE+++ ^MC
strokes ^N+CM+PLUR++++ ^NN2
prevented ^VL+ED+++++ ^VVD
, ^Y+COM+++++ ^,
one ^M+CARD+SING+ONE+++ ^MC1
would ^VM+++++PRDN+ ^VM
cause ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
major ^J++PRDV++++ ^JJ
bleed ^VL+BF+++++ ^VV0
; ^Y+SCOL+CLP++++ ^;
if ^C+SRD++++CND+ ^CS
, ^Y+COM+++++ ^,
on ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
other ^D++ATRB++++ ^JJ
hand ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
upper ^J++ATRB++++ ^JJ
boundary ^N+CM+SING+NOM+++ ^NN1
represents ^VL+Z+++++ ^VVZ
the ^DET+AT+SING+DEF+++ ^AT
truth ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
NNT ^N+PR+SING++++ ^NP1
is ^VL+Z++COP+++ ^VBZ
26 ^M+CARD+SING+MORE+++ ^MC
and ^C+CRD+++++ ^CC
approximately ^R++++++ ^RR
4 ^M+CARD+SING+MORE+++ ^MC
strokes ^N+CM+PLUR++++ ^NN2
would ^VM+++++PRDN+ ^VM
be ^VA+INF++++BE+ ^VBI
prevented ^VL+EN+PSV+AGLS+++ ^VVN
for ^I++++++ ^IF
every ^D+AT+SING+INDEF+++ ^AT1
major ^J++ATRB++++ ^JJ
bleeding ^J+ING+ATRB++++ ^JJ
episode ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
risk-benefit ^J++ATRB++++ ^JJ
ratio ^N+CM+SING++++ ^NN1
probably ^R++++++ ^RR
lies ^VL+Z+++++ ^VVZ
somewhere ^R+++++LOC+ ^RL
between ^I++++++ ^II
these ^D+DEM+PLUR++++ ^DD2
extremes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
closer ^R+++ER+++ ^RRR
to ^I++++++ ^II
that ^P+DEM+SING++++ ^DD1
asssociated ^VL+ED+++++ ^VVD
with ^I++++++ ^IW
the ^DET+AT+SING+DEF+++ ^AT
point ^N+CM+SING+++PMOD+ ^NN1
estimate ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
And ^C+CRD++CLS+++ ^CC
what ^P++WH+REL+OBJ++ ^DDQ
about ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
woman ^N+CM+SING++++ ^NN1
with ^I++++++ ^IW
lupus ^N+CM+SING+++PMOD+ ^NN1
nephritis ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
whose ^D++WH+REL+GEN++ ^DDQGE
plight ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
described ^VL+ED+++++ ^VVD
in ^R++++++MULTI1 ^RR
Part ^R_++++++MULTI2 ^RR
A ^ZZ++SING++++ ^ZZ1
of ^I++++++ ^IO
this ^D+DEM+SING++++ ^DD1
two-part ^J++ATRB++++ ^JJ
essay ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
prompted ^VL+ED+++++ ^VVD
us ^P+PER+PLUR+1+O++ ^PPIO2
to ^TO++++++ ^TO
find ^VL+INF+++++ ^VVI
that ^D+DEM+SING++++ ^DD1
trial ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
adding ^VL+ING++COMP+PREP++ ^VVG
plasmapheresis ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
regimen ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
prednisone ^N+CM+SING++++ ^NN1
and ^C+CRD+++++ ^CC
cyclophosphamide ^VL+BF+++++ ^VV0
? ^Y+QM+CLP++++ ^?
Unfortunately ^R++++++ ^RR
, ^Y+COM+++++ ^,
although ^C+SRD++++CONC+ ^CS
plasmapheresis ^N+CM+SING++++ ^NN1
did ^VA+ED++++DO+ ^VDD
produce ^VL+INF+++++ ^VVI
sharp ^R++++++ ^RR
declines ^VL+Z+++++ ^VVZ
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
substituted ^J+EN+ATRB++++ ^JJ
end-points ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
anti-dsDNA ^J++ATRB++++ ^JJ
antibodies ^N+CM+PLUR++++ ^NN2
and ^C+CRD+++++ ^CC
cryoprecipitable ^J++ATRB++++ ^JJ
immune ^J++ATRB++++ ^JJ
complexes ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
did ^VA+ED++++DO+ ^VDD
not ^XX++++++ ^XX
find ^VL+INF+++++ ^VVI
any ^D+AT+PLUR+INDEF+++ ^DD
benefit ^N+CM+SING++++ ^NN1
from ^I++++++ ^II
plasmapheresis ^N+CM+SING++++ ^NN1
in ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
clinically ^R++++++ ^RR
important ^J++ATRB++++ ^JJ
measures ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
renal ^J++ATRB++++ ^JJ
failure ^N+CM+SING++++ ^NN1
or ^C+CRD+++++ ^CC
mortality ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
When ^C+SRD+WH+CLS+++ ^CS
a ^D+AT+SING+INDEF+++ ^AT1
careful ^J++ATRB++++ ^JJ
statistical ^J++ATRB++++ ^JJ
analysis ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
emerging ^J+ING+ATRB++++ ^JJ
data ^N+CM+NEUT++++ ^NN
suggested ^VL+ED+++++ ^VVD
little ^D++SING++PRO+A+ ^DA1
hope ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
ever ^R++++++ ^RR
showing ^VL+ING++COMP+PREP++ ^VVG
clinical ^J++ATRB++++ ^JJ
benefit ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
the ^DET+AT+SING+DEF+++ ^AT
trial ^N+CM+SING++++ ^NN1
was ^VA+ED++++BE+ ^VBDZ
stopped ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
<h> ^FU+++++PMOD+ ^NULL
Conclusion ^N+CM+SING+++PMOD+ ^NN1
<p> ^FU++++++ ^NULL
Having ^VL+ING++COMP+VERB++ ^VHG
read ^VL+EN+PRF++++ ^VVN
the ^DET+AT+SING+DEF+++ ^AT
introduction ^N+CM+SING+NOM+++ ^NN1
to ^I++++++ ^II
this ^D+DEM+SING++++ ^DD1
series ^N+CM+NEUT++++ ^NN
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
two ^M+CARD+SING+MORE+++ ^MC
articles ^N+CM+PLUR++++ ^NN2
on ^I++++++ ^II
using ^VL+ING++COMP+PREP++ ^VVG
articles ^N+CM+PLUR++++ ^NN2
about ^I++++++ ^II
therapy ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
hope ^VL+BF+++++ ^VV0
that ^C+SRD+THT+COMP+VERB++ ^CST
you ^P+PER++2+++ ^PPY
are ^VA+++++BE+ ^VBR
developing ^VL+ING+PRG++++ ^VVG
a ^D+AT+SING+INDEF+++ ^AT1
sense ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
how ^P+G+WH+COMP+NOUN++ ^RRQ
to ^TO++++++ ^TO
use ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
medical ^J++ATRB++++ ^JJ
literature ^N+CM+SING++++ ^NN1
to ^TO++++++ ^TO
resolve ^VL+INF+++++ ^VVI
a ^D+AT+SING+INDEF+++ ^AT1
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
decision ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
First ^M+ORD+++++ ^MD
, ^Y+COM+++++ ^,
define ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
problem ^N+CM+SING++++ ^NN1
clearly ^R++++++ ^RR
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
use ^VL+BF+++++ ^VV0
one ^M+CARD+SING+ONE+++ ^MC1
of ^I++++++ ^IO
a ^D+AT+SING+INDEF+++ ^AT1
number ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
search ^N+CM+SING+++PMOD+ ^NN1
strategies ^N+CM+PLUR++++ ^NN2
to ^TO++++++ ^TO
obtain ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
best ^J++ATRB+EST+++ ^JJT
available ^J++ATRB++++ ^JJ
evidence ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
Having ^VL+ING++COMP+VERB++ ^VHG
found ^VL+EN+PRF++++ ^VVN
an ^D+AT+SING+INDEF+++ ^AT1
article ^N+CM+SING++++ ^NN1
relevant ^J++PRDV++++ ^JJ
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
therapeutic ^J++ATRB++++ ^JJ
issue ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
assess ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
quality ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
evidence ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
To ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
extent ^N+CM+SING++++ ^NN1
that ^C+SRD+THT+REL+++ ^CST
the ^DET+AT+SING+DEF+++ ^AT
quality ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
evidence ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
poor ^J++ATRB++++ ^JJ
, ^Y+COM+++++ ^,
any ^D+AT+PLUR+INDEF+++ ^DD
subsequent ^J++ATRB++++ ^JJ
inference ^N+CM+SING+NOM+++ ^NN1
( ^Y+PAR+LEFT++++ ^(
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
clinical ^J++ATRB++++ ^JJ
decision ^N+CM+SING++++ ^NN1
it ^P+IM++3+++ ^PPH1
generates ^VL+Z+++++ ^VVZ
) ^Y+PAR+RIGHT++++ ^)
will ^VM+++++PRDN+ ^VM
be ^VA+INF++++BE+ ^VBI
weakened ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
quality ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
evidence ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
adequate ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
determine ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
range ^N+CM+SING++++ ^NN1
within ^I++++++ ^II
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
true ^J++ATRB++++ ^JJ
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
effect ^N+CM+SING++++ ^NN1
likely ^J++ATRB++++ ^JJ
falls ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
Then ^R+++++TIME+ ^RT
, ^Y+COM+++++ ^,
consider ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
extent ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
which ^D++WH++++ ^DDQ
the ^DET+AT+SING+DEF+++ ^AT
results ^N+CM+PLUR++++ ^NN2
are ^VL+++COP+++ ^VBR
generalizable ^J++PRDV++++ ^JJ
to ^I++++++ ^II
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
at ^I++++++ ^II
hand ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
whether ^C+SRD+WH+REL+OBJ++ ^CSW
the ^DET+AT+SING+DEF+++ ^AT
outcomes ^N+CM+PLUR++++ ^NN2
that ^C+SRD+THT+REL+++ ^CST
have ^VL+BF+++++ ^VH0
been ^VA+EN+PRF+++BE+ ^VBN
measured ^VL+EN+PSV+AGLS+++ ^VVN
are ^VL+++COP+++ ^VBR
important ^J++PRDV++++ ^JJ
. ^Y+PER+CLP++++ ^.
If ^C+SRD++++CND+ ^CS
the ^DET+AT+SING+DEF+++ ^AT
generalizability ^N+CM+SING+NOM+++ ^NN1
is ^VL+Z++COP+++ ^VBZ
in ^I++++++ ^II
doubt ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
or ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
importance ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
outcomes ^N+CM+PLUR++++ ^NN2
questionable ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
support ^VL+BF+++++ ^VV0
for ^I++++++ ^IF
a ^D+AT+SING+INDEF+++ ^AT1
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
recommendation ^N+CM+SING+NOM+++ ^NN1
will ^VM+++++PRDN+ ^VM
be ^VA+INF++++BE+ ^VBI
weakened ^VL+EN+PSV+AGLS+++ ^VVN
. ^Y+PER+CLP++++ ^.
Finally ^R++++++ ^RR
, ^Y+COM+++++ ^,
by ^I++++++ ^II
taking ^VL+ING++COMP+PREP++ ^VVG
into ^I++++++ ^II
account ^N+CM+SING++++ ^NN1
the ^DET+AT+SING+DEF+++ ^AT
patient ^N+CM+SING++++ ^NN1
's ^GE++++++ ^GE
risk ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
adverse ^J++ATRB++++ ^JJ
events ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
assess ^VL+BF+++++ ^VV0
the ^DET+AT+SING+DEF+++ ^AT
likely ^J++ATRB++++ ^JJ
results ^N+CM+PLUR++++ ^NN2
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
intervention ^N+CM+SING+NOM+++ ^NN1
. ^Y+PER+CLP++++ ^.
This ^P+DEM+SING++++ ^DD1
involves ^VL+Z+++++ ^VVZ
a ^D+AT+SING+INDEF+++ ^AT1
balance ^N+CM+SING+NOM++PMOD+ ^NN1
sheet ^N+CM+SING++++ ^NN1
looking ^VL+ING++REL+SUBJ++MULTI1 ^VVG
at ^I++PPVB++++MULTI2 ^II
the ^DET+AT+SING+DEF+++ ^AT
probability ^N+CM+SING+NOM+++ ^NN1
of ^I++++++ ^IO
benefit ^N+CM+SING++++ ^NN1
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
the ^DET+AT+SING+DEF+++ ^AT
associated ^J+EN+ATRB++++ ^JJ
costs ^N+CM+PLUR++++ ^NN2
( ^Y+PAR+LEFT++++ ^(
including ^I++++++ ^II
monetary ^J++ATRB++++ ^JJ
costs ^N+CM+PLUR++++ ^NN2
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
issues ^N+CM+PLUR++++ ^NN2
such ^I++++++MULTI1 ^II
as ^I_++++++MULTI2 ^II
inconvenience ^N+CM+SING+NOM+++ ^NN1
) ^Y+PAR+RIGHT++++ ^)
and ^C+CRD+++++ ^CC
risks ^N+CM+PLUR++++ ^NN2
. ^Y+PER+CLP++++ ^.
The ^DET+AT+SING+DEF+++ ^AT
bottom ^J++ATRB++++ ^JJ
line ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
the ^DET+AT+SING+DEF+++ ^AT
balance ^N+CM+SING+NOM++PMOD+ ^NN1
sheet ^N+CM+SING++++ ^NN1
will ^VM+++++PRDN+ ^VM
guide ^VL+INF+++++ ^VVI
your ^D+PER++2+GEN++ ^APPGE
treatment ^N+CM+SING+NOM++PMOD+ ^NN1
decision ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
While ^C+SRD++++CONC+ ^CS
this ^P+DEM+SING++++ ^DD1
may ^VM+++++POS+ ^VM
sound ^VL+INF++COP+++ ^VVI
like ^I++++++ ^II
a ^D+AT+SING+INDEF+++ ^AT1
challenging ^J+ING+ATRB++++ ^JJ
route ^N+CM+SING++++ ^NN1
to ^I++++++ ^II
deciding ^VL+ING++COMP+PREP++ ^VVG
on ^I++++++ ^II
treatment ^N+CM+SING+NOM+++ ^NN1
, ^Y+COM+++++ ^,
it ^P+IM++3+++ ^PPH1
is ^VL+Z++COP+++ ^VBZ
what ^C+SRD+WH+CLS+++ ^DDQ
clinicians ^N+CM+PLUR+NOM+++ ^NN2
implicitly ^R++++++ ^RR
do ^VL+BF+++++ ^VD0
each ^D++SING++++ ^DD1
time ^N+CM+SING+++TIME+ ^NNT1
they ^P+PER+PLUR+3+S++ ^PPHS2
administer ^VL+BF+++++ ^VV0
therapy ^N+CM+SING++++ ^NN1
&lsqb; ^Y+PAR+LEFT++++ ^(
32 ^M+CARD+SING+MORE+++ ^MC
&rsqb; ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.
Making ^VL+ING++CLS+ADVL++ ^VVG
the ^DET+AT+SING+DEF+++ ^AT
process ^N+CM+PLUR+NOM+++ ^NN1
explicit ^J++PRDV++++ ^JJ
, ^Y+COM+++++ ^,
and ^C+CRD+++++ ^CC
being ^VM+ING++COMP+VERB+BE+MULTI1 ^VBG
able ^VM_+++++POS+MULTI2 ^JJ
to ^VM_++++++MULTI3 ^TO
apply ^VL+INF+++++ ^VVI
guidelines ^N+CM+PLUR++++ ^NN2
to ^TO++++++ ^TO
help ^VL+INF+++++ ^VVI
assess ^VL+INF+++++ ^VVI
the ^DET+AT+SING+DEF+++ ^AT
strength ^N+CM+SING++++ ^NN1
of ^I++++++ ^IO
evidence ^N+CM+SING+NOM+++ ^NN1
will ^VM+++++PRDN+ ^VM
, ^Y+COM+++++ ^,
we ^P+PER+PLUR+1+S++ ^PPIS2
think ^VL+BF+++++ ^VV0
, ^Y+COM+++++ ^,
result ^VL+BF+++++ ^VV0
in ^I++++++ ^II
better ^J++ATRB+ER+++ ^JJR
patient ^N+CM+SING+++PMOD+ ^NN1
care ^N+CM+SING++++ ^NN1
. ^Y+PER+CLP++++ ^.
<p> ^FU++++++ ^NULL
24 ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
Detsky ^J++ATRB++++ ^JJ
AS ^C+SRD+++++ ^CSA
, ^Y+COM+++++ ^,
Sackett ^N+PR+SING++++ ^NP1
DL ^M+CARD+SING+MORE+++ ^MC
. ^Y+PER+CLP++++ ^.
When ^R++WH+QUE+++ ^RRQ
was ^VL+ED++COP+++ ^VBDZ
a ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
negative ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
clinical ^J++ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
big ^J++PRDV++++ ^JJ
enough ^R++++++ ^RR
? ^Y+QM+CLP++++ ^?
How ^R+G+WH+QUE+++ ^RGQ
many ^D++PLUR++PRO+A+ ^DA2
patients ^N+CM+PLUR++++ ^NN2
you ^P+PER++2+++ ^PPY
needed ^VL+EN++CLS+++ ^VVN
depends ^VL+Z+++++MULTI1 ^VVZ
on ^I++PPVB++++MULTI2 ^II
what ^P++WH+QUE+++ ^DDQ
you ^P+PER++2+++ ^PPY
found ^VL+ED+++++ ^VVD
When ^R++WH+QUE+++ ^RRQ
was ^VL+ED++COP+++ ^VBDZ
a ^D+AT+SING+INDEF+++ ^AT1
" ^Y+QUO+++++ ^"
negative ^J++ATRB++++ ^JJ
" ^Y+QUO+++++ ^"
clinical ^J++ATRB++++ ^JJ
trial ^N+CM+SING++++ ^NN1
big ^J++PRDV++++ ^JJ
enough ^R++++++ ^RR
? ^Y+QM+CLP++++ ^?
How ^R+G+WH++++ ^RGQ
many ^D++PLUR++PRO+A+ ^DA2
patients ^N+CM+PLUR++++ ^NN2
you ^P+PER++2+++ ^PPY
needed ^VL+EN++CLS+++ ^VVN
depends ^VL+Z+++++MULTI1 ^VVZ
on ^I++PPVB++++MULTI2 ^II
what ^P++WH++++ ^DDQ
you ^P+PER++2+++ ^PPY
found ^VL+ED+++++ ^VVD
. ^Y+PER+CLP++++ ^.
Arch ^J++ATRB+++ONLY+ ^JJ
Intern ^N+CM+SING++++ ^NN1
Med ^VL+ED+++++ ^VVD
145. ^M+CARD+SING+MORE+++ ^MC
709-12 ^M+CARD+++HYPH++ ^MCMC
( ^Y+PAR+LEFT++++ ^(
1985 ^M+CARD+SING+MORE+++ ^MC
) ^Y+PAR+RIGHT++++ ^)
. ^Y+PER+CLP++++ ^.